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[Rh(CO]2Cl]2 has been shown to catalyze sequential, mechanistically- 
distinct transformations in one pot. Tandem allylic alkylation/cycloisomerization 
sequences have been developed to access valuable, complex structures from 
relatively simple substrates. 
A methodology for the enantioselective conjugate addition of 2-heteroaryl 
nucleophiles to a variety of Michael acceptors has been developed. This method 
was used successfully in an ongoing approach to the synthesis of cortistatin A. 10 
linear steps have been completed towards the synthesis of cortistatin A, including 
a highly regioselective propargylation to install a quaternary carbon and a 
diastereoselective intramolecular Diels-Alder reaction.    
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Chapter 1: [Rh(CO)2Cl]2-Catalyzed Domino Allylic and Allenic 
Alkylation/Cycloisomerization Sequences 
1.1 INTRODUCTION 
Vinyl alkylidene cyclopentanes, fused bicyclic 1,4-dienes, and unsaturated 
medium-sized rings are key structures found within multiple natural products and 
compounds of biological interest. Consequently, numerous reports have been 
published on the syntheses of these valuable targets.1-8 The most commonly 
employed method to construct these compounds is via transition metal-mediated 
cycloisomerization of an 1,6-enyne or 1,7-allenene (Schemes 1.1 and 1.2). This 
synthetic approach requires the synthesis of the intermediate 1,6-enyne or 1,7-
allenene, which is often performed via a classical substitution reaction or a 
transition metal-mediated allylic alkylation.  







R,R' = Alkyl, aryl, OPG, NPG
PG = protecting group





X = CH(CO2Me)2, 



























R,R' = alkyl, aryl
           N(R)PG, OPG
X = CH(CO2Me)2,




PG = protecting group
LG = leaving group  
The synthesis of chiral 1,6-enynes or 1,7-allenenes possessing secondary 
or tertiary allylic carbons is still a challenging problem because metal-free 
substitution reactions are typically incompatible with these substrates, and many 
transition metal-catalyzed allylic alkylation methods suffer from unpredictable or 
variable regioselectivity, as well as poor stereocontrol, particularly with regard to  
the stereochemistry at the allylic carbon and the double bond geometry of the 
starting allylic substrate.2, 9, 10  Prior research in the Martin group had shown that 
[Rh(CO)2Cl]2 is a unique and broadly useful catalyst for promoting allylic 
alkylations with a wide variety of allylic substrates. Advantages of this catalyst 
system include a predictable regioselectivity that always furnishes the product 
resulting from direct substitution of the leaving group, retention of 
stereochemistry at the allylic carbon, and minimal E/Z isomerization of double 
bonds.  
We envisioned that our [Rh(CO)2Cl]2–catalyzed allylic alkylation 
methodology could not only provide ready access to a variety of challenging 1,6-
enyne and 1,7-allenene intermediates, but might also be performed in tandem with 
the subsequent cycloisomerization as well. Although [Rh(CO)2Cl]2 was not 
known to catalyze cycloisomerizations, the transformation has been reported with 
 3 
other Rh(I) catalysts and may therefore be viable. Such a domino sequence would 
be advantageous over current methods to prepare vinyl alkylidene cyclopentanes, 
fused bicyclic 1,4-dienes, and unsaturated medium-sized rings because it would 
remove the need to isolate and purify the intermediate enyne or allenene, and 
would not require the use of two transition metal catalysts. It would allow access 
to functionally complex carbo- and heterocycles from simple starting materials in 
a single chemical step. Additionally, the development of methods to catalyze 
sequential transition metal-mediated transformations in one pot is an extremely 
challenging and valuable goal and would broaden the current scope of tandem 
transition metal catalysis.11 
1.2 UNIQUE ALLYLIC ALKYLATION METHODOLOGY DEVELOPED IN THE 
MARTIN GROUP 
Transition metal-catalyzed allylic alkylations are a widely-utilized and 
broadly-studied class of reactions for carbon-carbon  and carbon-heteroatom bond 
formations.2, 9, 10  A variety of metals, including Pd, Mo, Ir, Rh, Ru, and W, have 
been reported to catalyze allylic alkylations.  
Typically, the regioselectivity of transition metal-catalyzed allylic 
alkylations arise from a metal-specific bias for either the less or more substituted 
terminus of the allylic substrate (Scheme 1.3). Ruthenium, molybdenum, 
rhodium, iridium, and tungsten typically favor substitution at the more hindered 
allylic terminus, whereas palladium often exhibits the opposite bias.2, 12 Although 
this is an established trend, it should be noted that these biases can be overcome in 















Previous investigations in the Martin group had revealed that the 
commercially available complex [Rh(CO)2Cl]2 catalyzes allylic alkylations with a 
unique regioselectivity distinct from the trends typically observed.14 Generally, 
[Rh(CO)2Cl]2-catalyzed allylic alkylations proceed with direct substitution of the 
leaving group, irrespective of the substitution at the allylic termini.14 These 
advantageous properties were utilized by the Martin group in a variety of 
[Rh(CO)2Cl]2-catalyzed allylic alkylations with a diverse array of substrates, 
thereby establishing [Rh(CO)2Cl]2 as a unique and broadly useful catalyst for 
















































































Additionally, [Rh(CO)2Cl]2-catalyzed allylations proceed with 
preservation of the E/Z stereochemistry (Table 1.1, entry 1) and enantiopurity of 












The mechanistic explanation for this unique regioselectivity has not yet  
been determined. However, some  insights may be found in the work of Andrew 
Evans who has observed similar regioselectivity in a very limited number of 
cases, using a catalyst derived from Rh(PPh3)Cl and phosphite ligands.
15 He 
proposed that a !+" “enyl” complex 1.25 or 1.28 is formed, that in the presence 


























Additionally, Evans found that enantiomeric excess was largely 
maintained in enantiomerically enriched allylic carbonates (Scheme 1.6). This 
result provided additional evidence that the reaction proceeds via an enyl 
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complex, as the corresponding ! species would have undergone rapid bond 
rotation, leading to erosion of the enantiomeric excess. According to Evans’s 
rationale, our similar observation that [Rh(CO)2Cl]2-catalyzed allylic alkylations 
proceed with retention of enantiomeric excess suggests that our catalytic cycle is 
proceeding via an enyl complex (Scheme 1.4). 
Scheme 1.6 
Me
 5 mol% Rh(PPh3)3Cl
NaCH(CO2Me)2






98% ee 90% ee
 
Although Evans’s observations are similar to our work, it is important to 
note that they were only seen in very specific cases, namely those in which steric 
biases did not overwhelm this “memory effect.” For example, when Evans 
submitted differentially substituted allylic carbonates 1.32 and 1.33 to the same 
reaction conditions, only 1.32 led to excellent selectivity in favor of the product 
arising from direct substitution of the leaving group (Scheme 1.7). In the case of 
1.33, the opposite regioselectivity was favored, indicating that substitution at the 
allylic termini can override the memory effect. This is contrasted by our work 
(Table 1.1, entries 2 and 3) in which differentially substituted allylic carbonates 
furnish products arising from direct substitution of the product, thus emphasizing 










 5 mol% Rh(PPh3)3Cl
NaCH(CO2Me)2





From 1.32 = 42:1, 99%






1.3 1,6-ENYNE CYCLOISOMERIZATIONS 
Enyne cycloisomerizations have also proven to be an extremely useful 
class of reactions, having been employed as key steps in a variety of natural 
product syntheses.6 The cyclization of enynes to 1,4-dienes in the absence of 
transition metal catalysts, also known as the intramolecular Alder-ene reaction, 
tends to be either extremely difficult or impossible, depending upon the substrate. 
In those cases where it can be performed, temperatures in excess of 400 ˚C are 
commonly necessitated.  The discovery that transition metals can catalyze this 
transformation at much lower temperatures has greatly broadened the scope and 
practicality of this reaction, resulting in its wide-spread use.  To date, a variety of 
metals have been used to catalyze the cycloisomerization of enynes, including 
palladium, rhodium, ruthenium, platinum, iridium, gold, and nickel-chromium 
complexes.7, 16-18 
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Of the variety of metals that catalyze enyne cycloisomerizations, 
palladium catalysis has been employed most frequently, with Trost contributing 
the bulk of the research in this area. One report involves the cycloisomerization of 
1.36 in the presence of a Pd(II) catalyst to yield 1.37 in 91% yield. This 
intermediate was elaborated into two natural products, sterepolide and merulidial 
(Scheme 1.8).4 Although both 1,3- and 1,4-dienes can be formed via Pd-catalysis, 
Trost observed that oxygen substitution at the allylic position facilitates the 
exclusive formation of 1,3-dienes, a characteristic that was exploited in the 


































Trost has also demonstrated that cyclic alkenes could be used in 
intramolecular 1,6-enyne Pd-catalyzed cycloisomerizations, enabling access to 
bicyclic intermediates. This reaction was highlighted in his syntheses of corianin, 
picrotoxinin, and pictrotin (Scheme 1.9).3, 6 In these examples, a 1,4-diene was 
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produced exclusively due to lack of a #-hydrogen atom that would allow access to 



































1.3.1 Rh(I)-Catalyzed 1,6-Enyne Cycloisomerizations 
Although 1,6-enyne cycloisomerizations catalyzed by [Rh(CO)2Cl]2 have 
not been explicitly reported, products arising from such reactions have been 
isolated in minor amounts in Pauson-Khand reactions catalyzed by 
[Rh(CO)2Cl]2.
19 In the broader area of Rh(I) catalysis, Zhang and coworkers have 
reported the cycloisomerization of 1,6-enynes with the cationic catalyst 
[Rh(dppb)]+, which was derived from [Rh(dppb)Cl]2 and AgSbF6 (Scheme 
1.10).20 Zhang successfully used this method to access heterocycles, as well as 







10 mol % [Rh(dppb)Cl]2





X = C(CO2Et)2, O, NSO2Ph
1.47 1.48
 
Zhang proposed a catalytic cycle similar to that reported by Trost.7 The 
first step is complexation of rhodium to both the alkene and alkyne moieties to 
form 1.50. Oxidative cyclization affords a metallocyclopentene intermediate 1.51, 
which undergoes #-hydride elimination to form either a 1,3- or 1,4-diene, 
although Zhang observed only the 1,4-diene product. Reductive elimination of 
1.52 furnishes the product 1.53 and regenerates the active catalyst. Zhang reported 
that a cationic catalyst is crucial because a highly coordinatively unsaturated 
environment is necessary for the formation of the metallacyclopentene 























     Elimination
IV. Reductive











1.4 1,7-ALLENENE CYCLOISOMERIZATIONS 
Itoh and coworkers have shown that 1,7-allenenes 1.54 and 1.55 undergo 
[Rh(CO)2Cl]2-catalyzed cycloisomerizations to produce unsaturated medium-
sized rings 1.56 and 1.57 (Scheme 1.11).8 Itoh found that use of a CO atmosphere 





1.54 R = H
1.55 R = Me
2.5 mol% [Rh(CO)2Cl]2
1,4-dioxane, reflux, 2 h
CO (1 atm)




1.57, 91%  
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Although the mechanism of this reaction is unknown, Itoh proposed a 
possible catalytic cycle (Figure 1.2). Itoh postulated that initial complexation of 
rhodium to the terminal alkene and inner double bond of the allene affords 1.59. 
Allylic C-H activation furnishes 1.60, which undergoes cyclization and 
carbometallation to provide 1.61. Finally, a reductive elimination occurs to yield 
the observed product 1.62. Itoh did not remark on the selectivity of the reductive 






































1.5 TANDEM CATALYSIS 
Tandem catalysis has been defined by Bazan and coworkers as “synthetic 
strategies that involve the sequential use of catalytic reactions with minimal 
change in conditions.”21 The product of the first catalytic cycle becomes the 
reactant for the second catalytic cycle (Scheme 1.12) and can involve single or 







An example of tandem catalysis employing a single catalyst has been 
reported by Wren and coworkers, 22 in which an Ir-catalyzed hydroamination 
furnished an imine intermediate 1.64, which then participated in an Ir-catalyzed 













Choudary has reported an example of tandem catalysis employing 
multiple catalysts embedded in a layered double-hydroxide (LDH) matrix. Using 
Na2PdCl4, K2OsO4, and Na2WO4, Choudary created a trifunctional LDH-
embedded catalyst that facilitated a Heck coupling, asymmetric dihydroxylation, 
and oxidation of N-methylmorpholine to N-methylmorpholine N-oxide (Scheme 




























The advantages to using tandem catalysis are numerous. Product yields 
can be greatly increased due to the avoidance of the isolation and purification of 
intermediates.  In those cases when such intermediates are dangerous and highly 
reactive, this advantage results in increased personal and environmental safety. In 
addition, limitations presented by equilibrium-limited reactions can be overcome 
if they are performed in tandem with subsequent reactive catalytic cycles. In those 
cases, rapid consumption of the intermediate facilitates a constant funnelling of 
starting material into product in the equilibrium-limited process. 
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1.6 COMBINING ALLYLIC ALKYLATIONS WITH OTHER PROCESSES 
By combining our allylic alkylation methodology with other rhodium(I)-
catalyzed transformations, we  envisioned that [Rh(CO)2Cl]2  might be used to 
catalyze mechanistically distinct transformations in novel domino reaction 
sequences. Since propargyl malonates had been shown to be compatible 
nucleophiles in the allylic alkylation step, we could easily access intermediate 
1,6-enynes, which are known to undergo Rh(I)-catalyzed carbocyclizations, 
including Pauson-Khand reactions,23, 24 enyne cycloisomerizations,25 and [5+2] 
cycloadditions.26, 27 We envisioned three tandem sequences involving an initial 
allylic alkylation with a propargyl malonate, followed by one of several 



















































The three proposed tandem sequences share mechanistic similarities, 
insomuch as they have all been proposed to proceed via a metallocyclopentene 
intermediate (Figure 1.3). From this common intermediate, divergent pathways 
are available depending upon the nature of the R’ group and the reaction 
conditions. If R’ is a cyclopropyl group, then a [5+2] cycloaddition will 
commence. If R’ is an alkyl group or hydrogen, the reaction conditions will 
determine the ensuing pathway. Namely, under a CO atmosphere a Pauson-Khand 
reaction will occur, whereas in the absence of a CO atmosphere, an enyne 
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A tandem allylic alkylation/[5+2] cycloaddition has not been reported 
previously, and only one example of a tandem allylic alkylation/1,6-enyne 
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cycloisomerization has been reported by Trost. However, the chemistry reported 
by Trost suffers from the need to employ multiple catalysts (Scheme 1.16). Our 
strategy, on the other hand, seeks to use a single catalyst to perform 
mechanistically distinct transformations, which would offer much greater atom 
economy and efficiency than Trost’s method. 
Scheme 1.16 
5 mol % Pd(PPh3)4
THF



















Evans reported a tandem Rh-catalyzed allylic alkylation/Pauson-Khand 
with the use of [RhCl(CO)dppp]2 (Scheme 1.17).
28 The use of our methodology in 
such a sequence would offer increased practicality with the use of ligand-free 









R = H, Ph, Me
X = CH(CO2Me)2, O, NTs
M= Na, Li




1.7 ALLYLIC ALKYLATION/PAUSON-KHAND SEQUENCE 
The [Rh(CO)2Cl]2-catalyzed allylic alkylation/Pauson-Khand tandem 
sequence was developed by Kenny Miller. Several propargyl malonates added 
successfully to allylic trifluoroacetate 1.94 and subsequent heating under a carbon 








1.95, R = H
1.96, R = Ph
1.21, R = Me
10 mol% [Rh(CO)2Cl]2, NaH







1.97, R = H (THF, 73%)
1.98, R = Ph (THF, 68%)
1.99, R = Me (Bu2O, 67%)  
When substituted allylic trifluoroacetates were used, low yields of Pauson-
Khand adducts could be obtained with microwave heating (Scheme 1.19). This 
result is important as the allylic alkylation of 1.100 with Evans’s conditions 







10 mol% [Rh(CO)2Cl]2, NaH









1.8 ALLYLIC ALKYLATION/[5+2] CYCLOADDITION SEQUENCE 
The [Rh(CO)2Cl]2-catalyzed allylic alkylation/Pauson-Khand tandem 
sequence was developed by Brandon Ashfeld. Excellent yields were obtained for 
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the sequence with both racemic and chiral allylic substrates (Table 1.2).29 Regio- 
and diasteroselectivities observed were consistent with prior work reported by 













































n/a = not applicable  
1.9 DEVELOPMENT OF  [RH(CO)2CL]2-CATALYZED TANDEM ALLYLIC 
ALKYLATION/CYCLOISOMERIZATION SEQUENCES 
As the cycloisomerization of 1,6-enynes with a neutral Rh(I) species, such 
as [Rh(CO)2Cl]2, is unprecedented, our initial studies of a tandem allylic 
alkylation/cycloisomerization sequence began by establishing the efficacy of this 
single transformation. Enyne 1.113 was prepared from the reaction of malonate 
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1.112 with allylic bromide 1.110 in the presence of sodium hydride.   Malonate 
1.112 was prepared from the corresponding mesylate 1.111, and 1.110 was 

























Because Zhang had reported that cycloisomerizations of enynes can 
proceed at room temperature with cationic Rh(I) catalysts, the cycloisomerization 
of 1.113 was first attempted at room temperature in a variety of solvents with 10 
mol% of  [Rh(CO)2Cl]2 (Scheme 1.21).  This reaction failed to yield product, and 
only starting material was recovered.  The temperature of the reaction was 







rt  to 80 ºC
X
1.113 1.114
Solvents Screened:  DMF, THF, PhMe, CH3CN, DCE  
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More forcing conditions were employed until finally we found that when 
1.113 was heated in toluene or acetonitrile at 110 ˚C in a sealed vial, efficient 
conversion to the cycloisomerization product 1.114 was observed (Scheme 1.22).  
A minor amount (4%) of the conjugated diene 1.115 was also observed. This 
result represents the first 1,6-enyne cycloisomerization catalyzed by a neutral 

















1.9.1 Combining the Allylic Alkylation and Enyne Cycloisomerization 
We next focused on performing both the allylic alkylation and 
cycloisomerization in one pot.  Allylic carbonates cis- and trans-1.116 were both 
employed in order to probe the effect of E/Z stereochemistry upon the 
cycloisomerization. Despite prolonged reaction times, the domino sequence with 
both of these carbonates were unsuccessful, and only the intermediate enyne 


























2.0 Eq. 1.0 Eq.
 
This result was not entirely unexpected as both Kenny Miller and Brandon 
Ashfeld had found that the allylic alkylation/Pauson Khand and allylic 
alkylation/[5 + 2] cycloaddition domino sequences necessitated the use of an 
allylic trifluoroacetate to proceed with high efficiency. The use of allylic 
carbonates in those domino sequences failed to yield the desired products. 
Although the reason for this incompatibility of allylic carbonates with tandem 
catalysis is not entirely understood, it was postulated that the carbonate released 
in the allylic alkylation step might act as a ligand, thereby altering the metal 
species such that it no longer catalyzes the subsequent carbocyclization.   
In light of these findings, the domino sequence was next attempted with 
the allylic trifluoroacetates cis- and trans-1.117, which were prepared from the 
corresponding alcohols immediately prior to use.  Unfortunately, these reactions 
also failed to yield cycloisomerization product, and only the intermediate enyne 





















2.0 Eq. 1.0 Eq.
 
Zhang had reported that only Z-enynes undergo [Rh(dppb)]+-catalyzed 
cycloisomerizations, so we decided to optimize the allylic alkylation step to 
preserve the Z stereochemistry of the starting substrate 1.117.  An excellent 
cis/trans ratio of greater than 95:5 was achieved in acetonitrile at –40˚C (Scheme 
1.25). Toluene was a poor solvent for this reaction because the malonate ion was 












     0 ºC, 1 h., 3:1 cis/trans ratio
 !20 ºC, 1 h., 5:1/cis trans ratio
 !40 ºC, 4 h., >95:5 cis/trans ratio  
Using these optimized conditions for the allylic alkylation step, the 
domino sequence proceeded in moderate yield for the first time, indicating that 
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preservation of the Z stereochemistry was indeed crucial to the success of the 
reaction (Scheme 1.26).   Along with a 30% yield of the desired product 1.114, a 
minor amount of the Pauson-Khand product (1.118) was isolated, as well as a 







10 mol % [Rh(CO)2Cl]2
NaH, CH3CN, –40 ºC
















30% 5%  
Doubling the catalyst loading did not increase conversion to the product, 
and extended heating times led to decomposition of the intermediate 1.113.  
Interestingly, although doubling the initial catalyst loading did not lead to 
increased yield, adding an additional 10 mol% of catalyst before the second step 
led to a dramatic increase in yield (Scheme 1.27).  This result indicated that the 
catalytic species resulting from the first catalytic cycle was altered in such a way 










10 mol % [Rh(CO)2Cl]2
NaH, CH3CN, –40 ºC
110 ºC, 45 min











The optimized reaction conditions for the allylic alkylation step included 
the use of excess malonate in order to achieve high yields of product. However, it 
seemed possible that while excess malonate was advantageous for the first 
catalytic cycle, it might be thwarting the second catalytic cycle, perhaps via 
coordination to the rhodium catalyst. Kenny Miller had also observed that the 
presence of malonate resulted in diminished yields in the [Rh(CO)2Cl]2-catalyzed 


































In order to limit the amount of malonate present in the reaction, the 
stoichiometry of the starting materials was inverted, and the allylic 
trifluoroacetate 1.117 was used in excess. In the event, the entire domino reaction 
proceeded in 72% yield with only 10 mol% catalyst (Scheme 1.28).29 A range of 
stoichiometric equivalencies was screened, and the highest yield (72%) was 
obtained by using a two to one ratio of the trifluoroacetate to the malonate, thus 














10 mol % [Rh(CO)2Cl]2
NaH, CH3CN, –40 ºC











Although 1.114 had not been previously synthesized, similar compounds 
have been synthesized via transition metal-mediated enyne cycloisomerizations 
from the corresponding 1,6-enynes.20, 31, 32 Enyne cycloisomerization is the most 
frequently utilized synthetic approach to compounds of this type due to the 
extraordinary efficiency of the reaction. Our approach represents the first tandem 
allylic alkylation/cycloisomerization sequence used to synthesize vinyl alkylidene 
cyclopentanes. Although the first step could have been achieved via a simple SN2 
reaction (Scheme 1.20), this sequence has potential for application to substrates 
such as 1.120, that would not be amenable to classical substitutions (Scheme 
1.29). Furthermore, the ability of [Rh(CO)2Cl]2 to preserve Z stereochemistry in 
the allylic alkylation step is critical because a Z-enyne is required for efficient 
cycloisomerization. Because many transition metal catalysts isomerize double 
bonds in allylic alkylations, the use of our method for the construction of vinyl 













R,R' = Alkyl, aryl, OPG, NPG





X = CH(CO2Me)2, 
      NHPG, NHAr,OH
Ar = aryl
 
In addition to the efficient synthesis of 1.114, the importance of this 
results is underscored by the fact that there are few examples of the promotion of 
sequential, mechanistically-distinct reactions by a single transition metal 
catalyst.11 Furthermore, the absence of additives and ligands contributes to the 
operational simplicity of this methodology. 
1.9.2 Accessing Bicyclic Compounds 
The success of this reaction led us to explore synthetic variations that 
would allow access to other core structures. The formation of fused bicyclic 
compounds via tandem allylic alkylation/cycloisomerization was investigated 
with the allylic trifluoroacetate 1.124 and propargylic malonate 1.21.  As was 
observed with the domino sequence to furnish 1.114, an excess of the malonate 
led to incomplete conversion of intermediate enyne 1.125 to the desired product 












 10 mol % [Rh(CO)2Cl]2
CH3CN




  30 min.









In an effort to determine the efficiency of the second step, the enyne 
cycloisomerization was examined separately. In the event, it was found that the 
desired bicyclic adduct could be obtained in quantitative yield as a single isomer 





MeO2C10 mol % [Rh(CO)2Cl]2
MW, 110 ºC
CH3CN, 15 min
quant1.125 1.126  
In trials using an excess of the trifluoroacetate, the yields of the bicyclic 
product were found to be highly sensitive to the stoichiometric ratio of the allylic 
trifluoroacetate 1.124 to the propargylic malonate 1.21; the optimum ratio was 
1.5:1.0 (Scheme 1.32).33 Although the desired product was always the major 
product, double bond isomers were invariably isolated. The use of microwave 
heating minimized the amount of additional isomers, but not completely. A range 
of heating times ranging from 4 hours to 15 minutes was explored in an attempt to 
minimize isomerization. Although the yield did not decrease with shortened 
reaction times, neither did the number of isomers produced.   Reaction times less 
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than 30 minutes resulted in greatly diminished yields, as did performing the 










 10 mol % [Rh(CO)2Cl]2
CH3CN, 25 ºC (1h), then
110 ºC (30 min, µwave, 300 W)












In an effort to access heterocyclic fused bicycles, it was desirable to 
examine the use of heteroatom-nucleophiles with allylic trifluoroacetate 1.124. 
Towards that end, the reaction of propargylamine 1.130 with 1.129 was first 
studied (Scheme 1.33).  Tetrabutylammonium iodide (TBAI) was used as an 
additive based upon work performed by Kenny Miller, who found that TBAI was 
necessary to avoid complexation of the amine with the rhodium catalyst. Despite 
the use of forcing conditions, none of the desired product 1.131 was obtained. 














6 mol % [Rh(CO)2Cl]2
12 mol %TBAI
30 min, rt
30 min, 110 ºC, µwave, 300 W
DCE
X
1.0 Eq. 2.0 Eq.  
When the allylic alkylation was attempted with the corresponding allylic 
trichloroacetate 1.132 and propargylamine 1.130 in a variety of solvents, none of 
the desired product was obtained. Rather the trichloroacetamide 1.133 was 
consistently obtained in 36% to 52% yields (Table 1.4).  This product presumably 
arises from nucleophilic addition of the amine to the carbonyl group of the 
trichloroacetate, followed by loss of 2-cyclohexen-1-ol. Kenny Miller had also 





































THF 30 min at 23 ºC, then
30 min at 110 ºC (µwave, 300W)
39
CH3CN
30 min at 23 ºC, then
30 min at 110 ºC (µwave, 300W)
 52
30 min at 23 ºC, then
30 min at 110 ºC (µwave, 300W)
PhMe  36








The incompatibility of heteroatom-nucleophiles with the allylic alkylation 
of cyclic allylic trifluoroacetates, as well as the 40-65% yields observed for the 
domino sequence furnishing 1.126, indicate that this method is not the ideal 
synthetic approach to fused bicycles. Due to the lack of success in this area, 
further investigations with cyclic allylic substrates were not pursued.  
1.9.3 Allenic Alkylation/Cycloisomerization Sequences 
In light of Itoh’s findings, an allenic alkylation/cycloisomerization domino 
sequence was envisioned that would convert allenes into medium-sized rings in 
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one pot (Figure 1.4). As allenic alkylations had not been reported with 
[Rh(CO)2Cl]2, the development of such chemistry would also broaden our 
existing allylic alkylation methodology. Hence the first task was to develop 
conditions for the [Rh(CO)2Cl]2–catalyzed allylic alkylation of allenic substrates. 
Figure 1.4 
E = CO2Me


















Allenic alcohol 1.142 was first made according to known literature 
procedures in four steps from the TBS-protected propargyl alcohol 1.138 (Scheme 
1.34). 34 Allenic carbonate 1.143 was formed in 95% yield by reaction of 1.142 











    nBuLi, –78 ˚C;



























1.142 1.143  
[Rh(CO)2Cl]2-catalyzed allylic alkylation of allenic carbonate 1.143 with 
malonates 1.144 and 1.145 proceeded smoothly to provide the corresponding 
allenenes 1.130 and 1.131 in 80% and 83% yields respectively (Scheme 1.35). 












1.144 1.54, R = H, 80%














The domino sequence was attempted with the allenic carbonate in 
refluxing THF, but only the intermediate allenene 1.54 was recovered (Scheme 



















1.0 Eq. 2.0 Eq.
 
Based upon our prior success with allylic trifluoroacetates, the allenic 
trifluoroacetate 1.147 was employed as a substrate. The trifluoroacetate 1.147 was 
unstable and could not be purified, so the crude material was used.  The solvent 
was changed to acetonitrile, and the reaction was heated to 110 ˚C in a sealed vial, 
but the domino sequence did not furnish the desired product 1.137 (Scheme 1.37). 
Additionally, the malonates 1.144 and 1.145 were the only materials recovered 
from the reaction. When the allylic alkylation of 1.147 with 1.145 was attempted 

































In consideration of the instability of the allenic trifluoroacetate 1.147 to 
purification, as well as the modest yield obtained in the allylic alkylation step, we 
explored the use of other allenic substrates. Because carbonate leaving groups had 
inhibited other domino sequences, we sought to use a leaving group that was 
electronically similar to the trifluoroacetate group. Towards that end, allenic 
trichloroacetate 1.148 was identified and prepared in 85% yield from the 
corresponding allenic alcohol 1.142 in the presence of triethylamine and 







0 ˚C, 30 min
•
OCOCCl3
1.1481.142 85%   
Using allenic trichloroacetate 1.148 and an excess of malonate 1.144, the 
domino sequence was attempted, but only the intermediate allenene 1.54 and 








NaH (2.0 Eq.), 















As we had not independently verified that the cycloisomerization reaction 
would proceed in acetonitrile at 110 ˚C, the cycloisomerization reaction was 
investigated separately.  In the event, we found that cycloisomerization proceeded 





10 mol % [Rh(CO)2Cl]2
CH3CN
110 ˚C
Trial 1: 15 min.
Trial 2: 30 min.
1.561.54
Trial 1: 80%, 100% conversion
Trial 2: 60%, 100% conversion  
Based upon these findings, the allenic alkylation/cycloisomerization 
domino sequence was again attempted with abbreviated heating times (Scheme 









NaH (2.0 Eq.) 















 In consideration of our earlier findings that the use of excess malonate 
inhibited the allylic alkylation/enyne cycloisomerization, the domino sequence 
was attempted with an excess of the allenic trichloroacetate (Scheme 1.42). 







NaH (1.0 Eq.), 













1.5 Eq. 1.0 Eq.
 
Based upon Zhang’s report that cationic rhodium catalysts are effective 
promoters of enyne cycloisomerization, we explored the generation of a cationic 
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species from  [Rh(CO)2Cl]2. Cationic transition metal species are often generated 
by the abstraction of a halogen atom from a neutral metal catalyst, with the 
assistance of a silver salt (Equation 1.1). The generation of a cationic metal 
species is facilitated by electron-rich ligands that stabilize the resultant positive 
charge. However, [Rh(CO)2Cl]2 is a poor candidate for such a transformation due 
to the electron-withdrawing nature of the CO ligands.  However, a simple ligand 
exchange, in which the CO ligands are replaced by phosphine ligands, can easily 
remedy this problem.  Thus, in order to generate a cationic rhodium species from 
[Rh(CO)2Cl]2, triphenylphosphine and the silver salt were sequentially added.  As 
there is no need for a cationic species in the first step of the domino sequence, 
initial experiments were performed in which the triphenylphosphine and silver 
hexafluoroantimonate were added immediately before the cycloisomerization 
step.  However, these conditions only led to a low recovery of the starting 
malonate and intermediate allenene (Scheme 1.43). 
Equation 1.1 
MLnX + AgSbF6 [MLn] AgX+
X = halide
[SbF6]


















20 mol % PPh3
30 mol % AgSbF6
110 ºC (15 min to 1 h) or









1.0 Eq. 1.5 Eq.
 
Variations on the timing of the addition of the phosphine ligand and silver 
salt were examined. When triphenylphosphine was added prior to the allylic 
alkylation and AgSbF6 was added prior to the cycloisomerization, none of the 
desired product was isolated. However, when both the ligand and silver salt were 
added in the first step a 55% yield of the desired product was isolated (Scheme 
















10 mol % [Rh(CO)2Cl]2
20 mol % PPh3
















1.0 Eq. 1.5 Eq.
 
It was reported by Ito that slightly higher yields of allene-ene 
cycloisomerization products could be obtained under a carbon monoxide 
atmosphere rather than an argon atmosphere.8 Accordingly, the domino sequence 
was conducted under a CO atmosphere and, to our delight, the desired products 
1.56 and 1.57 were formed in 72% and 75% yields, respectively (Scheme 1.45). 












10 mol % [Rh(CO)2Cl]2
20 mol % PPh3














1.153, R = H




1.54, R = H
1.55, R = Me
1.56, R = H, 72%




Although neither 1.56 nor 1.57 have been elaborated to natural products, 
unsaturated seven-membered rings are found in numerous sesquiterpenoid and 
diterpene natural products, making the efficient construction of such rings an 
important undertaking.1 The tandem allenic alkylation/cycloisomerization 
sequence offers an atom economical approach to medium-sized carbocycles and 
has the potential for elaboration to heterocycles with the employment of 
heteroatom-nucleophiles. Although the sequence to furnish 1.56 and 1.57 could 
also be performed efficiently in two steps using a classical substitution reaction 
rather than an allylic alkylation as the first step, the domino sequence would be 
particularly useful with allenic substrates such as 1.155, for which substitution via 









10 mol % [Rh(CO)2Cl]2
20 mol % PPh3

















R,R' = alkyl, aryl
           N(R)PG, OPG
X = CH(CO2Me)2,







1.9.4 Allenic Alkylations with Heteronucleophiles 
The compatibility of heteronucleophiles with allenic substrates in 
[Rh(CO)2Cl]2-catalyzed allylic alkylations was examined with allenic carbonate 
1.143 and several heteronucleophiles, including pyrrolidine, benzylamine, N-
methylaniline, and o-phenylphenol (Table 1.5).  Although the reactions with 
pyrrolidine and benzylamine did not give the desired products, the reaction of N-
methylaniline with allenic carbonate 1.143 produced the aniline 1.164 in 99% 
yield and >95:5 regioselectivity (Table 1.5, entry 3).  To our further delight, it was 
discovered that o-phenylphenol 1.165 also reacted with allenic carbonate 1.143 to 




























Entry Nucleophile Conditions PDT Yield(%)
01
2







CH3CN  >99:5 regioselectivity
3
LiHMDS, CuI











Although such substrates cannot be elaborated to cyclized products, if 
functionalized nucleophiles such as 1.168 were used, then medium-sized rings 
containing enamine functionality could be accessed with the tandem allenic 
alkylation/cycloisomerization sequence (Scheme 1.47). Although we did not 
pursue these reactions, we have established proof of principle for the viability of 
















10 mol % [Rh(CO)2Cl]2
20 mol % PPh3
30 mol % AgSbF6







1.10 SUMMARY AND CONCLUSIONS 
Several novel [Rh(CO)2Cl]2-catalyzed allylic 
alkylation/cycloisomerization tandem sequences were developed that access 
complex molecules from simple starting materials in one pot. Both the allylic 
alkylation/enyne cycloisomerization and allenic alkylation/cycloisomerization 
tandem sequences are unprecedented.  
The success of the domino sequences was dependent upon the nature of 
the allylic substrate, failing when allylic or allenic carbonates were employed. 
The reason for this may be due to an interaction between the carbonate and the 
rhodium catalyst, altering its reactivity such that it cannot promote the subsequent 
catalytic cycle. This problem was overcome by using allylic trifluoroacetates or, 
in the case of allenic substrates, using allenic trichloroacetates.  
The stoichiometry of the malonate and allylic substrate proved to be 
greatly important in the allylic alkylation/enyne cycloisomerization sequence, 
with excess malonate resulting in significantly diminished yields of cycloadducts. 
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By using an excess of the allylic trifluoroacetate, a good yield of the desired 
adduct could be attained. Cyclic allylic substrates are much less amenable to 
allylic alkylation with [Rh(CO)2Cl]2, in comparison to their acyclic counterparts. 
This observation is consistent with Takeuchi’s reports using iridium catalysts and 
indicates that this methodology is not the ideal synthetic approach to fused 
bicyclic compounds. 
The allenic alkylation/cycloisomerization sequence necessitated the 
formation of a cationic rhodium catalyst in situ, but led to good yields of medium-
sized rings under an atmosphere of carbon monoxide. Novel allenic alkylations 
were established that proceed with excellent regioselectivity and yields. In 
addition to stabilized carbon nucleophiles, oxygen and nitrogen nucleophiles are 
amenable to the alkylation of allenes. These results not only broaden the scope of 
our [Rh(CO)2Cl]2-catalyzed allylic alkylation methodology, but also establish 
proof of principle for the viability of allenic alkylation/cycloisomerization 
sequences to furnish heterocycles.  
The possibilities of using the established domino sequences with diverse 
allylic compounds and nucleophiles are numerous. Such sequences could be 
applied to the concise synthesis of a variety of cyclic scaffolds.  In addition, such 
tandem processes are often used in library synthesis and the incorporation of these 
reactions into a library synthesis could lead to a diverse array of functionally 




 Chapter 2: Enantioselective Conjugate Addition Employing 2-
Heteroaryl Nucleophiles 
2.1.  INTRODUCTION 
In the context of ongoing efforts in the Martin Group towards the total 
synthesis of cortistatin A, it was necessary to add a furan-2-yl nucleophile 
enantioselectively to 2-cyclopenten-1-one via a 1,4-addition (Scheme 2.1).  
However, at the time this work was initiated, there were no known reports of such 
a transformation.  Indeed, there were no reported methods for the enantioselective 
1,4-addition of any 2-heteroaryl nucleophiles to Michael acceptors, despite the 
wide prevalence of heteroaromatic compounds in drug-like molecules and the 
general utility that such a method would offer to both synthetic and medicinal 































The establishment of such a method would be applicable not only to the 
Martin Group’s synthesis of cortistatin A, but to a number of other biologically 
relevant molecules as well, such as Merck & Co.’s recently patented series of 
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niacin receptor agonists (Figure 2.1).35 These compounds are potential drugs for 



























These compounds are currently synthesized as racemic mixtures via multi-
step syntheses.  Merck’s synthetic route to pyrazole 2.8 consists of eight steps 













































In the case of oxazole-substituted pyrazole 2.13, the synthetic sequence is 
much shorter and proceeds through a 3-(5-methyloxazol-2-yl)cyclopentanone 






















If it were possible to add a thiophen-2-yl nucleophile enantioselectively to 
2-cyclopenten-1-one, then the 3-(5-methylthiophene-2-yl)cyclopentanone 
intermediate 2.17 could be accessed in only one step. By employing the same 
final step used by Merck to synthesize pyrazole 2.13 from intermediate 2.14, both 













In addition to Merck’s niacin agonists, UCB patented 2.18, an 
anticonvulsant with applications in treating neurological disorders such as 
epilepsy. The structure contains a #-thiophen-2-yl lactam, which could be 
accessed via an enantioselective 1,4-addition of thiophene to a five-membered  













2.2 RACEMIC CONJUGATE ADDITION METHODOLOGIES EMPLOYING 
HETEROAROMATIC NUCLEOPHILES 
Two dominant approaches to adding heteroaromatic nucleophiles to 
enones have been reported in the literature.  The first approach involves lithiation 
of the heteroaromatic compound followed by transmetallation to a metal, usually 
zinc or copper (Scheme 2.5).  The newly formed organometallic reagent is then 
added to a Michael acceptor, with or without the assistance of a Lewis acid. The 
second approach is simply a classical Friedel-Crafts alkylation and requires the 





























2.2.1 Lithiation/Metalation Approach 
There are several reports that apply the lithiation/metalation approach to 
the racemic 1,4-addition of heteroaromatic nucleophiles to Michael acceptors. 
Lipshutz has added higher order furan-2-yl cyanocuprates, which were prepared 
from 2-lithiofuran and copper cyanide, to 5- and 6-membered enones, achieving 
moderate yields of products.37  
Knochel has reported a general method for the addition of mixed 
diorganozincs to 2-cylcohexen-1-one, in the presence of TMSBr.38 The 
heteroaromatic nucleophiles are prepared by lithiation at the 2-position and 
subsequent transmetallation to trimethylsilylmethylzinc bromide. A variety of 2-
heteroaryl nucleophiles can be used, including pyrrol-2-yl, thiophen-2-yl, furan-2-











2.26, X = O, 73%
2.27, X = S, 58%












–30 ˚C to RT, 12 h
2.29, X = O, 85%
2.30, X = S, 59%
2.31, X = NMe, 78%  
Although no enantioselective variants of the lithiation/metalation approach 
exist, Ribagorda and coworkers have reported two examples of a 
diastereoselective 1,4-addition of 2-heteroaryldimethylaluminum nucleophiles to 
the meso, pro-chiral cyclohexadienone derivative 2.32.39 The aluminum 
compounds are prepared via lithiation of the corresponding heteroaryl compound 
and subsequent in situ transmetallation to aluminum with AlMe2Cl.  Using this 
method, both benzofuran-2-yl- and thiophen-2-ylaluminum reagents were added 
to compound 2.32 in good yield and modest diastereomeric ratio (4:1) (Table 2.1, 
entries 1 and 2).  In the case of the pyrid-3-ylaluminum substrate 2.37, both the 
yield and diastereomeric ratio were poor (Table 2.1, entry 3).  One limitation of 









































2.2.2 Friedel-Crafts Approach 
Furan compounds are also viable Friedel-Crafts partners, and the 
conjugate addition of furans to enones can be induced in the presence of a Lewis 
acid. Furan is a highly reactive nuclephile, which has historically been 
problematic in Friedel-Crafts alkylation reactions due to polymerization side-
reactions that reduce product yields.  More recent reports, however, indicate that 
this limitation can be overcome by simply using mild conditions.40  
Kraus has reported the addition of furan derivatives to enones in the 
presence of stoichiometric TMSI.41 One advantage of Kraus’s method is that 
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either the silyl enol ether or ketone product can be selectively isolated, depending 
upon the workup conditions. 
Heteroaromatic compounds other than furan have also been employed in 
Friedel-Crafts conjugate addition reactions.  Indole, for example, has been widely 
used, but will preferentially react at the C3-position.  Pyrrole, on the other hand, 
will react smoothly at the 2-position, as will thiophene.42 Benzofuran and 
benzothiophene have not been reported to be effective partners in Friedel-Crafts 
reactions.  Common reported problems with these Friedel-Crafts reactions include 
polyalkylation, polymerization, and low regioselectivity when two or more 
reactive sites are available.  
A few enantioselective Friedel-Crafts methods have been published that 
utilize heteroaryl compounds.43, 44 These methods limit the acceptor to either $,#-
usaturated aldehydes (Scheme 2.8) or unsaturated 2-acyl imidazoles (Scheme 2.9) 
and the nucleophile scope is limited to pyrrole and indole.  There are no examples 























































,   H2O
2.46
79% yield; 72% ee
 
2.3 ENANTIOSELECTIVE CONJUGATE ADDITION EMPLOYING TRANSITION 
METAL CATALYSIS 
 To date the most promising work in the area of enantioselective conjugate 
addition has emerged from the field of transition metal catalysis.  A variety of 
transition metals have been employed, including ruthenium, iridium, nickel, 
palladium, rhodium, and copper,45 and as a result there are currently a large 
number of methods that produce enantioenriched #-alkyl and #-aryl carbonyl 
compounds.  The methods most relevant to our synthetic goals have employed 
palladium and rhodium catalysts, although copper catalysts have been used to a 
lesser extent. 
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2.3.1 Copper Catalysis 
The majority of the seminal work in the area of copper-catalyzed 
conjugate addition methodology has focused on dialkylzinc nucleophiles,46-51 with 
far fewer reports using diphenylzinc nucleophiles.52-54 Most of the prolific 
research in this area has been focused on ligand design, not on developing the 
nucleophile or acceptor scope, and has most frequently employed diethylzinc as 
the sole nucleophile and either chalcone or 2-cyclohexen-1-one as the sole 
acceptor.  Of the several hundred ligands that have been developed to date, the 
most popular and successful ligands include Feringa’s phosphoramidite ligands 
and Hoveyda’s modular peptide ligands (Figure 2.3). Copper sources include a 
wide range of both Cu(I) and Cu(II) salts, with Cu(OTf)2 being the most 

































Although much of the work reported in the area of Cu-catalyzed conjugate 
additions is limited to the use of dialkylzinc reagents, recent progress has been 
made in expanding the nucleophile scope to include aryl substrates. Towards that 
end, there are now several examples that employ diphenylzinc reagents, although 
the scope of the phenyl ring is still somewhat unexplored and there are no 
examples to date using heteroaromatic substrates. In this area, Hoveyda has 
successfully added diphenylzinc reagents to #-disubstituted 2-cylcohexen-1-one 
and 2-cyclohepten-1-one acceptors in high yields and excellent ee (Scheme 2.10) 
with the use of a chiral bidentate N-heterocyclic carbene silver complex 2.52 
(Figure 2.4).55 Although impressive, this method does have its limitations in that it 
is incompatible with 2-cyclopenten-1-one, a Michael acceptor that has a long 




chiral NHC complex 2.52
3 eq. Ph2Zn, 2.5-5 mol % (CuOTf)2 C6H6





n = 1: 95% yield; 97% ee
n = 2: 88% yield; 96% ee









Recently, Hoveyda was able to overcome this limitation by using phenyl 
aluminum reagents instead of diphenylzinc,56 which were prepared in the same 
way as Ribagorda’s protocol.39 These more reactive aryl nucleophiles were added 













2.5 mol %chiral NHC complex 2.52
3 eq. Me2(Ar)Al, 5 mol % (CuOTf)2
























Alexakis has recently published a similar method employing 
phenylaluminum reagents and a catalyst system derived from copper 
thiophenecarboxylate (CuTC) and the phosphoramidite ligand 2.57.57 Alexakis 
only reported one example of an aryl addition to 3-methylcyclopent-2-one.  In the 
event, phenyldiethylaluminum was added in the presence of 10 mol % of CuTC 












10 mol % CuTC, 11 mol % 2.57
3 eq. PhEt2Al, 





n = 1, R = sec-Butyl: 58% yield; 98.6% ee






R R = 2-napthyl
 
In addition to phenylzinc and phenylaluminum reagents, phenyl Grignard 
reagents have been employed with copper catalysts, albeit to a lesser degree and 
with limited nucleophile and electrophile scope.58   
2.3.2 Palladium Catalysis 
The palladium-catalyzed addition of aryl nucleophiles to 2-cyclopenten-1-
one has been quite useful. Miyaura, the leader in this field, has successfully used 
dicationic benzonitrile palladium(II) complexes with a variety of aryl 
nucleophiles, including aryl boronic acids, aryl trifluoroborates, aryl bismuth, and 
aryl silicon reagents to achieve highly enantioselective 1,4-additions to a variety 
of enones (Table 2.3).59, 60 In the case of triarylbismuths (method D), the active 
catalyst is a highly electrophilic nitrile-free catalyst, generated in situ in the 
presence of Cu(BF4)2, via ligand exchange of the benzonitrile and the copper salt. 
In the case of aryltrifluoroborates (method B), the addition of a copper salt is 
unnecessary to generate the active catalyst, because the BF3 released in the 
reaction serves the same purpose. In contrast, aryl boronic acids are reactive 
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enough that a nitrile-free catalyst is not necessary.  The presence of AgBF4 in 


























































A: ArB(OH)2, [Pd(L)PhCN)2](SbF6)2, AgBF4, acetone-H2O, 0 ˚C
B: [ArBF3]K, [Pd(L)PhCN)2](SbF6)2, MeOH-H2O, –15!5 ˚C
C: ArSiF3, [Pd(L)PhCN)2](SbF6)2, ZnF2, MeOH-H2O, 0!5 ˚C










 Minnaard and co-workers have used a catalyst derived from palladium 
trifluoroacetate and Me-DUPHOS to transfer a variety of electron-neutral and 
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electron-rich aryl boronic acids to enones.62 Minnaard’s method is also 
compatibile with 2-cyclopenten-1-one, furnishing adducts in 82% ee. 
2.3.3 Rhodium Catalysis 
The field of rhodium catalysis has produced the most relevant methods to 
our synthetic goals. In particular, Hayashi has used a variety of aryl sources, 
including aryl boronic acids, aryl titanium reagents, and arylzinc chlorides with a 
variety of Rh(I) catalysts (Table 2.4).63-69 In all of Hayashi’s examples, reactions 
with 2-cyclopenten-1-one proceeded in high yields and excellent ee’s, far superior 
to both the copper- and palladium-catalyzed methods. In many cases, Hayashi has 
























R = H, 4-CF3, 4-OMe
M [Rh] Temp. Ar–M Eq. Solvent Yield (%) ee (%)Entry
1a B(OH)2 [Rh(acac)(C2H4)2]/(S)-BINAP 100 ˚C 2.5 Dioxane/H2O 93 97
2a,b B(OH)2 35 ˚C 2.5 Dioxane/H2O 95 98
3a,b,c Ti(OiPr)3 [Rh(OH)(S)-BINAP]2 20 ˚C 1.6 THF 56 >99
4c Ti(OiPr)4Li [RhCl(C2H4)2]2/(S)-BINAP 20 ˚C 1.5 THF 83-94 96-99
5a,b,c ZnCl 2.63 20 ˚C 1.5 THF 92 90











 Hayashi has also reported the [Rh(OH)(S)-BINAP]2-catalyzed addition of 
3-thiopheneboronic acid to a variety of Michael acceptors (Table 2.5).70 This was 
the first example of an enantioselective conjugate addition employing a 
heteroaromatic nucleophile. The major limitation of this reaction, however, is that 
the catalyst needed for this transformation is [Rh(OH)(S)-BINAP]2, which is 








3 mol % [Rh(OH)((S)-binap]2
dioxane/H2O




















Oi and coworkers found that organosiloxane nucleophiles add to a range 
of acyclic and cyclic enones, including 2-cyclopenten-1-one, in the presence of a 
cationic Rh(I)/BINAP complex.71 Although this method has achieved high ee’s 
and yields, it requires high temperatures and long reaction times.  
2.4 OBSTACLES TO EMPLOYING 2-HETEROARYL COMPOUNDS 
In light of the prolific research that has been performed in the area of 
enantioselective 1,4-additions of aryl compounds to enones it is perhaps 
surprising that very few examples have been reported in which heteroaromatic 
compounds have been used.  This notable absence can be explained, however, by 
the well-documented obstacles to using such heteroaromatic substrates, 
particularly 2-heteroaromatic compounds. 
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 2.4.1 Protodeboronation of 2-Heteroaromatic Boronic Acids 
Aryl boronic acids are the preferred aryl substrate in both the rhodium and 
palladium-catalyzed methods, owing in large part to their commercial availability.  
Unfortunately, however, aryl boronic acids are known to suffer from 
protodeboronation, so the aryl boronic acid is often used in large excess (up to 
five-fold). In the case of heteroaromatic boronic acids, the propensity for 
protodeboronation is much greater, with the highest rate being observed for 2-
heteroarylboronic acids.  This increased susceptibility to protodeboronation is due 
to the proximity of the heteroatom to the boron, which accelerates the rate of 
boron-carbon hydrolytic cleavage.72-76 Indeed, Hayashi reported that “to the best 
of our knowledge, heteroaromatic groups have not been introduced 
enantioselectively by the rhodium-catalyzed asymmetric 1,4-addition, probably 
due to the instability of the corresponding boronic acids under the reaction 
conditions, the reactions typically being carried out in dioxane/H2O at 100 ˚C.”
70 
In order to circumvent these problems, it was necessary to use the highly reactive 
catalyst [Rh(OH)BINAP]2 in order to effect the conjugate addition of 3-
thiopheneboronic acid at milder temperatures (Table 2.5).  Hayashi did not report 
the addition of 2-thiopheneboronic acid to enones or enoates, presumably because 
that substrate will not survive the 40 ˚C temperature long enough to undergo 
transmetallation. 
2-Heteroarylboronic acids have also been problematic in Pd-catalyzed 
Suzuki-Miyaura reactions, owing to competitive protodeboronation reactions 
(Scheme 2.12).77 For example, Buchwald has reported problems with Suzuki-
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Miyaura reactions between furanyl- and pyridyl boronic acids and less reactive 























2.4.2 Attempts to Circumvent Protodeboronation  
Attempts to circumvent the instability of boronic acids have often 
involved the use of their more stable, boronate ester derivatives.  However, even 
in those cases, deleterious protodeboronation reactions often occur, as 
exemplified by Lautens’s failed attempt to achieve a successful Heck cross-
coupling reaction between a stablized 2-thophenylboronate ester and a strained 
olefin (Scheme 2.13).  Despite screening a wide variety of solvents, water ratios, 

























Bases screened: Na2CO3, KF, CsF, Ba(OH)2, NaOH, and Tl2CO3  
Potassium trifluoroborate salts, which have also been prepared from the 
corresponding boronic acid by treatment with KHF2, have exhibited slight 
advantages over their boronic acid counterparts, primarily because their increased 
stability to air and water facilitates both their preparation and storage.60 Darses has 
reported the use of a variety of aryl and alkenyltrifluoroborates with a cationic 
Rh(I) complex to afford 1,4-addition products with high ee’s.80-82 One significant 
advantage that Darses found with using trifluoroborates was the ability to reduce 
the nucleophile equivalency to 2.0 equivalents, which is far superior to the 5.0 
equivalents often necessitated with the use of arylboronic acids. Darses reported 
two examples utilizing 3-thiophenyltrifluoroborate (Scheme 2.14), but no other 










3 mol % [Rh(cod)2][PF6]/(S)-binap]2
PhMe/H2O
105–110 ˚C, 2 h
BF3K
2.76 2.77
R O R O
S
R = C5H11: 84% yield; 90% ee
R = C6H13: 73% yield; 87% ee
2.78
 
One major disadvantage in using aryltrifluoroborates is that metal 
insertion into the carbon-boron bond can be very slow in the absence of a base, 
because the electronegative effect of the fluorine atoms substantially reduces the 
nucleophilicity of the organoboron species. In response to this problem, Miyaura 
and Yamamoto developed cyclic triolborates, which are also air- and water-stable 
but have a much greater transmetallation efficiency than aryltrifluoroborates.83 
When employing anhydrous DMF as the solvent, 2-thiophenyl- and 2-pyridyl-
triolborates were effective Suzuki coupling partners (Schemes 2.15 and 2.16).  It 
is important to note that Miyaura’s conditions necessitated aqueous DMF for the 
smooth coupling of the vast majority of aryltriolborates, the exception being the 
2-heteroaryltriolborates where it was crucial that anhydrous solvent be used in 
order to prevent water-catalyzed protodeboronation.   As a result of the anhydrous 
conditions required in these cases, it was also necessary to add phosphine ligands 
as phosphine-free Pd(OAc)2-catalyzed Suzuki couplings typically require the 
presence of water to promote the reduction of Pd(OAc)2 to Pd(0).  The addition of 
a copper additive in the case of pyrid-2-yltriolborate 2.82 was found to be 
































Burke and co-workers recently developed N-methyliminodiacetic acid 
(MIDA) boronates as an alternative solution to the use of unstable 2-
heteroaromatic boronic acids (Table 2.6).84 These MIDA boronates can be 
hydrolyzed slowly in situ with the addition of K3PO4 at 60 ˚C, thereby slowly 
releasing small amounts of the reactive, but unstable boronic acids during the 
course of the reaction. The rate of hydrolysis increases with temperature. Using 
this method, Burke was able to employ 2-thiophenyl-, 2-furanyl-, 2-benzofuranyl, 
2-pyrrolyl-, 2-pyridyl and 2-indolyl-MIDA boronates in a variety of coupling 
reactions in high yields. Although this solution is promising in the context of Pd-
catalyzed couplings, the requirement of base is potentially incompatible with 
Rh(I)-catalyzed conjugate addition chemistry.  In addition, the synthesis of some 
of the 2-heteroaryl MIDA boronates is low yielding, e.g. 2-pyridyl-boronates, 






































2.5 RECENT EXAMPLES OF ENANTIOSELECTIVE CONJUGATE ADDITION 
EMPLOYING 2-HETEROARYL COMPOUNDS 
At the outset of this research there were no examples of the 
enantioselective conjugate addition of 2-heteroaryl compounds.  However, during 
the course of this work and concurrent with our own research, two different 
reports were published illustrating the successful use of a limited range of 2-
heteroaryl compounds. 
The first example was reported by Ishihara and co-workers, who described 
one example of a Rh(I)-catalyzed enantioselective addition of 2-thiopheneboronic 
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acid to a Michael acceptor (Scheme 2.17). Ishihara’s reaction did not suffer from 
deleterious protodeboronation of 2.89, which is somewhat surprising because the 
reaction was conducted under reflux in aqueous toluene.85 However, the 
electronically biased nature of the electrophile was likely a contributing factor to 
the success of the 1,4-addition.  In light of the biased acceptor used, the high 
temperatures employed, and the necessity for aqueous solvent, this method does 
not appear to be generalizable to other 2-heteroaromatic compounds and simple 




















A more general method was published by Frost and coworkers in 2008.86 
In this procedure, various thiophen-2-ylzinc chlorides were employed in Rh-
catalyzed enantioselective conjugate additions to cyclic enones and 5,6-dihydro-
2H-pyran-2-one (Table 2.7, entries 1–7). The catalyst system used is derived from 
Me-DUPHOS and [Rh(C2H4)2Cl]2. 2-Cyclopenten-1-one is a poor substrate in this 
method, the corresponding reaction with 2-thiophenylzinc chloride proceeding in 
only 26% ee. Frost also reported two examples of the addition of furan-2-yl zinc 
bromide to 2-cylcohexen-1-one and 5,6-dihydro-2H-pyran-2-one, those reactions 






3 mol % [RhCl(C2H4)2]2/(R,R-Me-DUPHOS)





























ZnCl O 1 81 92





























2.6 MODEL STUDIES INVOLVING FURAN-2-YL ZINC AND TITANATE REAGENTS 
Based upon the literature precedent available at the time we initiated this 
research, the most relevant methodology for our purposes was clearly that 
developed by Hayashi. Therefore, initial trials used catalyst conditions that were 
identical to those reported by Hayashi.  In order to avoid the problems of 
protodeboronation associated with 2-heteroarylboronic acids, we started with 5-
methylfuran-2-ylzinc chloride (2.99) which was prepared from lithiation at the 5-
position of 2-methylfuran and subsequent transmetallation to zinc chloride. In the 
event, 2.99 was added to 2-cyclopenten-1-one in the presence of [RhCl(S)-




 10 mol% [RhCl((S)-BINAP)]2, TMSCl, 2.6
THF, 0 oC, 1 h; then









Disappointingly, however, the enantiomeric excess of the desired adduct 
was about 0%. In an effort to improve the enantiomeric excess, a variety of chiral 
ligands were screened (Table 2.8) with 5-methylfuran-2-ylzinc chloride as the 
model substrate.  Much to our surprise, none of these ligands increased the 







 10 mol% [Rh(cod)Cl]2
Ligand, 2.6
TMSCl, THF, 23 °C

































Reaction conditions: 10 mol % of [Rh(cod)Cl]2, 0.75 mmol of TMSCl, ligand/Rh (1.1:1), 1.0 mmol of furan-2-ylzinc chloride,
0.5 mmol of 2-cyclopenten-1-one. aDetermined by HPLC analysis (OD-H chiral column, 98:2 hexanes/2-propanol, 0.5 mL/min).












The enantiomeric excess was determined by chiral HPLC analysis of the 
the enantioenriched substrate and comparison to a racemic standard. The 1,4-
adduct 2.100 could not be separated via chiral HPLC, and therefore the ee was 
determined by evaluation of the derivative 2.101, formed from NaBH4 reduction 
of the 1,4-adduct (Scheme 2.19).  The four diastereomers could be separated by 
chiral HPLC and the enantiomeric pairs could be designated on the basis of 










cis/trans = 3:1  
In considering the reaction, we envisioned the catalytic cycle to be similar 
to that proposed by Hayashi (Figure 2.5).  The first step in the cycle is 
transmetallation of the furan-2-ylzinc species 2.102 to rhodium, producing the 
chiral furan-2-ylrhodium species 2.103.  TMSCl activates the enone towards 
addition and in the second step, an enantiodiscriminating olefin insertion takes 
place, leading to rhodium enolate 2.106. The active rhodium species is 
regenerated by the assistance of TMSCl which silylates the enolate oxygen of 









































In order to achieve enantiodiscrimination in the insertion step, one face of 
the olefin must be selectively accessible to the nucleophile (Figure 2.6).87 Before 
our ligand screening, we had presumed that our absence of ee resulted from poor 
olefin discrimination in this step of the cycle.  However, in light of the fact that a 
variety of ligands did not alter the ee at all, we began to suspect that the problem 







2.6.1 Background Reaction 
In an effort to probe the reaction further, a fortuitous control experiment 
was performed in which the influence of the rate of addition of the nucleophile 
was examined. Interestingly, slow addition (2 mmol/hr) of the nucleophile 2.99 to 
2-cylopenten-1-one resulted in a modest ee of 18% (Scheme 2.20).  This was the 
















The influence of the rate of addition of the nucleophile upon the 
enantiomeric excess of the product is consistent with the presence of a competing 
background reaction.  In order to investigate that possibility, a second control 
reaction was performed in the absence of catalyst.  In the event, the 1,4-addition 
product 2.100 was obtained in 81% yield, confirming that a background reaction 
was likely occurring (Scheme 2.21). This result strongly suggested that the low 
enantiomeric excess resulted from an incomplete transmetallation step in the 
















With the presence of a background reaction, there are presumably two 
competing pathways (Equation 2.1).  If the transmetallation of the furylzinc 
chloride to the rhodium is slow compared to the uncatalyzed addition of furylzinc 
chloride to 2-cyclopenten-1-one, enantioselectivity will be diminished.  The 
magnitude of diminishment will be relative to the difference in the competing 





















The rate of addition of the nucleophile to the reaction will further bias this 
competition.  If the nucleophile is added via a fast addition, considering there is 
substoichiometric catalyst present, there will be a much greater concentration of 
2.102 in solution relative to the catalyst.  Without any catalyst to react with, the 
excess nucleophile cannot undergo transmetallation and will proceed along the 
competing pathway to furnish racemic material. Slowing the addition of the 
nucleophile has the effect of lowering the concentration of the nucleophile, 
relative to the catalyst, and thereby decreasing the bias towards the undesired 
competing pathway.  
There is no literature precedent for the conjugate addition of a simple 
furan-2-ylzinc chloride to an enone, which is why this background reaction was 
not anticipated.  In fact, much more complex furan species have been employed to 
accomplish the same transformation, such as Lipshutz’s higher order 
cyanocuprates and Knochel’s mixed diorganozincs.37, 38 Furan-2-ylzinc chloride is 
not only much simpler to synthesize, but is also more atom economical.  In 
comparison, Lipshutz’s method only transfers one of two furan ligands from 
copper and Knochel’s method requires a sacrificial dummy ligand on zinc.           
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2.6.2 Employing Furan-2-yl Titanates 
Although employing slow addition did result in an improved ee, it was not 
high enough to be synthetically useful.  Therefore, efforts were focused on finding 
a different organometallic species that did not suffer from a competing 
background reaction.  Towards that end, we investigated the use of 2-
heteroaryltitanium reagents. 
While there is no literature precedent regarding the use heteroaryltitanium 
species in Michael reactions, furan-3-yl titanates have been used infrequently in 
1,2-additions to aldehydes.  Sibi employed a furan-3-yltitanium reagent, in a 
diastereoselective 1,2-addition to an aldehyde in his synthesis of Ricciocarpins A 











































A similar 1,2-addition was employed by Boukouvalas in his synthesis of 
(+)-Zerumin B,89 as well as in his synthesis of  (+)-Dysidiolide.90 Other than these 
examples, however, the use of heteroaryltitanium reagents in organic synthesis 
has been relatively unexplored.91  
In the area of alkyltitanium reagents, Lipshutz has reported the conjugate 
addition of butyltitanates in the presence of TMSCl and catalytic CuI•LiCl 





    5.5 mol % CuI·LiCl








In contrast to the dearth of reactions involving heteroaryltitanium reagents, 
aryltitianium reagents have been used more frequently.  As mentioned above, 
Hayashi has used aryltitanium triisopropoxides [ArTi(OPr-i)3] and aryltitanates 
[ArTi(OPr-i)4]Li in Rh-catalyzed 1,4-additions (Table 2.4).  While both 
organometallic reagents worked well, the “ate” species furnished higher yields 
with 2-cyclopenten-1-one than did the neutral titanium reagent.  
With no literature precedent to indicate whether furan-2-yl titanates would 
participate in uncatalyzed conjugate additions, like their zinc counterparts, we 
attempted the reaction using 5-methylfuran-2-yltitanate with our standard 
conditions. To our delight, the conjugate addition adduct was obtained in 85% 
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yield and 84% ee (Table 2.9, entry 1). By screening a variety of ligands, this ee 
was improved to 90% with the use of (R)-Tol-BINAP (Table 2.9, entry 5). 
Table 2.9 
O Ti(OiPr)4Li
 10 mol% [Rh(cod)Cl]2
20 mol% Ligand






















n.d. = not determined
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Although high ee had been achieved with the titanate, a control 
experiment was performed to test for the presence of any background reactions.  
Subjection of furan-2-yl titanate 2.116 to the reaction conditions, in the absence of 
catalyst, furnished the 1,4-addition product in 10% yield, indicating that a minor 
background reaction was present (Scheme 2.24).  Considering that a 90% ee had 
been achieved using titanate 2.116, it is plausible that the ee for the Rh-catalyzed 


















Although we were pleased with the ee of the reaction, the catalyst loading 
was still rather high.  However, we found that changing the rhodium pre-catalyst 
to [Rh(C2H4)2Cl]2 enabled the catalyst loading to be reduced by half without 
compromising the yield or enantioselectivity (Scheme 2.25). Enantiomeric excess 
was determined by HPLC analysis of the derivative 2.119, which was formed by 
NaBH4 reduction of 2.118 (Scheme 2.26). 
Scheme 2.25 
O Ti(OiPr)4Li
 5 mol% [Rh(C2H4)Cl]2
11 mol% (R)-Tol-BINAP
2.6, TMSCl, THF, 
23 °C


















cis/trans = 3:1  
To date, this result represents the only example of an enantioselective 
addition of a furan-2-yl nucleophile to 2-cyclopenten-1-one. At the time it was 
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discovered, it was also the first example of an enantioselective 1,4-addition of a 2-
heteroaromatic nucleophile to a Michael acceptor.  Additional noteworthy 
attributes of the reaction include the fact that it is performed in anhydrous solvent 
and that it is not necessary to perform this chemistry in a glovebox as the active 
catalyst can be generated in situ using standard Schlenk technique. 
2.7 EXTENSION TO OTHER 2-HETEROAROMATIC NUCLEOPHILES AND 
MICHAEL ACCEPTORS 
Due to the lack of literature precedent for adding 2-heteroarylnucleophiles 
to Michael acceptors, we thought it would be valuable to generalize our reaction 
to include other heteroaromatic substrates and Michael acceptors. A variety of 
heteroaromatic compounds were identified as desirable nucleophiles (Figure 2.7).  
Of these compounds, only thiophene had been added to an enone 
enantioselectively.  It was postulated that the titanate derivatives of all of these 
compounds could be made by facile direct lithiation at the 2-position and 
























2.7.1 Studies with Benzofuran 
Initial attempts to add the benzofuran-2-yl titanate 2.125 to 2-cyclopenten-
1-one using the same reaction conditions previously established for furan failed to 
furnish any of the desired 1,4-adduct 2.126.  However, subsequent screening of 
conditions led to the discovery that the temperature at which the 
benzofuranyltitanate 2.125 is prepared is of critical importance, with lower 
temperatures facilitating higher yields (Table 2.10).  
Table 2.10 









   0 ˚C





















n.d. = not determined  
This temperature sensitivity was surprising as it had not been observed 
previously with furan.  Subsequent experiments with the furan-2-yltitanate 2.117 
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indicated that slightly higher yields could be obtained with furan by also 
preparing its titanate complex at –78 ˚C (Scheme 2.27).  In light of these findings, 
the titanate complexes of all subsequent 2-heteroaryl substrates were also 
prepared at –78 ˚C.   
Scheme 2.27 
O Ti(OiPr)4Li
 5 mol% [Rh(C2H4)Cl]2
11 mol% (R)-Tol-BINAP
2.6, TMSCl, THF, 
23 °C










In addition to temperature sensitivity, further optimization with 
benzofuran revealed that the choice of rhodium pre-catalyst dramatically affects 
product yields.  A dramatic increase in yield was observed by simply using 
[Rh(acac)cod] as the pre-catalyst rather than [Rh(C2H4)2Cl]2 (Scheme 2.28). 
Hayashi has reported that the acetylacetonato (acac) ligand retards the 
transmetallation step because of the high stability of the rhodium-acac moiety,94 
which was a disadvantage in his method.  However, in the context of our 
experiments with benzofuran, the presence of an acac ligand was clearly 
advantageous.    
Scheme 2.28 






81% yield, 93% ee
n-BuLi, –78 ºC!0 ºC, THF;






As it is known that [Rh(acac)cod] is a very active conjugate addition 
catalyst by itself,95 a control reaction was performed in the absence of chiral 
ligand (Scheme 2.29).  None of the desired product was obtained, indicating that 
[Rh(acac)cod] is not an active catalyst for this transformation.   
Scheme 2.29 
 10 mol% [Rh(acac)cod]
2.6, TMSCl, THF
X
n-BuLi, –78 ºC!0 ºC, THF;







Since Hayashi reported [Rh(OH)BINAP]2 to be an extremely active 
catalyst for the conjugate addition of 3-thiopheneboronic acid, this catalyst was 
also tested in our optimization studies. [Rh(OH)BINAP]2 is known to be 
extremely air-sensitive and is typically made and handled in a glovebox.  As it is 
undesirable to develop a method that requires a glovebox, the in situ preparation 
of [Rh(OH)BINAP]2 was attempted in a Schlenk flask.  During the preparation the 
catalyst solution turned black, which is a possible indication of catalyst 
decomposition.  Nonetheless, this black solution was used immediately in the 
conjugate addition reaction, but failed to produce any of the desired product.      
Scheme 2.30 
 10 mol% [Rh(OH)BINAP]2
2.6, TMSCl, THF
X
n-BuLi, –78 ºC!0 ºC, THF;







Finally, additional ligand screening led to the identification of (R)-MeO-
BIPHEP as the optimal ligand of choice.   In the presence of [Rh(acac)(R)-MeO-










96% yield, 98% ee
n-BuLi, –78 ºC!0 ºC, THF;





Gratifyingly, when these newly optimized catalyst conditions were applied 
to the addition of furan-2-yl titanate 2.116 to 2-cyclopenten-1-one, a similar 
improvement in ee was also observed (Scheme 2.32).  Having optimized the 
reaction conditions for benzofuran and furan, our attention then was directed to 
applying these optimized conditions to our other target heterocycles (Figure 2.7). 
Scheme 2.32 






90% yield, 98% ee
n-BuLi, –78 ºC!0 ºC, THF;





2.7.2 Studies with Benzothiophene 
Optimization studies with benzothiophen-2-yl titanate showed a similar 
dependence upon the choice of rhodium pre-catalyst, as was seen with 
benzofuran. In all cases, [Rh(acac)cod] furnished the best yields (Table 2.11).  
Additionally, (R)-MeO-BIPHEP proved to be a superior ligand to (R)-Tol-












n.d. = not determined
[Rh] Pre-catalyst/Ligand
















n-BuLi, –78 ºC!0 ºC, THF;




2.7.3 Studies with Indole 
In agreement with benzothiophene, benzofuran, and furan, [Rh(acac)(R)-
MeO-BIPHEP] was a superior catalyst to [Rh(C2H4)2(R)-Tol-BINAP] in the 
addition of N-methylindol-2-yl titanate 2.129 to 2-cyclopenten-1-one (Scheme 
2.33). Although the yield was lower than the other heterocycles surveyed, the 




























n-BuLi, –78 ºC!0 ºC, THF;





In an effort to increase the yield of the indole addition, a variety of ligands 
from the (R)-MeO-BIPHEP family were screened (Table 2.12).  Unfortunately, 




11 mol% (R)-MeO-BIPHEP Ligand






























n-BuLi, –78 ºC!0 ºC, THF;






One interesting observation in the case of the indole nucleophile was that 
the nature of the group on indole nitrogen was critical to the outcome of the 1,4-
addition.  For example, when the titanate of 1-(phenylsulfonyl)-1H-indole was 




11 mol% (R)-MeO-BIPHEP Ligand







n-BuLi, –78 ºC!0 ºC, THF;






The explanation for this result may be found in the preparation of titanate 
species 2.132.  Titration of 2.132 with iodine indicated that the titanate species 
may not have been formed.  In order to establish which step of the titanate 
preparation was problematic, a deuterium quench was performed on the lithiated 
intermediate 2.134 (Scheme 2.35).  Quantitative deuterium incorporation was 
observed, indicating that lithiation had been quantitative, and thus the problem 






















Without any literature precedent about indol-2-yl titanates to inform our 
research, it was difficult to identify possible explanations for this obstacle.  The 
fact that the solution containing the supposed titanate species 2.132 could not be 
titrated with iodine is inconsistent with the possibility that only the lithiated indole 
2.134 and unreacted titanium tetraisopropoxide were in solution.  Had that been 
the case, the lithiated species 2.134 would have reacted with iodine, giving the 
false impression that the transmetallation had succeeded.  In fact, that is a 
drawback in using iodine for the titration of titanates, but we are unaware of a 
titration method that can distinguish between a titanium and lithium species.  
One possible explanation may be that transmetallation did occur, but due 
to the oxaphilic nature of titanium, an unreactive complex, such as 2.136, may 
have formed (Figure 2.8).  Without isolating a crystal of such a complex, 










2.7.4 Studies with Thiophene 
Using our optimized conditions, thiophen-2-yl titanate 2.137 was added to 
2-cyclopenten-1-one in moderate yield and excellent enantiomeric excess 
(Scheme 2.36). In view of the poor enantioselectivity reported by Frost for the 
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addition of thiophen-2-ylzinc reagents to 2-cyclopenten-1-one, e.g. 26%, it is 










60% yield, 95% ee
n-BuLi, –78 ºC!0 ºC, THF;




Frost’s observed ee is consistent with a background reaction like what we 
had observed in the case of furan.  To investigate this possibility, a control 
reaction was performed with thiophen-2-ylzinc chloride in the absence of catalyst.  
In the event, the 1,4-adduct was obtained in 80% yield (Scheme 2.37).  This result 
emphasizes the critical importance of the metal in furnishing adequate ee.  
Scheme 2.37 













2.7.5 Studies with N-Methylpyrrole 
Of all the heterocycles examined, N-methylpyrrol-2-yl titanate 2.139 was 
the most difficult substrate to work with due to the propensity of the 1,4-addition 
product to polymerize under the acidic conditions of the workup.  A number of 
alternative workup conditions were screened in an effort to hydrolyze the silyl 
enol ether without inducing polymerization, including the use of fluoride sources, 
hydroxide, and other basic conditions, but none were an improvement upon the 
 95 
standard workup conditions using dilute aqueous HCl.  One change that did 
slightly improve the outcome with this substrate was the use of TESCl in place of 
TMSCl as the Lewis acid.  Ultimately, the 1,4-adduct was achieved in 43% yield 











43% yield, 93 % ee
n-BuLi, –78 ºC!0 ºC, THF;





2.7.6 Studies with Benzothiazole, Pyridine, and N-methyl-imidazole 
Preliminary studies with benzothiazole, pyridine, and N-methyl-imidazole 
did not yield promising results.  In all three cases, the formation of the titanate 
was problematic.  Similar to what was seen in the case of 1-(phenylsulfonyl)-1H-
indole, deuterium quenching experiments with benzothiazole (Scheme 2.39) 
indicated that lithiation was quantitative, but titration with iodine indicated that a 
reactive titanate may not have been formed.  In all cases the prepared solution of 
titanate was carried forward through the reaction in the chance that the iodine 
titration was not reliable.  However, in all of those cases, no product was obtained 
and only starting material was recovered.  Similar problems were encountered 























2.7.7 Expanding the Scope of the Michael Acceptor 
In addition to testing a variety of heteroaromatic nucleophiles, Michael 
acceptors other than 2-cyclopenten-1-one were investigated.  The $,#-unsaturated 
compounds of interest include five- and six-membered enones, unsaturated 












2.6 2.144 2.145 2.21 2.146 2.147  
Furan and was added to both enones and unsaturated lactones efficiently, 
the reactions of enones typically furnished higher yields of adducts than enoates 
(Table 2.13).  In contrast, N-methylpyrrole gave unsatisfactory yields, ca. 20-
30%, with lactones.  The best examples with furan and N-methylpyrrole titanates 


























































nBuLi, –78 ºC!0 ºC; then
Ti(OiPr)4, –78 ºC, THF
ArTi(OiPr)4Li
aReaction conditions: 10 mol % [Rh], Rh:L (1:1.1), [Rh] = [Rh(cod)acac]; L = (R)-MeO-BIPHEP,
 0.45 mmol TMSCl, 0.30 mmol Michael acceptor, 0.6 mmol 2-heteroaryl titanate, THF (–78 ºC to RT).
bIsolated yield after flash chromatography. cDetermined by HPLC analysis (OD-H or AD chiral column).
dHPLC  analysis was performed on the  four diastereomeric alcohol derivatives of the product, formed by
 NaBH4 reduction of product.  
Thiophene was not explored with other acceptors as Frost had already 
reported similar examples.  Benzofuran-2-yl titanate added efficiently to lactone 
2.146 (Table 2.14, entry 3) in good yield and excellent ee. The best examples with 
benzofuran, thiophene, benzothiophene, and N-methylindole titanates are 
summarized in Table 2.14.96 
 98 
Table 2.14 
aReaction conditions: 10 mol % [Rh], Rh:L (1:1.1), [Rh] = [Rh(cod)acac]; L = (R)-MeO-BIPHEP,
 0.45 mmol TMSCl, 0.30 mmol Michael acceptor, 0.6 mmol 2-heteroaryl titanate, THF (–78 ºC to RT).
bIsolated yield after flash chromatography. cDetermined by HPLC analysis (OD-H or AD chiral column).
dHPLC  analysis was performed on the  four diastereomeric alcohol derivatives of the product, formed by





















































nBuLi, –78 ºC!0 ºC; then
Ti(OiPr)4, –78 ºC, THF
ArTi(OiPr)4Li
 
2.7.8 Revisiting Zinc Reagents 
During the course of these studies, we observed that the yields of the 
additions of 2-heteroaryl titanates to $,#-unsaturated carbonyl compounds were 
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not satisfactory in some cases, even though the enantioselectivities in these 
reactions were consistently high. Although we had established that both thiophen-
2-yl- and furan-2-yl zinc chloride added readily to 2-cyclopenten-1-one in the 
absence of a transition metal catalyst, it was unknown whether similar 
background reactions would be problematic with other 2-heteroarylzinc chlorides. 
As the zinc reagents are typically more stable at room temperature than the 
titanates, we thought that they might furnish higher yields in some cases.  
Therefore, a variety of 2-heteroarylzinc chlorides were prepared and used 
in those cases where the titanates did not furnish sufficient product yields. A 
screening of pre-catalysts and chiral ligands (e.g., (R)-Tol-BINAP, Josiphos, 
Walphos, and Carreira’s diene) with benzofuran-2-yl zinc chloride 2.152 
identified the catalyst system derived from [Rh(COD)acac] and (R)-MeO-
BIPHEP to be optimal, in agreement with our observations from the titanate 
system. In a model reaction, the enantioselective addition of benzofuran-2-yl zinc 
chloride 2.152 to 2-cyclopenten-1-one proceeded in 91% yield and 91% ee (Table 
2.15, entry 1).  
Encouraged by this result, we extended this reaction to other cyclic enones 
and unsaturated lactones and lactams, and these conjugate additions also 
proceeded in good yield and excellent ee’s (Table 2.15, entries 2–4). Similarly, 
benzothiophen-2-yl zinc chloride 2.152 added to several Michael acceptors in 
!98% ee and moderate to excellent yield (Table 2.15, entries 5–7).96 Preliminary 
experiments with the addition of N-methylindolezinc chloride to 2-cyclopenten-1-





































































Reaction conditions: 10 mol % [Rh], Rh:L (1:1.1), [Rh] = [Rh(cod)acac]; L = (R)-MeO-BIPHEP,
 0.45 mmol TMSCl, 0.30 mmol Michael acceptor, 0.6 mmol 2-heteroaryl titanate, THF (–78 ºC to RT).
aReactions performed by Lily Abbott. bIsolated yield after flash chromatography. cDetermined by HPLC 











2.8 SUMMARY AND CONCLUSIONS 
A useful methodology has been developed for the enantioselective 
conjugate addition of 2-heteroaryl nucleophiles to a variety of Michael acceptors, 
including enones, unsaturated lactones and lactams.  By employing 2-heteroaryl 
titanium and zinc reagents, problems associated with protodeboronation of the 
corresponding boronic acids can be avoided entirely. We found that the nature of 
the organometallic reagent can have a dramatic effect on ee.  In many cases the 
titanate reagents afforded higher ee’s than their zinc counterparts, particularly in 
the case of furan, thiophene, and N-methylindole.  However, in other cases, 
reactions involving zinc reagents proceeded in higher yields. 
Additional attributes of the methodology include its practical nature, as the 
active catalyst does not require the use of a glovebox, and the use of anhydrous 
solvent, which allows for the possibility of isolation of silyl enol ether 
intermediates. The application of this method to the Martin Group’s synthesis of 
cortistatin A has been successful and investigations into other applications of this 







Chapter 3: Studies Towards the Total Synthesis of Cortistatin A 
3.1 INTRODUCTION 
Cortistatin A (2.1) is a novel steroidal alkaloid that was isolated from the 
marine sponge Corticium simplex  in 2006 by Kobayashi and coworkers (Figure 
3.1).97 Owing to its unique structure and impressive biological activity, cortistatin 
A has generated great interest from the synthetic community.  In fact, in the short 
time since its isolation, 13 synthetic approaches to cortistatin A have been 












In 2007, Kobayashi isolated several additional members of the cortistatin 
family (Figure 3.2).98, 99 Of these, cortistatin J exhibits the most promising 
biological properties, and as a result, several synthetic approaches toward this 















cortistatin A: R = H, 2.1









cortistatin C: R = H, 3.2














cortistatin K: R = H, 3.9






















cortistatin G: C1-C2, saturated, 3.6





3.2 BIOLOGICAL ACTIVITY OF THE CORTISTATINS 
Members of the cortistatin family exhibit antiangiogenic properties against 
human umbelicial vein endothelial cells (HUVECs).  Angiogenesis, which is the 
process of capillary blood vessel generation, is a critical requirement for the 
growth of solid tumors, as well as the progression of diabetic retinopathy, 
psoriasis, and rheumatoid arthritis. 
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Tumors can exist in the human body for months to years without 
producing symptoms or undergoing rapid growth.  However, if at some point the 
cells within the tumor “switch” to an angiogenic phenotype, the tumor becomes 
vascularized, which then leads to rapid disease progression via perfusion and 
paracrine effects.100, 101 As a result of vascularization, the tumor becomes perfused 
and thus has an increased access to nutrients and oxygen, as well as an increased 
efficiency in excreting waste metabolites (Figure 3.3). In addition, paracrine 
effects are manifested when the capillary endothelial cells, which line the new 
blood vessels, start producing a variety of growth factors, including fibroblast 
growth factors, heparin-binding epithelial growth factor, granulocyte colony-
stimulating factor, platelet-derived growth factor, and insulin-like growth factor I.  
These perfusion and paracrine effects work synergistically to increase the growth 












Figure 3.3 (Source: New England Journal of Medicine)100 
 
An additional complication of angiogenesis is that it decreases the 
responsiveness of tumor cells to traditional chemotherapeutic reagents. This is 
due to the building of interstitial pressure within the tumor as a result of 
compressed, leaky blood vessels. 
When used in conjunction with traditional chemotherapeutics, 
antiangiogenics have proven to be very successful in preventing tumor growth.  In 
fact, in some animal studies, the use of antiangiogenics have led to disease 
elimination.102 An additional promising factor is that resistance to antiangiogenic 
agents has not yet been observed.103 Due to these promising therapeutic 
characterists, natural products that exhibit antiangiogenesis are of great interest to 
the medicinal community.  
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After isolating cortistatins A, B, C, and D, Kobayashi tested these 
compounds for their activity against several cell lines including: HUVECs; 
normal human dermal fibroblast (NHDF); and three cancer lines including KB 
epidermoid carcinoma cells (KB3-1), human chronic myelogenous leukemia cells 
(K562), and murine neuroblastoma cells (Neuro2A). HUVEC cell lines are the 
standard cell lines used in testing for antiangiogenic activity 
Kobayashi’s screenings revealed cortistatin A to be the most biologically 
active of the cortistatins, exhibiting an IC50 of 1.8 nM and a selectivity index of 
>3000 for HUVECs in comparison to NHDF, KB3-1, K562, and Neuro2A cells. 
The high selectivity of cortistatin A for HUVECs suggests that its mode of action 
is an antiangiogenic pathway, rather than one of general cytotoxicity.  The second 
most potent member of the family was determined to be cortistatin J, exhibiting 
an IC50 of 8 nM and a selectivity index of 300–1100 for HUVECs in comparison 
to NHDF, KB3-1, K562, and Neuro2A cells. 
In light of the impressive biological activity possessed by cortistatins A 
and J, along with the low natural abundance of the cortistatins, these natural 
products are ideal targets for synthetic organic chemists. 
3.3 BUXUS AND CIMICIFUGA ALKALOIDS 
The core structure of cortistain A possesses an oxabicyclo[3.2.1]octene 
moiety contained within a 9(10%19)-abeo-androstane skeleton (Figure 3.X).  
Although the structure is rare, the 9(10%19)-abeo-androstane skeleton is not 
unique and, in fact, is a common motif in the natural products derived from the 


















9(1019)-abeo-androstane skeleton indicated in blue
2.1
 
Buxus alkaloids are contained within the family Buxaceae, which belongs 
to the Euphoribales order.  They are classified as triterpenoidal alkaloids that are 
found natively in a variety of plants and trees, and they have been used as folk 
medicines throughout Asia for a range of ailments including rheumatism, malaria, 
gonnorrhoea, and skin infections. They usually contain either a 9(10%19)-abeo-
14$-methylpregnane skeleton 3.11 or a 9#,19-cyclo-14$-methylpregnane 
skeleton 3.12 (Figure 3.5).104 Some have oxygen substitution at C2, C6, C11 or 
C16, and many vary in their degree of unsaturation. With the exception of a very 
few cases, they all contain an amino group at C3 and C20, a trans-relationship 
between the C5-H and C8-H, as well as the C13-Me and C14-Me; and a 
quaternary center at C4. To date, over 37 natural products with the core structure 

















































9(10!19)-abeo-14"-methylpregnane skeleton 9#,19-cyclo-14"-methylpregnane skeleton
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In contrast to the Buxaceae family, only one alkaloid (Figure 3.6) 
containing the 9(10%19)-abeo-androstane skeleton has been isolated from the 
plants of Cimicifuga.105 The biological activity of cimicifol (3.13) has not been 
evaluated; however, the plant from which it was extracted, C. foetida, has been 
used in traditional Chinese medicine for anti-inflammatory, antipyretic and 






















3.4 MARTIN GROUP APPROACH TO CORTISTATIN A 
In our retrosynthetic analysis, that is outlined in Scheme 3.1, we identified 
three key synthetic transformations that would allow for both the facile 
construction of our target and methodology development. The first key step, an 
enantioselective conjugate addition employing a furan nucleophile, was entirely 
unprecedented and would have applications to numerous compounds beyond 
cortistastin A (see Chapter 2). The second key step, a diastereoselective Diels-
Alder cycloaddition employing a highly functionalized furan and a dienophile that 
serves as an ethylene surrogate, represented an opportunity to broaden existing 
methodology. Furans are known to be challenging Diels-Alder partners, mainly 
due to the propensity of the oxabicyclic product to undergo retro-[4+2] 
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cycloadditions.106 Furthermore, methods for diastereoselective Diels-Alder 
rections with masked ethylenes, such as a vinyl sulfoxide wherein the sulfoxide 
moiety can be reductively removed, are not well-developed and have only been 
applied to very simple furans with modest to good diastereomeric excess and poor 
endo/exo ratios.107 Finally, the cascade RCM key step would be the first example 
of this reaction with such an advanced and functionalized interemediate.108  As the 
use of metathesis is ubiquitous in organic synthesis, having been used frequently 
on process scale, the extension of this method to more complex substrates would 
be valuable. Hinging upon these three key synthetic transformations: a cascade 
RCM to access the core structure, a diastereoselective Diels-Alder reaction, and 
an enatioselective conjugate addition, our proposed approach would access the 
natural product in enantiopure form in only 20 steps.         
The proposed retrosynthesis begins with a late-stage introduction of the 
isoquinoline unit via 1,2-addition of 7-bromoisoquinoline to ketone 3.14, 
followed by silane promoted ionization of the hydroxyl moiety to provide a 
carbocationic intermediate. Hydride reduction from the less hindered face of that 
intermediate would generate compound 2.1 and establish the requisite 
stereochemistry at C17.109, 110 Compound 3.14 arises from a trans diaxial opening 
of epoxide 3.15 with an acetate nucleophile.  The regioselectivity for this SN2-like 
attack is well precedented in the Martin Group.111  The dimethylamino functional 
group would arise from removal of the nosyl-protecting group and methylation, 
using Fukuyama’s method.112 
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Epoxide 3.15 would arise from an alcohol-directed expoxidation of 2.2.  
The amino moiety would then be installed at C3 with a simultaneous 
sterochemical inversion via the Fukuyama-Mitsunobu protocol.113 The 9(10%19)-
abeo-androstane skeleton would arise from a key cascade RCM (right to left) of 
2.3, forming the BCD rings of cortistatin A in a single step.  Grubbs catalyst is 
expected to load onto the more reactive terminal olefin, directing the RCM from 
right to left. This key transformation, if successful, would represent the first yne-
ene-yne cascade RCM on such a highly functionalized substrate,108 as well as an 
expeditious route to the 9(10%19)-abeo-androstane molecular scaffold.      
The RCM precursor 2.3 would be accessed via double Lindlar reduction of 
3.16, followed by an Ohira-Bestmann transformation of both aldehydes into 
alkynes.114, 115 The highly substituted tetrahydrofuran 3.16 would arise from the 
ozonolytic cleavage of oxabicycle 3.17, which could be obtained from an 
asymmetric Diels-Alder reaction between furan 3.18 and a chiral vinyl sulfoxide 
(after desulfurization).106, 107 There are very few examples of Diels-Alder reactions 
with highly functionalized 2,5-disubstituted furan substrates, despite the frequent 
presence of oxabicycles in natural products.  Thus, successfully achieving this 
transformation in the proposed cortistatin synthesis would broaden existing 
methodology.   
The Diels-Alder precursor 3.18 is a 2,5-disubstituted furan containing 
three chiral centers.  The chiral center at the propargylic carbon could be 
constructed from an asymmetric addition of an acetylide fragment to aldehyde 
3.20 using chemistry developed by Carriera.116-118 The remaining two chiral 
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centers are contained within the cyclopentanone ring, but there is no known 
method for synthesizing this compound enantioselectively.  Constructing 3.22 
requires an asymmetric 1,4-addition of furan derivative 3.23 to 2-
methylcyclopentenone, a transformation for which there was no precedent.  
Subsequent enolate alkylations, with the methylation occurring first, should 













































































































































reduction via hydride delivery 












3.5 CONCURRENT SYNTHETIC APPROACHES TO CORTISTATIN A 
At the time that we initiated our studies, there were no reported syntheses 
of cortistatin A. However, due to the impressive biolgoical properties of this 
natural product, several research groups have been working towards syntheses of 
cortistatin A. Consequently, and concurrently with our research, numerous partial 
and full synthetic approaches have been published. Despite the large number of 
publications to date, however, our synthetic approach remains both novel and 
competitive. Additionally, none of the problems we identified in our 
retrosynthetic analysis have been addressed by any of the published syntheses.  
3.5.1 Total Syntheses 
Only three total syntheses have been reported to date.  The first total 
synthesis of (+)–cortistatin A was reported by Baran in 2008.119 This report was 
followed shortly thereafter by syntheses from Nicolaou and Shair.120, 121   
3.5.1.1  Baran’s Total Synthesis of (+)–Cortistatin A 
Although technically a total synthesis, Baran’s synthesis of cortistatin has 
also been characterized as a semi-synthesis, because of his use of the very highly 
functionalized starting material, prednisone (3.25). Prednisone is a commerically 
available corticosteroid that costs approximately $1/gram.  Baran’s approach 
capitalizes upon the inherent stereochemistry and functionality in prednisone in 
order to achieve an efficient and enantioselective synthesis of cortistatin A.  
Beginning with prednisone, Baran utilized a two-step sequence involving 
selective borane reduction of the alpha-hydroxy ketone, sodium periodate 
cleavage of the resultant diol, and carbonyl protection to give 3.26.  Epoxidation 
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of 3.26 from the less hindered face was effected with t-butyl hydroperoxide, and 
reductive animation and N-formylation produced 3.27.  Opening of the epoxide 
with tetrabutylammonium acetate furnished 3.28. Hydration of the trisubstituted 
olefin, reaction of the intermediate with triethylformate, and in situ solvolysis of 
the acetate afforded 3.29.  The angular methyl group was dibromonated via the 
assistance of a neighboring oxygen-centered radical, and a subsequent SN2 
reaction furnished cyclopropyl intermediate 3.31 and setting the stage for the key 
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92% (over 2 steps)
 
Reaction of 3.31 with SmI2 generated a samarium stabilized ketyl radical, 
which underwent a cyclopropane ring opening to afford samarium enolate 3.33.  
Homolytic cleavage of the carbon-bromine bond afforded the conjugated the di-
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enolate 3.34, which was trapped at the alpha position with an electrophilic 











































































Baran’s endgame was intiated with E2 elimination of bromide ion from 
3.36 using lithium carbonate. Reduction of the orthoamide and ketone fuctions 
with alane and subsequent acetylation gave the late-stage intermediate 3.37. The 
oxabicycle was then formed via SN2’ displacement of the C11 acetate. Following 
deprotection of the cyclopentanone group, 3.38 was transformed into an alkenyl 
iodide via an intermediate hydrazone.  The final two steps of the synthesis utilized 
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a Stille coupling with isoquinoline 3.39 and a chemoslective reduction to yield 

























































While Baran’s approach is certainly impressive, one major drawback is 
that the chemistry developed is heavily directed by the starting material, 
prednisone, and is therefore not generalizable to simpler systems.  As a result, 
while Baran has provided an elegant solution to the problem of cortistatin A, he 
has not developed methodological solutions that are likely to have an impact 
beyond this particular natural product. 
3.5.1.2  Nicolaou’s Total Synthesis of (+)–Cortistatin A 
Nicolaou’s total synthesis of (+)–cortistatin A, which was published 
approximately five months after Baran’s report, utilized the commercially 
available Hajos-Parrish ketone (3.41) as the starting material.120  Using a five step 
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protocol developed by Danishefsky,122 Nicolaou transformed the Hajos-Parrish 
ketone into 3.42.  Employing the stereochemistry inherent in the molecule to 
direct the dihydroxylation of the exocyclic double bond, a diol was furnished 
stereoselectively and protected to furnish 3.43.  Subsequent enolate formation and 
trapping with PhNTf2 produced a vinyl triflate that was converted to the ester 3.44 
via a palladium-catalyzed caboxymethylation. Reduction of 3.44 to the alcohol 
and oxidation produced the aldehyde 3.45. Protection of the aldehyde as its 
dithiane followed by oxidation employing the Parikh-Doering protocol gave an 
intermediate aldehyde that was transformed into the acetylene 3.48 by treatment 





















2) [Pd(PPh3)4], CO, 
    DMF/MeOH
64% (over 2 steps)
72% (over 2 steps) 3.44
1) DIBAL-H
2) Dess-Martin periodinane



























32% (over 2 steps)







Following another palladium-catalyzed coupling with 3.49, reduction of 
the alkyne, and deprotection of the aldehyde produced 3.51, setting the stage for 
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Nicolaou’s key step.  Using K2CO3, a cascade sequence was initiated with the 
formation of a tetrahydrofuran ring via a Michael addition.  The intermediate 
enolate participated in an intramolecular aldol condensation and dehydration 





















































Completion of the synthesis involved functional manipulation of the A and 
D rings (Scheme 3.7).  Beginning with a series of protection, deprotection, and 
oxidation steps, 3.54 was transformed into cyclopentanone 3.55. Vinyl triflate 
formation and subsequent Suzuki-Miyaura coupling to install the isoquinoline 
furnished 3.57.  Reduction of the cyclopentene double bond proceeded 
chemoselectively to afford 3.58.  From 3.58 a TMS enol ether was formed, which 
underwent subsequent oxidation to an enone. Epoxidation of the enone furnished 
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3.59.  The reduction of the cyclohexanone proceeded without any 
stereoselectivity, furnishing a disappointing mixture (1:1) of diastereomers.  The 
final step, an epoxide opening, also proceeded in poor regioselectivity, giving a 









    TMSO(CH2)2OTMS
2) TBAF
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    CeCl3
80%, 1:1 d.r.
chromatographic separation
























  Beginning from the Hajos-Parrish ketone 3.41, Nicolaou’s synthesis 
required 32 steps and proceeded in 0.009% yield.  The highlight of the synthesis 
is certainly the key cascade sequence to construct the oxabicycle moiety.  
 120 
Although earlier steps in the synthesis proceed smoothly, Nicolaou’s synthesis 
suffers from disappointing diastereoselectivity and regioselectivity in the final 
steps, drastically lowering the overall yield and practicality of the synthesis. 
3.5.1.3  Shair’s Total Synthesis of (+)–Cortistatin A 
Like Nicolaou, Shair also began his synthesis of (+)–cortistatin A with the 
Hajos-Parrish ketone (3.41).  Borrowing from the same Danishefsky protocol as 
did Nicolaou, Shair accessed 3.62 in two steps.121  Deprotonation at the &-position 
of the $,#-unsaturated ketone 3.62 using a dimsyl anion and subsequent 
alkylation at the alpha-position with 3.63 occurred smoothly.  Preparation of the 
TBS silyl enol ether, arising from trapping of the thermodynamic enolate, 
produced 3.64.  Diastereoselective hydrogenation of 3.64, followed by a 
Rubottom oxidation and alcohol protection furnished 3.65.  Unmasking of the 
ketone function in 3.65 and aldol condensation, followed by SOCl2-mediated 
elimination furnished 3.66.  Selective enolate formation and trapping with 
phenyltriflimide afforded a vinyl triflate, which was transformed into allyl silane 


















































   HF, PhMe
3) MEMCl, 
    iPrEt2N
55% (over 5 steps)
1) PPTS, acetone/H2O
2) NaOMe, MeOH




     Pd(PPh3)4




Chemoselective cyclpropanation of 3.67 with dibromocarbene, followed 
by fluoride-mediated ring expansion furnished 3.69. Tetraene intermediate 3.71 
was formed via palladium-catalyzed coupling between vinyl bromide 3.69 and 
vinyl boronate ester 3.70. Dihydroxylation of 3.71 proceeded with excellent 
selectivity at the trans-disubstituted double bond only, in a 10:1 dr. Protection of 
the resultant diol and desilylation followed by oxidation of the primary aldehyde 





















  CHBr3, KOtBu TASF, 80 ºC
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2) Ac2O, Et3N, DMAP












With aldehyde 3.72 in hand, Shair successfully executed the key step of 
his synthesis, an aza-Prins cyclization (Scheme 3.10) In the presence of 
dimethylamine and zinc bromide, intermediate iminium 3.73 was presumably 
formed.  Shair postulated that the minimization of A1,3-strain led to the preference 



































65% (over 3 steps)
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Following interception of Baran’s cyclopentanone intermediate 3.38, Shair 
reproduced Baran’s chemistry to complete all but the very last reduction step, in 
which he employed triisopropylbenzenesulfonyl hydrazide 3.76 to produce 

































Shair’s total synthesis proceeds in 26 steps and 0.14% overall yield from 
the Hajos-Parrish ketone 3.41.  The highlight of Shair’s synthesis is the aza-Prins 
cyclization, which occurred with excellent diastereoselectivity. In light of the 
replication of Baran’s chemistry in the last three of four steps, coupled with the 
extremely low 20% yield for the final reduction, which is much lower than 
Baran’s conditions, Shair’s approach is best regarded as a formal synthesis, rather 
than a total synthesis. 
3.5.2 Formal Syntheses 
Hirama and coworkers published a formal synthesis of cortistatin A in two 
parts, the first part detailing the synthesis of the core with all four rings intact, and 
the second detailing elaboration of that core to Nicolaou’s advanced intermediate 
3.58.123, 124   
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Beginning with the same starting material as Shair, which was derived 
from the (+)–Hajos-Parrish ketone 3.41 using known chemistry, Molander’s 
conditions125 were employed to alkylate the enone, furnishing indanone 3.77.  A 
stereoselective reduction of 3.77 with NiCl2/NaBH4 furnished the trans-fused 
ketone 3.78.126  Selective TMS enol ether formation, followed by oxidation using 
Saegusa’s conditions provided 3.79 in excellent yield.  Transformation of 3.80 
into a vinyl triflate and subsequent palladium-catalyzed methoxycarbonylation 
afforded diene 3.81.  Reduction of the ester moiety to an aldehyde was performed 
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85% (over 2 steps)
Ref. 123
 
With both C and D rings intact, elaboration of intermediate 3.82 to the 
tetracyclic core of the natural product took place in four steps.  A Knoevenagel 
reaction between 3.82 and cyclohexane-1,3-dione afforded 3.84, which underwent 
a spontaneous 6"'electrocyclization to afford 3.85 in 5:1 dr.  Conversion of 3.85 
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into alkyl iodide 3.86 occurred smoothly and in good yield.  The oxabicycle was 
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2) PPh3, I2
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In a separate publication, Hirama reported elaboration of the core structure 
3.87 to Nicolaou’s advanced intermediate 3.58 in seven steps (Scheme 3.14).  
Following protecting group manipulation and oxidation of the secondary alcohol, 
the isoquinoline unit was added via 1,2-addition to the cyclopentanone carbonyl.  
Screening of reagents led to the discovery that the organocerium reagent derived 
from 3.90 in the presence of BuLi and cerium chloride afforded an excellent yield 
of the desired product. A modified Barton-McCombie radical deoxygenation 
occurred with concomitant chloride removal to yield 3.93 as a single isomer.  


















–60 ºC to –20 ºC;



















































73% over 2 steps
71%
 
Hirama accessed the core of cortistatin A in 14 steps and 12.3% overall 
yileld.  His formal synthesis, beginning with the Hajos-Parrish ketone, proceeded 
in 22 steps and 4.6% overall yield.  Factoring in Nicolaou’s endgame, a total 
synthesis of cortistatin A employing Hirama’s approach would proceed in 27 
steps and 0.27% overall yield.  The highlight of Hirama’s synthesis is the key 
Knoevenagel/electrocyclization sequence which forms both C and D rings in one 
step and in excellent yield.  Additionally, the installation of the isoquinoline was 
much higher yielding than Baran’s protocol, although it is unknown if the 
isoquinoline cerium reagent would be compatible with the uprotected hydroxy 
groups present in Baran’s advanced intermediate 3.38. 
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3.5.3 Partial Syntheses 
The largest body of work in this area has been on partial syntheses of 
cortistatin A.  Due to the complexity of the natural product and the impressive 
biological activity which calls for examination of simpler analogs, efforts have 
been focused on synthesizing either the core or partial core of cortistatin A. 
3.5.3.1  Danishefky’s Synthesis of the (+)–Cortistatin A Core 
Beginning with the Hajos-Parrish ketone and aryl bromide 3.94, 
Danishefsky and coworkers accessed the full core of cortistatin A in only nine 
steps and 5.4% overall yield (Scheme 3.15).122 All four rings and three of the eight 




















Highlights of the synthesis include a cascade sequence similar to that 
reported by Hirama, in which addition of the aryllithium reagent derived from 
aryl bromide 3.97 added to aldehyde 3.96; subsequent migration of the carbamate 
afforded quinone methide 3.100.  Spontaneous 6"'electrocyclization occurred to 
yield the tetracycle 3.101, but with the wrong stereochemistry.  However, upon 
heating, 3.101 underwent epimerization to yield the desired stereoisomer, 
presumably through a retro 6"-pathway.  The mesylated alcohol 3.103 was 
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formed in two steps and 78% overall yield. The final step involved a fluoride-











































































3.5.3.2  Sarpong’s Synthesis of the (+)–Cortistatin A Core 
Sarpong and coworkers reported a synthesis of the racemic core of 
cortistatin A, which proceeded in 15 steps and 3.1% overall yield from 


















Highlights from the synthesis include a key PtCl2-catalyzed 
cycloisomerization to form the seven-membered C ring.128  Further 
functionalization of the C ring proceeded via epoxide intermediate 3.109.   Base-
mediated epoxide opening, followed by an oxidative dearomatization promoted 










































An important advantage of this approach is that the advanced starting 
material 3.105 has previously been made in enantiopure form by Oppolzer,129 
allowing this route to be easily adapted to an enantioselective synthesis.   
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 3.5.3.3 Corey’s Synthesis of the (+)–Cortistatin A Core 
Corey published a semisynthetic approach to a minimal carbocyclic core 
of cortistatin A that started from (+)-estrone and proceeded in seven steps and 



















Key steps from the synthesis include a benzylic oxidation step to install a 
cyanide functional handle, which was then reduced to a primary amine and 
























































While this core structure could not be elaborated to cortistatin A in any 
practical sense, Corey utilized it for the preparation of cortistatin A-inspired 
analogs, some of which proved to exhibit remarkable antiangiogenic activity.131  
3.5.3.4 Yang’s Synthesis of the (+)–Cortistatin A Core 
Yang and coworkers reported a synthesis of a core of cortistatin A, which 
proceeded in eight steps and 10.9% overall yield (Scheme 3.21).132 The starting 
























Key steps include an intramolecular Diels-Alder reaction of a furan to 
form both C and D rings of the core, followed by an acid-catalyzed ring opening  
of 3.122 to furnish phenol 3.123.  The final step employed chemistry almost 
identical to that used in Sarpong’s synthesis, namely a hypervalent iodine-












































Although all four rings are constructed in Yang’s synthesis, it is unlikely 
that 3.120 can be transformed into cortistatin A, due to the absence of 
functionality in both the A and B rings.  While the intramolecular Diels-Alder and 
subsequent ring opening is impressive, the novelty of the final sequence is 
undermined by Sarpong’s prior publication employing similar hypervalent iodine 
chemistry.  
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3.5.3.5 Danishefsky’s Synthesis of a Minimal Cortistatin Core 
In a second publication, Danishefsky described a slightly different 
approach to the BCD ring core of cortistatin A.  Beginning from known 
compound 3.124, the BCD rings were formed in eight steps and 17.7% overall 








3.124 3.125  
The key step in this short sequence was a [3+2] cycloaddition between 
nitrone 3.126 and the benzyne generated from 3.127. Danishefsky postulated that 
the regioselectivity of this cycloaddition is controlled by the electron-donating 
methoxy group ortho to the aryne, via an induced polarization of the reactive 
frontier orbitals of the aryne. The cycloadduct was reduced with Zn/AcOH and an 
intermediate was intercepted (3.129) that was almost identical to intermediate 
3.100 in Danishefsky’s earlier reported synthesis. Danishefsky also used the same 
endgame as reported previously, submitting this intermediate to an 























































3.5.3.6 Gung’s Synthesis of a Minimal Cortistatin Core 
Gung reported a synthesis of a racemic BCD ring framework of the 
cortistatin core. Starting from furan 3.132, the sequence proceeded in eight steps 










Key steps in Gung’s synthesis include an RCM to form a macrocyclic 
allene 3.134 and a palladium-catalyzed [4+3] cycloaddition, which Gung 
postulated proceeded via the cationic "-allyl intermediate 3.136 (Scheme 3.26).  
The cycloaddition is somewhat novel, but suffers from a low yield. Furthermore, 
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the lack of functionality of core structure 3.133 makes it impractical for 




























3.5.3.7 Kobayashi’s Synthesis of the AB rings of the Cortistatin Core 
Kobayashi reported a 22 step synthesis of the AB ring core of cortistatin 
A, starting from commercially available D-mannitol (Scheme 3.27) that 



















Highlights of the synthesis include a Suzuki cross-coupling between the 
vinyl boronate ester 3.140 and 7-bromo-1-chloroisoquinoline 3.141, followed by a 
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Johnson-Claisen rearrangement to establish the correct stereochemistry at the 
isoquinoline-bearing carbon.  The AB rings were constructed via a Michael-aldol 
double cyclization that proceeded with 5:1 trans/cis selectivity to furnish 3.146 in 

























































The major disadvantage in Kobayshi’s approach is its length.  In fact, 
Kobayashi’s synthesis of the AB core is lengthier than Baran’s total synthesis of 
cortistatin A.  In addition, Kobayashi’s synthesis lacks chiral economy as all but 
one of the stereocenters in the starting material, D-mannitol, are discarded in the 
first few steps of the synthesis.        
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3.5.3.8 Magnus’s Synthesis of the ABC rings of the Cortistatin Core 
Magnus and coworkers reported a concise synthesis of the ABC rings of a 
racemic cortistatin A core. This synthesis proceeded in 30% overall yield from 












2.98 3.24 3.147  
Key steps include addition of cyclopropenyllithium 3.149 to aldehyde 
3.148 and a subsequent [4+2] intramolecular cycloaddition to form a mixture 
(1:1) of diasteromeric products.  Following reduction of the oxabicyclic double 
bond to furnish 3.152, both diasteromers were subjected to triflic anhydride and 
base, which catalyzed a cyclopropylcarbinyl rearrangement to afford 3.147 as a 






























































3.5.3.9 Sorensen’s Synthesis of the Cortistatin Core 
The most recent approach to the cortistatin core was reported by 
Sorensen.137 Starting from the Hajos-Parrish ketone 3.41, Sorenson accessed 
















Key steps include a [3+2] dipolar cycloaddition to produce 3.156 with 
perfect regio- and diastereoselectivity, and a hypervalent iodine-mediated 
oxidative cyclization to produce 3.154 (Scheme 3.32). Although a similar 
oxidative dearomatization was exploited in the syntheses by both Sarpong127 and 
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Yang,132 the concomitant oxidation of the aldoxime into a nitrile oxide, leading to 
























































3.6 STUDIES TOWARD THE MARTIN GROUP APPROACH 
3.6.1 Conjugate Additions Employing Furan-2-yl Nucleophiles 
Having previously discovered conditions for enantioselectively adding a 
furan nucleophile to cyclopentenone (see chapter 2), we applied those conditions 
to the first key step of our cortistatin synthesis.  Although we had previously used 
cyclopentenone as a substrate, our synthetic approach called for the use of 2-
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methylcyclopent-2-enone (3.24). However, in a model reaction with the furan-2-
yltitanate 2.116, none of the desired product was obtained (Scheme 3.33), 
illustrating that 2-methylcyclopentenone was incompatible with our methodology.  
This was not entirely surprising since there are virtually no examples of 
enantioselective conjugate additions with $-substituted Michael acceptors, likely 
due to steric buttressing between the $-substituent and the chiral rhodium species 














nBuLi, –78 ºC!0 ºC; then
Ti(OiPr)4, –78 ºC, THF
 
Fortunately, since our methodology employs non-aqueous conditions, it 
seemed plausible that the intermediate silyl enol ether could be isolated and the 
enolate generated therefrom trapped in a subsequent step with a methylating 
reagent.  However, efforts to isolate the TMS enol ether 3.160 were fraught with 
difficulties.  The TMS enol ether is very easily hydrolyzed, making workup 
difficult, and it cannot be purified via distillation nor with chromatography on 














nBuLi, –78 ºC!0 ºC; then
Ti(OiPr)4, –78 ºC, THF
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It was desirable to obtain a more stable silyl enol ether, but it was uknown 
if more hindered alkylchlorosilanes would effectively catalyze the reaction.  
Gratifyingly, chlorotriethylsilane was an effective Lewis acid catalyst in the 
conjugate addition, and the TES enol ether 3.161 was isolated in 95% yield 
(Scheme 3.35).  The TES enol ether (3.161) was much easier to handle and could 
be purified via chromatography on neutral alumina. Additionally, this enol ether 
could be methylated in the presence of tetrabutylammonium 



















nBuLi, –78 ºC!0 ºC; then
Ti(OiPr)4, –78 ºC, THF
 
Satisfied with this result, we extended these conditions to other furan 
derivatives possessing side-chains that could be eventually transformed into a 
furylacetylaldehyde. Accordingly, furan compounds 3.163 and 3.164 were 
prepared by addition of a furanyl cuprate to ethylene oxide, followed by 



















O n-BuLi, CuCN, THF





With these substituted furans in hand, the Rh-catalyzed conjugate addition 
was attempted in the presence of TESCl, but none of the TES enol ether product 
was formed (Scheme 3.37), nor was the hydrolyzed adduct isolated. This was 
unexpected as prior experiments using the analogous zinc chlorides had furnished 







































nBuLi, –78 ºC!0 ºC; then
ZnCl2 (0 ºC) or Ti(OiPr)4 (–78 ºC) 
THF
 
Further investigation revealed that furan derivatives 3.163 and 3.164 may 
not have formed the necessary titanate (Scheme 3.38).  Deuterium quench 
experiments confirmed that deprotonation was occurring quantitatively; however, 
iodine titration revealed that titanate formation had not occurred (Scheme 3.38). It 
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is unclear why iodine would fail to react with the resultant solution as it should 
contain either the aryllithium or the aryltitanate. It is possible that iodine is a poor 
titrant for some furyltitanates. For this reason the subsequent reaction was always 







PG = Bn, 3.164













Although is not obvious why 2-methylfuran is compatible with titanate 
formation but 3.163 and 3.164 are not, our concurrent methodological studies on 
heteroaryl conjugate additions had revealed that titanate formation can sometimes 
be problematic. One such substrate that we had observed similar problems with 
was benzenesulfonylindole.  In that case, we postulated that coordination of the 
sulfonyl oxygen to titanium may have resulted in an unreactive titanate species.  
In the present case, an analogous chelation may be occurring between titanium 
and the oxygen in the furan side chain.  
In order to avoid furan derivatives with oxygenated side chains, addition 
reactions of 2-allylfuran and vinylfuran were evaluated. In the case of 2-
allylfuran, the deprotonation step was troublesome (Scheme 3.39). Considering 
that the allylic hydrogens are weakly acidic, it is conceivable that non-selective 
deprotonation was occurring in the presence of n-BuLi, leading to a mixture of 
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undesired products, perhaps via a ring-opening pathway.  This hypothesis is 
supported by the lack of literature precedent for direct lithiation of 2-allylfuran at 
the C5 position.   
Scheme 3.39 







In the case of 2-vinylfuran, deprotonation with sec-BuLi also was not 
clean, leading to substantial decomposition (Scheme 3.40).  It is known that n-
BuLi will add into vinylfuran at the terminal alkene carbon and this type of side 
reaction may have been occurring with sec-BuLi. It has been reported that the use 
of m-tolyllithium as the base avoids that particular problem. 139 However, use of 
m-tolyllithium led only to recovery of starting material (Scheme 3.40). One 
possible explanation for these poor results may be that the vinylfuran is always 
contaminated with silanol by-products, an artifact of the preparation of vinylfuran, 


































In light of these findings, it was decided to install the furan side chain at a 
later time.  Thus, efforts were then focused on methylation of the TES enol ether. 
3.6.2 Methylation of the TES Enol Ether  
Of the numerous ways that have been reported to methylate enolates 
generated from silyl enol ethers, the most frequently used methods employ either 
a dry fluoride source or an alkylithium to generate the enolate, followed by 
subsequent addition of iodomethane. Variations on these two approaches were 
screened, with the best result deriving from the use of methyllithium as the 
nucleophile in the presence of hexamethylphosphoramide (HMPA) and 
TiCl(OiPr)3 as additives (Table 3.1, entry 9).  These rather unusual conditions 
were discovered in a footnote of a report by Noyori on enolate alkylations.140 
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Table 3.1 
O OTES conditions O O
Me
1                      CsF, MeI, Et3N in CH3CN                                          10% (+ hydrolysis pdt and low mass recovery)
2                     TBAT, MeI, Et3N in DCM/PhMe 
a                                50% (+ hydrolysis pdt)     
3                     TBAT, MeI, Hunig's base in DCM/PhMe                     24% (hydrolysis pdt is major pdt)
4                     TBAT, MeI, NaH in DCM/PhMe                                  68% (hydrolysis pdt is minor pdt)
5                     MeI, NaH in DCM/PhMe (24 h)                                  Unreacted Starting Material
6                     MeI, NaH in DCM/PhMe (>3 d)                                   22% (1:1 mixture of hydrolysis and desired pdt) 
7                     MeLi, MeI in THF (0 ˚C)                                              50% (mixture of desired and polyalkylated pdts)
8                     MeI, MeLi, HMPA in THF (–78 ˚C)                              24% mixture of desired and polyalkylated pdt 
9                     MeI, MeLi, HMPA, TiCl(OiPr)3 in THF (–78 ˚C)           67% (only one diastereomer isolated)
Conditions ResultsEntry
a slow addition of TES enol ether and Et3N to the solution of TBAT via syringe pump (0.1 mL/1 h)
3.177 3.178
 
Unfortunately, when these reaction conditions were scaled up from a 50 
milligram scale to a multi-gram scale, the yields plummeted to the 30% to 50% 
range. Due to these problems, efforts were focused on an alternative synthetic 
route.  
It was envisioned that TES enol ether 3.177 could participate in a 
Mukaiyama-aldol reaction to form 3.179 that, when subjected to MsCl and 
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triethylamine, could undergo an elimination to form exocyclic alkene 3.180.   
Reduction of this enone using Li/NH3 could lead to the desired TMS enol ether 























The first step of the newly devised synthetic strategy was attempted using 
1,3,5-trioxane as the formaldehyde source and TiCl4 as the Lewis acid catalyst.
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As formaldehyde sources are notoriously difficult to work with and 
difficult to dry thoroughly, a condensation reaction was performed with  
Eschenmoser’s salt (Scheme 3.43).  Although the starting material was 
completely consumed, a complex mixture of compounds was isolated that 














Kobayashi has reported the use of lanthanide triflates to catalyze aldol 
reactions with aqueous formaldehyde and TMS enol ether ethers.142 Based upon 
these results, a variety of lanthanide Lewis acids were tested, and a moderate 
yield of the desired product 3.184 could be obtained in 44% yield (Table 3.2, 
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entries 4 and 5).  The majority of the mass balance, however, was still the 









Eq. Formaldehyde (37% wt in H2O)
THF, rt
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The aldol product 3.184 was moved forward and successfully converted 
into enone 3.187 in one pot (Scheme 3.44) using conditions reported by 
Magnus.143 The product was not carried on further as it was a model substrate and 
cannot be transformed into the target compound 3.182.  However, it did establish 













3.184 3.187  
Concurrent with exploring the alternative strategy described above, further 
efforts were made to optimize the conditions for large-scale methylation of the 
TES enol ether. The effects of solvent, equivalents of methyllithium, and 
additives were examined.  It was observed that the rate of enolate formation 
varied greatly with solvent.  In toluene, enolate formation was quite slow and 
required the addition of HMPA to go to completion.  In THF the enolate formed 
without the addition of additives and in diethyl ether the enolate did not form to 
any significant extent, even in the presence of additives.  
In addition to optimizing these variables, it occurred to us that a possible 
obstacle for the methylation reaction could be the triethylsilanol impurity that co-
elutes with 3.177 during chromatography on alumina.  Triethylsilanol is produced 
during the workup following the conjugate addition reaction and is difficult to 
remove without hydrolyzing 3.177.  Gratifyingly, it was found that the majority of 
this silanol could be removed via kugelrohr distillation, under vacuum, without 
destroying the TES enol ether in the process.  This purification, in conjunction 
with the use of toluene as a solvent and HMPA as the additive provided the best 
result to date.  In the event, one major diastereomer was isolated in 70% yield, 
indicated in the 1H NMR spectrum by the presence of only one doublet at 1.13 
ppm, which corresponded to the methyl group  (Scheme 3.45). These results were 
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reproducible on multi-gram scale. The relative stereochemistry was assigned to be 
trans based upon the spectral data for proton Ha, which had an apparent td 
splitting pattern with coupling constants of 11.4 and 6.1 Hz. Ha is coupling to 
protons Hb, Hc, and Hd and will exhibit the largest coupling with those protons 
that are trans to it. Since two of the three couplings are large, it is reasonable to 
conclude that two of the three coupled protons are trans to Ha, which would 
obviously require that Hb be trans to Ha since both Hc and Hd cannot both 
simultaneously be trans to Ha.  
Scheme 3.45 
MeLi (1.5 eq.), MeI (5.0 eq) 














(app td, J = 11.4, 6.1 Hz)
relative stereochemistry shown  
3.6.3 Propargylation and Side-Chain Installation 
The propargylation of 3.178 was predicted to be nontrivial due to the 
question of regioselectivity, as well as the fact that quaternary carbons are 
difficult to create.  Initially, the soundest approach appeared to be to make the 
more substituted TMS sily enol ether first and then propargylate it in a second 
step. However, all attempts to prepare this sily enol elther met with failure.  Thus, 
efforts were focused instead on direct propargylation. 
A variety of solvents, bases and propargyl sources were screened. The use 
of propargyl bromides 3.189 and 3.191 did not furnish any of the desired product, 
 152 
with only recovered starting material being recovered in a low mass balance. The 
use of HMPA and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU) 
resulted in slightly decreased yields of product. A profound solvent effect was 
observed, with toluene and THF consistently furnishing the best yields and 
dioxane and DMSO furnishing the lowest yields. The reaction time was crucial, 
with times longer than 2 h resulting in diminished yields. Optimal results were 
obtained using NaHMDS (0.9 equivalents) and TMS-protected propargyl iodide 
3.190 in THF in the presence of a slight excess of the ketone. It was crucial that 
the propargyl iodide 3.190 be prepared immediately prior to use and kept in the 
dark. The reaction proved to be extremely regio- and stereoselective, furnishing 
only one diastereomer in 81% yield (Scheme 3.46). nOe studies did not elucidate 
which diastereomer was formed because weak nOe correlations were found 
between Ha and methyl group, as well as between Ha and the protons on the 
propargylic carbon, Hb and Hc.  Derivatization of 3.188 to its phenyl hydrazone 





















NaHMDS, THF, –78 ºC!RT, 
then                        0 ºC, 2 h





weak nOe correlation between
Ha/Hb, Ha/Hc, and Ha/methyl
Solvents screened: PhMe, Et2O, DMSO, THF, dioxane, PhH








With 3.188 in hand, functionalization at C5 of the furan ring was 
attempted (Scheme 3.47). In an effort to avoid two separate steps, the formation 
of intermediate dianion 3.192 was attempted using excess sec-BuLi, followed by 
addition of allyl bromide. In the reaction, a solution of furan 3.188 was prepared 
in THF and two equivalents of sec-BuLi were added dropwise at –78 ˚C. The 
resultant solution was warmed to 0 ˚C for 90 min, and then allyl bromide was 
added at –78 ˚C. None of the desired product 3.193 was obtained, nor was starting 
material recovered. Attempts to isolate the TES enol ether 3.194 also failed and 
































Protection of the neopentyl ketone as its 1,3-dioxolane was attempted in 
the presence of ethylene glycol and pyridinium para-toluenesulfonate in refluxing 
benzene, with the aid of a Dean-Stark apparatus, but this reaction was low 
yielding, likely due to the steric hindrance presented by the adjacent quaternary 













3.188 3.195  
The order of the synthetic sequence was altered so that the protection of 
the ketone would precede propargylation. Towards that end, 3.178 was protected  
as its ketal in quantitative yield.  Subsequent allylation of the furan ring proceeded 
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smoothly to give 3.197 in 72% yield (89% BRSM), and deprotection of the 
ketone occurred in quantitative yield to furnish 3.198. Propargylation of 3.198 
using the optimized conditions for 3.178 provided the desired product 3.193 in 
83% yield as one major diastereomer (Scheme 3.49). Attempts to isolate a crystal 
via formation of the p-nitrohydrazone and phenylhydrazone derivatives were 





































NaHMDS, THF, –78 ºC"RT, 
then                        0 ºC, 2 h
                83%
3.199  
Although it was necessary to introduce two protection/deprotection steps 
in order to functionalize the furan at C5, there was no loss in overall yield due to 
the excellent conversion in both of those steps. 
3.6.4 Functionalization of the Furan Side Chain  
In order to convert the allyl side chain of 3.193 to the requisite 
arylacetylaldehyde 3.20, a one-step oxidative cleavage was attempted. Ozonolysis 
of 3.193 followed by reduction of the intermediate ozonide led to a low mass 
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balance of a complex mixture of products (Table 3.3, entry 1). It is well-known 
that furan can participate in [4+3] and [3+2] cycloadditions with ozone, 
furnishing unstable adducts that readily undergo ring opening.144 If the furan ring 
reacted preferentially with ozone over the terminal double bond, a variety of 
unwanted oxidation products could potentially be formed, many of which would 
be polar enough to be lost in the aqueous phase during workup. Oxidation of 
3.193 under Johnson-Lemieux reaction conditions also led to low mass recovery 
of a complex mixture of products (Table 3.3, entry 2). Interestingly, other 
reported efforts to perform Johnson-Lemieux reactions on similar compounds 
have also failed to furnish the desired aldehydes.145 Submission of 3.193 to 
potassium permanganate and tetrabutylammonium chloride in DCM,146 also 
known as “purple DCM,” resulted only in recovered starting material (Table 3.3, 
















   AcOH/NaOAc buffer workup (pH=3.7)
Low mass recovery, complex mixture
X
Low mass recovery, complex mixture
Recovered starting material only
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A two-step oxidation involving dihydroxylation of the olefin to the diol 
and subsequent cleavage was also investigated. The use of potassium osmate(VI) 
dihydrate and N-methylmorpholine-N-oxide (NMO) as the oxidant provided the 
desired diol in low yield. Reacting 3.193 with commercially available asymmetric 
dihydroxylation reagent (ADMix-$) led to a moderate 56% yield of 3.200. 
Despite the observation that methanesulfonamide slows the dihydroxylation of 
mono-substituted olefins,147 the use of methanesulfonamide was necessary to 
achieve moderate conversion.  The absence of this additive led to isolation of only 
starting material. Literature precedent involving the dihydroxylation of vinyl 
furan indicates that very long reaction times (96 h) are necessary to achieve high 
yields.148 In light of this, prolonged reaction times may be necessary improve the 










AD-Mix! , t-BuOH/H2O (1:1)
CH3SO2NH2, RT, 16 h
Entry Conditions Results
1 56% yield, 80% BRSM
2 K2OsO4(2H2O), NMO
Acetone:H2O (1:1), 18 h




Subsequent oxidative cleavage of diol 3.200 occurred smoothly in the 
presence of sodium periodate to yield the desired furylacetylaldehyde 3.20 in 75-
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100% yields (Scheme 3.50). Purification of this material on silica gel led to 
decomposition and low recovery of the desired aldehyde. Therefore, in most cases 













3.200 3.20  
3.6.5 Diastereoselective Alkynylation  
With aldehyde 3.20 in hand, an asymmetric alkynylation was attempted 
using conditions reported by Carriera.118 In the presence of both triethylamine and 
Hunig’s base, the aldehyde was completely consumed, but the desired product 
was not isolated (Table 3.5). Using different alkynes, e.g., phenylacetylene and 1-
hexyne, did not appear to affect the reaction. Drying zinc triflate thoroughly under 
vacuum immediately prior to use did not affect the reaction. Similarly, distillation 
of the alkynes immediately prior to use did not improve the reaction. Although 
Carreira has reported that this chemistry is not very sensitive to air, the reaction 
was also performed under argon, but that did not alter the outcome. Monitoring of 




















Et3N Ph Aldehyde consumed; complex mixture isolated
iPr2EtN Ph Aldehyde consumed; complex mixture isolated
3.20
Et3N nBu Aldehyde consumed; complex mixture isolated







R = Ph: 3.201 
R = nBu: 3.202
 
Although Carreira’s work in this area is certainly the most well-developed 
and commonly used, there are other methods for effecting the asymmetric 
addition of alkynes to aldehydes. Shibasaki has reported a method employing 
indium bromide and (R)-BINOL to add phenylacetylene to a variety of aldehydes 
in good yield and high enantiomeric excess.149 However, when these conditions 
were applied to aldehyde 3.20, the desired product was not obtained and a 






















It is known that arylacetylaldehydes can be problematic to work with due 
to their propensity to enolize and undergo self-condensation. In order to minimize 
deleterious self-condensation reactions, the modified aldehyde 3.205 was 
prepared, in which the ketone is protected (Scheme 3.52). Although it is sterically 
hindered, the ketone could be a potential aldol partner and may be contributing to 



























Upon submission of 3.205 to Carreira’s conditions, this substrate proved 






















Pu has also reported a method for enantioselective acetilide addition to 
aldehydes, but unfortunately it necessitates the use of a glovebox.150 Future trials 
may be successful using a slow addition of the aldehyde with the conditions 
reported by Carreira. Due to the high reaction concentration required with 
Carreira’s method (2 M in DCM), it would be necessary to peform this reaction 
on a reasonable scale.  
Thus, the use of a diastereoselective alkynlation may not be feasible with 
furylacetyl aldehyde 3.20. However, it would be worthwhile to try this reaction on 
larger scale, using a very slow addition. 
3.6.6 Diels-Alder Key Step 
Early in our investigations, we probed the feasibility of an intermolecular 
Diels-Alder reaction. Our approach was based upon Kagan’s reports that furan 
and chiral vinylsufonium salt 3.19 produced Diels-Alder adducts in high yields 


























1) DCM, 0 ºC, 60 h
2) NaOH
90%
93% de 89% de
3.19 2.5
3.207-endo 3.207-exo
endo:exo = 1.2:1  
Diastereoselectivity in this reaction is contingent upon two things: 
conformational selectivity of the dienophile and facial selectivity in the Diels-
Alder transition state.  In the context of conformational preferences of the 
dienophile, it is known that vinyl sulfoxides can exist in either the s-cis or s-trans 








s-cis 3.19 s-trans 3.19  
Kagain has stated, without explanation, that approach from si face of the 
sulfoxide is the preferred pathway. Kagan postulated that the s-cis conformer is 
preferred in the Diels-Alder transition state as it allows the most sterically 
accessible approach to the si face of the sulfoxide, away from the bulky p-tolyl 





















We investigated the application of Kagan’s reaction conditions to our 
Diels-Alder key step. It was first necessary to synthesize the chiral dienophile 
3.19, which proved much more difficult than anticipated.  The synthesis involves 
a four-step sequence starting from the sodium salt of p-toluenesulfinic acid.  The 
first two steps include the formation of p-tolylsulfinylchloride, followed by 
displacement of chloride ion with (–)-menthol (Scheme 3.55).  The product 3.210 
was isolated via recrystallization in consistently poor yields, most likely due to 















The third step of the sequence involved the reaction of a vinyl Grignard 
reagent with 3.210 to furnish the optically active vinylsulfoxide 3.212. The 
literature conditions reported for the generation of 3.212 are very diverse, ranging 
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from 10 minutes at –58 ˚C in toluene to reflux for 3 h in diethyl ether.153, 154 All 
attempts to reproduce the results from those literature procedures failed and 

























After screening a number of conditions, we found that a 64 % yield of the 
desired sulfoxide 3.212 could be obtained in benzene at room temperature in the 
presence of 1.3 eq. of the vinyl Grignard reagent. It was critical to keep the 
Grignard reagent within a strict stoichiometric range, and to prepare the Grignard 





















1 Benzene 23 ºC 2.5 <5
2 THF –58 ºC 2.5 <5
3 Et2O –58 ºC 2.5 <5
4 THF –58 ºC 1.5 5
5 Benzene 23 ºC 1.5 53
6 Benzene 23 ºC 1.3 64
7 Benzene 23 ºC 1.0 50
 
The final step of the synthesis of the dienophile 3.212 was a 
straightforward alkylation of the sulfoxide with Meerwein’s reagent (Scheme 
3.57). The desired product 3.19 was isolated easily and used without purification 







3.212 3.19  
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In an effort to simplify the analysis of the reaction, the asymmetric Diels-
Alder step was first attempted with the model substrate dimethylfuran (3.213).  
By using dimethylfuran, the total number of possible diastereomers would be 
minimized to four, and the issue of regioisomers would be eliminated completely.  
To our delight, the formation of endo-3.214 and exo-3.214 was achieved in 73% 
yield and 77% and 82% diastereomic excess, respectively. The best results were 
achieved when the reaction was conducted in chloroform at –20 ˚C (Table 3.7, 
entry 5).  The diastereomeric excess was determined by 1H NMR integration of 
the proton alpha to the sulfoxide moiety. Four distinct chemical shifts are 







































DCM, rt, 2.5h 70 2:1 50 62
DCM, 0 ºC, 36h 95 1.6:1 60 66
CHCl3, 0 ºC, 36h 86 1.6:1 60 68
DCM, –20 ºC, 2.5 h 0
CHCl3, –20 ºC, 36h 73 2:1 77 82
n/a n/a n/a
n/a = not applicable  
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The endo/exo ratios we observed were in agreement with those that Kagan 
observed when reacting 3.19 with furan.6 Endo/exo assignments were based upon 
nOe correlations between the vinyl proton and the pseudo-axial proton alpha to 
the sulfoxide moiety (Figure 3.9). The exo products exhibited an nOe correlation 





















Noe observed b/w Ha and Hd
2.82 ppm (Hd)
VS.
ENDO PRODUCT EXO PRODUCT  
Confirmation of the structures of the Diels-Alder adducts was obtained by 
Noah Benjamin, who obtained crystal structures of both the major endo and major 
exo adducts.  The major endo product is shown in Figure 3.10 and the major exo 







Figure 3.10: Endo Main 
 
Figure 3.11: Exo Main 
 
With the successful extension of Kagan’s Diels-Alder chemistry to 2,5-
disubstituted furans, we tried the reaction with the more complex substrate 2.100 
(Scheme 3.58).  Compound 2.100 was employed in racemic form because at the 
time this experiment was performed we had not yet established conditions for the 
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enantioselective conjugate addition of furan to cyclopentenone.  When 2.100 was 
submitted to the asymmetric Diels-Alder reaction two major products were 
obtained.  A total of 16 possible diastereomers can be produced by the reaction of 
racemic 2.100 with the chiral dienophile 3.19.  Although the NMR evidence is not 
conclusive due to overlapping signals in the proton spectrum, it is consistent with 
an oxabicycle such as 3.215 due to the presence of vinyl protons at 6.50 ppm and 
6.33 ppm in the 1H NMR spectrum, which is similar to the oxabicyclic compound 
3.214. Additionally, 1H NMR spectrum shows the disappearance of the furan 
protons at 5.92 ppm and 5.86 ppm from the starting material, as well as the 
presence of a new tolyl group.  It was not discernible by NMR whether the two 
major products differ only at the stereochemistry at the cyclopentanone, or if they 
are endo/exo- or regioisomers.  Better assignments would require the separation 













1. DCM, –20 ˚C









This example raises the issue of regioselectivity. In addition to the 
possibility of forming endo/exo isomers, there is the further complication of 
forming regioisomers, leading to an increased number of products. Even if the 
reaction proceeds with exo selectivity, regiosisomers can lead to different 
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enantiomers following desulfurization (Figure 3.12). The same analysis with an 































Similar problems arise in terms of endo/exo selectivity (Figure 3.13). Even 
if regioselectivity is high, endo/exo isomers can lead to different enantiomers 
following desulfurization. Thus, in order to achieve excellent enantiomeric excess 
of the desulfurized Diels-Alder adducts, the reaction must also exhibit endo/exo- 
and regioselectivity as well. Kagan’s method suffers from low endo/exo 



































In response to the  lack of methodologies available to achieve this 
transformation in high endo/exo-, regio-, and diastereoselectivity, we began our 
own methodological development in this area. Progress towards a solution to this 
problem has been made in the Martin group by Noah Benjamin and will be 
reported in due course. In the context of cortistatin A, however, a different 
solution to this problem was recently discovered that precludes the need to 
perform an intermolecular Diels-Alder reaction. 
3.6.7 Altered Synthetic Route 
Since the alkynylation step had proven to be far more problematic than 
anticipated, it was necessary to alter our synthetic approach. Because we had 
already previously discovered that ADMix was an effective dihydroxylation 
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reagent for 3.193, we postulated that the desired stereochemistry at C3 could be 
established via the Sharpless asymmetric dihydroxylation reaction. Subsequent 
transformation of the terminal alcohol into an alkene could be performed at a later 
stage to access 3.221, but prior to the cascade RCM (Scheme 3.59).  In addition, it 
occurred to us that an intramolecular Diels-Alder pathway would also be available 
if we functionalized the secondary alcohol as its vinyl sulfonate derivative 3.224. 
Intramolecular Diels-Alder reactions are often much more facile, regio-, and 
stereoselective than their corresponding intermolecular variants and this was of 

















































In this area, Metz and coworkers have reported an intramolecular Diels-
Alder of 3.226 to give 3.227 (Scheme 3.60).155 The reaction proceeded to give 
only a single diastereomer.156 The vinylsulfonate intermediate 3.226 was not 


















The stereochemistry of the secondary alcohol is important as it will direct 
the facial selectivity in the Diels-Alder reaction. In our strategy, the (S)-alcohol 
3.229 would yield the wrong stereochemistry at the oxabicyclic bridgehead 
carbons (Scheme 3.62), but the (R)-alcohol 3.228 would furnish the desired 
adduct (Scheme 3.61). This is fortuitous since the (R)-alcohol has the 










































































 Transition State  
According to the Sharpless AD mnemonic, the desired (R)-alcohol will be 
produced using ADMix-# in the dihydroxylation step. In the event, racemic furan 
3.193 was dihydroxylated to produce diol 3.200 in 50% yield. The primary 































The alcohol was sulfonylated with vinylsulfonyl chloride to produce 3.224 
in quantitative yield (Scheme 3.64). This intermediate was isolable and did not 
undergo spontaneous cycloaddition, although after standing at room temperature 

































 By heating furan 3.224 in benzene for 24 h, conversion to the Diels-Alder 
adduct 3.223 was complete, and a 95% yield of two diastereomers (1:1 ratio) was 
obtained (Scheme 3.65). Since we started from racemic furan 3.193, the two 
diastereomers must differ in the stereochemistry of the chiral carbons that are $ 
and # to the carbonyl group in the cyclopentanone ring. Furthermore, the fact that 
we only isolated two diastereomers is very promising because that is the 
minimum number of diastereomers that could be isolated after the Diels-Alder 
step is two, and this would only happen if both the dihydroxylation and Diels-
Alder reactions had occurred with perfect diastereoselectivity.  Gratifyingly, the 
two diasteromers were separable by silica chromatography and were fully 
characterized by NMR, IR, and mass spectrometry. A large coupling between Ha 
and Hb is present in the NMR spectrum for both diastereomers, which is 
consistent with an axial-axial coupling and thus the equatorial placement of the 
carbosiloxy moiety (Figure 3.14). Efforts are ongoing to obtain a crystal structure 
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of each individual diastereomer to verify their relative and absolute 




























2 hours:  50% conversion
6 hours:  80% conversion























3 coupling = 12.1 Hz (ax-ax coupling)  
3.7 SUMMARY AND CONCLUSIONS 
 Cortistatin A is an exciting natural product that presents both valuable 
biological activity and novel structural challenges. The antiangiogenic properties 
of cortistatins A and J ensure that these natural products, as well as their analogs, 
will be continue to studied for years to come. Due to the lack of natural 
abundance of the marine sponge from which the cortistatins are derived, the need 
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for efficient methods to access these molecules is great. Progress has been made 
towards the establishment of practical syntheses of these compounds, but 
certainly room for improvement still exists.  
 At the outset of our studies, we identified three key synthetic 
transformations for which there existed little or no precedent. We successfully 
developed a solution for the first of those steps, an enantioselective conjugate 
addition of furan to cyclopentenone. We then extended our solution to developing 
a broad methodology that is applicable to many compounds beyond cortistatin A 
(see chapter 2). The second key step, an intermolecular, diastereoselective Diels-
Alder reaction, was examined and we advanced the field in this area by extending 
this chemistry to 2,5-disubstituted furans. However, we eventually replaced this 
intermolecular reaction with an extraordinarily efficient intramolecular Diels-
Alder reaction. This discovery broadens the existing methodology available for 
intramolecular Diels-Alder reactions with substituted furans. The third key step, a 
cascade RCM, was not examined but the Martin group plans to pursue this 
approach in the future. 
 We have accessed an advanced intermediate in our synthesis of cortistastin 
A by an approach that requires only 10 linear steps and proceeds in 17% overall 
yield (40% based on recovered starting material). Most of the steps used 
commercially available or inexpensive starting materials and were high yielding, 
including challenging transformations such as the installation of a quaternary 
carbon via an enolate alkylation and the intramolecular Diels-Alder cycloaddition.    
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 Our synthetic route has the advantage that it can also access cortistatin J 
without any alteration, as well as a simpler core structure that could potentially be 
used for analog synthesis. These additional synthetic targets may also be pursued 



















Chapter 4: Experimental Procedures 
4.1 GENERAL 
Unless otherwise noted, solvents and reagents were used without 
purification. Tetrahydrofuran (THF) and diethyl ether (Et2O) were dried by 
passage through two columns of activated neutral alumina. Methanol (CH3OH), 
acetonitrile (CH3CN), and N,N-dimethylformamide (DMF) were dried by passage 
through two columns of activated molecular sieves. Toluene was dried by 
sequential passage through a column of activated neutral alumina followed by a 
column of Q5 reactant. Methylene chloride, triethylamine, and NN-
diisopropylamine were distilled from calcium hydride prior to use. Benzene was 
distilled from sodium/benzophenone. Acetone was distilled from molecular 
sieves. All solvents were determined to contain less than 50 ppm H2O by Karl 
Fischer coulometric moisture analysis. All reactions were performed in flame-
dried glassware under argon or nitrogen unless otherwise indicated. Volatile 
solvents were removed under reduced pressure using a Buchi rotary evaporator. 
Infrared (IR) spectra were obtained using a FTIR 1600 spectrophotometer using 
sodium chloride plates and reported as wave numbers. Low resolution chemical 
ionization mass spectra were obtained with a TSQ-70 instrument. High resolution 
measurements were made with a VG Analytical ZAB2-E instrument. Analytical 
thin layer chromatography was performed using 250 micron 60F-254 silica gel 
plates. The plates were visualized with UV light, p-anisaldehyde, and potassium 
permanganate. Flash column chromatography was performed according to Still’s 
 180 
procedure (Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923) using 
ICN Silitech 32-63 D 60A silica gel. 
1H nuclear magnetic resonance (NMR) spectra were obtained at either 
600, 500, or 400 MHz as solutions in CDCl3 unless indicated otherwise. 
13C NMR 
were obtained at either 125, 100 or 75 MHz in the indicated deuterated solvent. 
Chemical shifts are reported in parts per million (ppm, "), and referenced to TMS, 
and coupling constants are reported in Hertz (Hz). Spectral splitting patterns are 
designated as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; comp, 
complex; br, broad; and app, apparent.  
Reagent Preparation. All reagents were freshly distilled or otherwise 
purified immediately prior to use. Cyclopentenone, cyclohexenone, and 
chlorotrimethylsilane were distilled over calcium hydride; furan, benzofuran, 
pyrrole, thiophene, benzothiophene were distilled over potassium hydroxide; 1-
methyl-5,6-dihydropyridin-2(1H)-one, butenolide, and N-methylindole were 
prepared and purified according to known literature procedures;157 titanium 
tetraisopropoxide was purchased from Aldrich (98% pure) and distilled; ZnCl2 
was fused under reduced pressure; [Rh(COD)acac] and [RhCl(C2H4)]2 were 
purchased from STREM and used without purification; (R)-MeO-BIPHEP was 
received from Solvias and dried under vacuum prior to use. (R)-Tol-BINAP was 
purchased from STREM, and traces of phosphine oxide were removed via flash 
chromatography. Tetrahydrofuran (THF) was passed through a column of neutral 

























(1.114). To a to a solution of [Rh(CO)2Cl]2 (10 mol %) in degassed MeCN (0.75 
mL) was added 1.117 (169 mg, 0.67 mmol) and the solution was stirred for 10 
min at –40 ˚C.  In a separate flask, 1.21 (50 mg, 0.27 mmol) was added to a slurry 
of NaH (16 mg, 0.41 mmol, 60% dispersion in mineral oil) in MeCN (2.0 mL) at 
room temperature, and the mixture was stirred for 30 min.  The resulting solution 
of sodium enolate was then added via syringe to the solution of 1.117 and 
[Rh(CO)2Cl]2 at –40 ˚C.  The reaction mixture was stirred for 6 h at –40 ˚C, 
whereupon it was transferred to a screw cap vial that was sealed and heated at 110 
˚C (bath temperature) until the intermediate enyne 1.113 was consumed (30 min).  
The reaction mixture was diluted with H2O (2 mL) and Et2O (2 mL), and the 
layers were separated.  The aqueous phase was extracted with Et2O (5 x 2 mL), 
and the combined organic fractions were dried (MgSO4) and concentrated under 
reduced pressure.  The crude residue was purified by flash chromatography 
eluting with pentane/Et2O (5:1) to furnish 49 mg (72%) of 1.114 as a pale yellow 
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oil: 1H NMR (500 MHz) ( 5.50'5.41 (app ddq, J = 15.7, 6.4, 0.6 Hz, 1 H), 5.52-
5.22 (comp, 2 H), 3.74 (s, 3 H), 3.73 (s, 3 H), 3.04'2.98 (comp, 2 H), 2.85-2.80 
(m, 1 H), 2.52-2.48 (ddd, J = 12.9, 7.4, 1.8 Hz, 1 H), 1.92-1.87 (dd, J = 12.9, 11.6 
Hz, 1 H), 1.69-1.67 (dd, J = 6.4, 1.6 Hz, 3 H), 1.61-1.55 (comp, 3 H);  13C NMR 
(500 MHz) ( 172.5, 172.4, 141.4, 132.3, 126.8, 117.5, 58.5, 52.8, 52.7, 46.8, 40.9, 
36.8, 17.9, 14.6; mass spectrum (CI) m/z 252.1361 [C14H20O4 requires 252.1362] 
253 (base), 252, 221, 193, 192.  
NMR Assignments. 1H NMR (500 MHz) ( 5.50'5.41 (app ddq, J= 15.7, 
6.4, 0.6 Hz, 1 H, C9-H), ( 5.52-5.22 (comp, 2 H, C2-H & C8-H), ( 3.74 (s, 3 H, 
C13-H), ( 3.73 (s, 3 H, C14-H), ( 3.04'2.98 (comp, 2 H, C4-H & C7-H), ( 2.85-
2.80 (m, 1 H, C4-H), ( 2.52'2.48 (ddd, J=12.9, 7.4, 1.8 Hz, 1 H, C6-H), ( 1.92-
1.87 (dd, J=12.9, 11.6 Hz, 1 H, C6-H),  ( 1.69-1.67 (dd, J=6.4, 1.6 Hz, 3 H, C10-
H),  ( 1.61-1.55 (comp, 3 H, C1-H);  13C NMR (500 MHz) ( 172.5 (C11), 172.4 
(C12), 141.4 (C3), 132.3 (C8), 126.8 (C9), 117.5 (C2), 58.5 (C5), 52.8 (C13), 























2,2(1H)-dicarboxylate (1.118).  To a solution of [Rh(CO)2Cl]2 (10 mol %) in 
degassed PhMe (1.25 mL) was added 1.113 (30 mg, 0.126 mmol), and the 
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solution was stirred for 20 min at room temperature. The mixture was then sealed 
in a screw cap vial under an atmosphere of argon and heated to 110 ˚C for 15 min. 
The reaction mixture was cooled to room temperature and was then filtered 
through a short plug of silica gel eluting with Et2O (15 mL), and the filtrate was 
concentrated under reduced pressure. The crude residue was purified by flash 
chromatography, eluting with pentane/Et2O (5:1) to yield 1.118 as a minor side-
product:  1H NMR (500 MHz) ! 3.79 (s, 3 H), 3.76 (s, 3 H), 3.27 (d, J = 17.1 Hz, 
1 H), 3.12 (d, J = 17.1 Hz, 1 H), 3.11–3.06 (m, 1 H), 2.64 (dd, J = 12.6, 7.3 Hz, 1 
H), 2.43 (dt, J = 11.7, 6.2 Hz, 1 H), 1.82 (t, J = 12.99 Hz, 1 H), 1.71–1.69 (m, 3 
H), 1.63 (dqd, J = 15.1, 7.5, 5.4 Hz, 1 H), 1.32–1.26 (m, 1 H), 1.04 (t, J = 7.4 Hz, 
3 H); 13C NMR (500 MHz) ! 211.8, 176.2, 172.1, 171.6, 131.3, 60.4, 53.2, 53.1, 
50.6, 46.5, 34.7, 34.0, 22.2, 13.1, 8.5; mass spectrum (CI) m/z 281.1383 
[C15H21O5 requires 281.1388] 309, 281 (base). 
NMR Assignments: 
1H NMR (500 MHz) ! 3.79 (s, 3 H, C15-H), 3.76 (s, 
3 H, C14-H), 3.27 (d, J = 17.1 Hz, 1 H, C9-H), 3.12 (d, J = 17.1 Hz, 1 H, C9-H), 
3.11–3.06 (m, 1 H, C4-H), 2.64 (dd, J = 12.8, 7.3 Hz, 1 H, C11-H), 2.43 (dt, J = 
11.7, 6.2 Hz, 1 H, C5-H), 1.82 (app t, J = 12.8 Hz, 1 H, C11-H), 1.71–1.69 (m, 3 
H, C8-H), 1.63 (dqd, J = 15.1, 7.5, 5.4 Hz, 1 H, C6-H), 1.32–1.26 (m, 1 H, C6-H), 
1.04 (t, J = 7.4 Hz, 3 H, C7-H); 1H NMR (500 MHz) ! 211.8 (C1), 176.2 (C3), 
172.1 (12), 171.6 (C13), 131.3 (C2), 60.4 (C10), 53.2 (C14), 53.1 (C15), 50.6 























Dimethyl 2-(but-2-ynyl)-2-(cyclohex-2-enyl)malonate (1.125) (AJS-II-
16). Allylic trifluoroacetate 1.124 (100 mg, 0.52 mmol) was added to a solution of 
[Rh(CO)2Cl]2 (10 mol%, 8 mg, 0.021 mmol) in CH3CN (1 mL), and the solution 
was stirred for 10 min at room temperature. In a separate flask malonate 1.21 
(0.21 mmol) was added to a slurry of NaH (60% w/w in mineral oil, 0.42 mmol) 
in CH3CN (1 mL) at room temperature, and the mixture was stirred for 30 min. 
The resulting sodium enolate was added via syringe to the solution of 1.124 and 
[Rh(CO)2Cl]2 at room temperature. The mixture was then sealed in a screw cap 
vial under an atmosphere of argon, and heated to 110 ˚C for 45 min. The reaction 
mixture was cooled to room temperature and was then filtered through a short 
plug of silica gel eluting with Et2O (25 mL), and the filtrate was concentrated 
under reduced pressure. The crude residue was purified by flash chromatography, 
eluting with pentane/Et2O (5:1) to furnish 40 mg (72%) of 1.125 as a colorless oil. 
1H NMR (500 MHz) !  5.78–5.70 (comp, 2 H), 3.75 (s, 3 H), 3.70 (s, 3 H), 3.14–
3.08 (m, 1 H), 2.84 (dq, J = 17.1, 2.5 Hz, 1 H), 2.76 (dq, J = 17.1, 2.5 Hz, 1 H), 
1.96–1.93 (comp, 2 H), 1.88–1.76 (comp, 2 H), 1.75 (t, J = 2.5 Hz, 3 H), 1.61–
1.52 (m, 1 H), 1.37–1.29 (m, 1 H); 13C NMR (100 MHz) ! 170.7, 170.4, 128.7, 
127.7, 78.7, 73.8, 60.7, 52.4, 52.2, 38.7, 24.9, 24.2, 23.0, 22.3, 3.6. 
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NMR Assignments: 1H NMR (500 MHz) !  5.78–5.70 (comp, 2 H, C1-H 
& C2-H), 3.75 (s, 3 H, C8-H), 3.70 (s, 3 H, C9-H), 3.14–3.08 (m, 1 H, C6-H), 
2.84 (dq, J = 17.1, 2.5 Hz, 1 H, C12-H), 2.76 (dq, J = 17.1, 2.5 Hz, 1 H, C12-H), 
1.96–1.93 (comp, 2 H, C3-H), 1.88–1.76 (comp, 2 H, C4-H & C5H), 1.75 (t, J = 
2.5 Hz, 3 H, C15-H), 1.61–1.52 (m, 1 H, C4-H), 1.37–1.29 (m, 1 H, C5-H); 13C 
NMR (100 MHz) ! 170.7 (C8), 170.4 (C9), 128.7 (C1), 127.7 (C2), 78.7 (C13), 
73.8 (C14), 60.7 (C7), 52.4 (C10), 52.2 (C11), 38.7 (C6), 24.9 (C3), 24.2 (C5), 





































                  1.127                                            1.126 
Procedure for the [Rh(CO)2Cl]2-Catalyzed Tandem Allylic Alkylation/ 
Cycloisomerization to furnish (E)-dimethyl 3-ethylidene-3,3a,7,7a-
tetrahydro-1H-indene-1,1(2H,6H)-dicarboxylate (1.126) and dimethyl 3-
ethyl-7,7a-dihydro-1H-indene-1,1(2H,6H)-dicarboxylate (1.127).  Allylic 
trifluoroacetate 1.117 (130mg, 0.67 mmol) was added to a solution of 
[Rh(CO)2Cl]2 (10 mol%, 17 mg, 0.045 mmol) in MeCN (0.75 mL), and the 
solution was stirred for 10 min at 0 ˚C.  In a separate flask, malonate 1.21 (83mg, 
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0.45 mmol) was added to a slurry of NaH (60% dispersion in mineral oil, 22mg, 
0.54 mmol) in MeCN (2.0 mL) at room temperature, and the mixture was stirred 
for 30 min.  The resulting solution of sodium enolate was then added via syringe 
to the solution of 1.117 and [Rh(CO)2Cl]2 at ambient temperature.  The reaction 
mixture was stirred for 1 h at rt, then sealed in a screw cap vial and heated to 110 
˚C in the microwave (300 W, cooling) for 30 minutes. The reaction mixture was 
filtered through a plug of silica gel with Et2O and then concentrated under 
reduced pressure.  The crude residue was purified by flash chromatography 
eluting with pentane/Et2O (5:1) to furnish an inseparable mixture of 1.126 and 
1.127 (40–65%, ca. 3:1 ratio of 1.126:1.127): 1H NMR (500 MHz) ! 6.24 (dd, J = 
9.8, 2.5 Hz, 0.25 H), 5.85–5.81 (m, 0.75 H), 5.73–5.68 (m, 1 H), 5.22–5.16 (m, 
0.75 H), 3.73 (s, 0.75 H), 3.72 (s, 2.25 H), 3.70 (s, 2.25 H), 3.67 (s, 0.75), 3.48 (br 
d, J = 13.3 Hz, 0.25 H), 3.21–3.16 (comp, 1.5 H), 3.05 (d, J = 17.0 Hz, 0.25 H),   
2.81–2.76 (comp, 1.5 H), 2.65 (d, J = 17.0 Hz, 0.25 H), 2.26–2.12 (m, 1 H), 2.06–
1.95 (m, 1.75 H), 1.59–1.56 (m, 2.25 H), 1.29–1.23 (m, 0.75H), 1.16–1.05 (m, 1 
H), 1.00 (t, J = 15.2 Hz, 0.75 H); 13C NMR (125 MHz) ! 172.6, 172.4, 171.2, 
170.5, 142.0, 134.4, 129.8, 128.7, 126.9, 126.1, 121.5, 117.3, 62.4, 61.6, 52.7, 
52.5, 51.9, 49.5, 42.9, 42.8, 42.7, 34.5, 26.3, 25.6, 24.7, 21.1, 20.6, 14.7, 12.5; MS 
(CI/CH4) m/z (rel intensity, %) 293([M+C2H5]




NMR Assignments. 1H NMR (500 MHz) ! 6.24 (dd, J = 9.8, 2.5 Hz, 0.25 
H, C7a-H), 5.85–5.81 (m, 0.75 H, C7-H), 5.73–5.68 (m, 1 H, C8-H & C8a-H), 
5.22–5.16 (m, 0.75 H, C12-H), 3.73 (s, 0.75 H, C1a-H), 3.72 (s, 2.25 H, C1-H), 
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3.70 (s, 2.25 H, C1-H), 3.67 (s, 0.75, C1a-H), 3.48 (br d, J = 13.3 Hz, 0.25 H, 
C11a-H), 3.21–3.16 (comp, 1.5 H, C6-H & C4-H), 3.05 (d, J = 17.0 Hz, 0.25 H, 
C4a-H),  2.81–2.76 (comp, 1.5 H, C11-H & C4-H), 2.65 (d, J = 17.0 Hz, 0.25 H, 
C4a-H), 2.26–2.12 (m, 1 H, C9a-H, C12a-H), 2.06–1.95 (m, 1.75 H, C9-H & 
C10a-H), 1.59–1.56 (m, 2.25 H, C13-H), 1.29–1.23 (m, 0.75H, C10-H), 1.16–
1.05 (m, 1 H, C10a-H & C10-H), 1.00 (t, J = 15.2 Hz, 0.75 H, C13a-H); 13C NMR 
(125 MHz) ! 172.6 (C2a), 172.4 (C2), 171.2 (C2a), 170.5 (C2), 142.0 (C5), 134.4 
(C5a), 129.8 (C6a), 128.7 (C8a), 126.9 (C7), 126.1 (C8), 121.5 (C7a), 117.3 
(C12), 62.4 (C3), 61.6 (C3a), 52.7 (C1), 52.5 (C1 & C1a overlap), 51.9 (C1a) , 
49.5 (C11a), 42.9 (C11), 42.8 (C6), 42.7 (C4a), 34.5 (C4), 26.3 (C9a), 25.6 






MeO2C CO2Me  
                                 1.54                                1.55 
General Procedure for the [Rh(CO)2Cl]2-Catalyzed Allenic Alkylation 
to furnish dimethyl-2-allyl-2-(4-methylpenta-2,3-dienyl)malonate (1.54) or 
dimethyl-2-(2-methylallyl)-2-(4-methylpenta-2,3-dienyl)malonate (1.55). 
Allenic carbonate 1.143 (1.0 mmol) was added to a solution of [Rh(CO)2Cl]2 (10 
mol%, 0.1 mmol, 39 mg) in CH3CN (5 mL), and the solution was stirred for 10 
min at room temperature. In a separate flask malonate 1.144 or 1.145 (1.5 mmol) 
was added to a slurry of NaH (60% w/w in mineral oil, 1.4 mmol) in CH3CN (5 
 188 
mL) at room temperature, and the mixture was stirred for 20 min. The resulting 
sodium enolate was added via syringe to the solution of 1.143 and [Rh(CO)2Cl]2 
at room temperature. The mixture was then sealed in a screw cap vial under an 
atmosphere of argon, and stirring was continued until the starting carbonate was 
consumed (as indicated by TLC analysis). The reaction was then filtered through 
a short plug of silica gel eluting with Et2O (50 mL), and the filtrate was 
concentrated under reduced pressure. The crude residue was purified by flash 
chromatography, eluting with pentane/Et2O (5:1) to furnish 1.54 or 1.55. 




MeO2C R  
R = H: 1.56 
R = Me: 1.57 
Procedure for the [Rh(CO)2Cl]2-Catalyzed Tandem Allylic 
Alkylation/Cycloisomerization to furnish dimethyl-5-(propan-2-
ylidene)cyclohept-2-ene-1,1-dicarboxylate (1.56) or dimethyl-3-methyl-5-
(propan-2-ylidene)cyclohept-2-ene-1,1-dicarboxylate (1.57). Allenic 
trichloroacetate 1.148 (0.45 mmol, 110 mg) was added to a solution of 
[Rh(CO)2Cl]2 (10 mol%, 0.045 mmol, 17 mg), triphenylphosphine (20 mol%, 
0.09 mmol, 24 mg), and silver hexafluoroantiminate (30 mol%, 0.14, 48 mg ),  in 
MeCN (1.5 mL), and the solution was stirred for 10 min at 0 ˚C.  In a separate 
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flask, malonate 1.144 or 1.145 (0.67 mmol) was added to a slurry of NaH (60% 
dispersion in mineral oil, 0.63 mmol) in MeCN (2.0 mL) at room temperature, 
and the mixture was stirred for 30 min.  The resulting solution of sodium enolate 
was then added via syringe to the solution of 1.148 and [Rh(CO)2Cl]2 at ambient 
temperature.  The resultant solution was stirred until the starting trichloroacetate 
was consumed (as indicated by TLC analysis).   The argon atmosphere was then 
exchanged for a CO atmosphere, and  the vial was sealed with a screw cap and 
heated to 110  ˚C in the microwave (300 W, cooling) for 15 min. The reaction 
mixture was filtered through a plug of silica gel with Et2O and then concentrated 
under reduced pressure.  The crude residue was purified by flash chromatography 
eluting with pentane/Et2O (5:1) to furnish 1.56 in 72% yield and 1.57 in 75% 


















N-Methyl-N-(4-methylpenta-2,3-dienyl)aniline (1.164). Allenic 
carbonate 1.143 (25 mg, 0.16 mmol) was added to a solution of [Rh(CO)2Cl]2 (10 
mol%, 0.016 mmol, 6 mg) and tetrabutylammonium iodide (20 mol%, 0.032 
mmol, 12 mg) in MeCN (1.6 mL), and the solution was stirred for 5 min at room 
temperature.  N-methylaniline (43 mg, 0.40 mmol) was added to the reaction 
mixture via syringe.  The mixture was stirred at room temperature for 16 h, under 
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an atmosphere of argon, and then heated to 60 ˚C (oil bath temperature) for 1 h.  
The solvent was removed under reduced pressure and the residue was purified by 
flash chromatography, eluting with pentane/Et2O (10:1) to yield 1.164 (29 mg, 
99%) as an amber-colored oil: 1H NMR (500 MHz) ! 7.25–7.19 (m, 2H), 6.75–
6.72 (m, 2H), 6.69–6.66 (dddd, J = 7.3, 7.3, 0.98, 0.98 Hz, 1H), 4.95–4.91 (m, 
1H), 3.90 (d, J = 5.9 Hz, 2 H), 2.93 (s, 3H), 1.59 (s, 3 H), 1.59 (s, 3H); 13C NMR 
(125 MHz) ! 204.5, 151.2, 130.9, 118.3, 114.8, 98.5, 86.3, 54.0, 39.9, 22.3; IR 
(thin film) 2906, 2359, 1961, 1599, 1505, 1362, 1200, 748, 690 cm–1; HRMS 
calculated for C13H17N 188.1439, found 188.1435. 
NMR Assignments. 1H NMR (500 MHz) ! 7.25–7.19 (m, 2H, C9-H), 
6.75–6.72 (m, 2H, C8-H), 6.69–6.66 (dddd, J = 7.3, 7.3, 0.98, 0.98 Hz, 1H, C10-
H), 4.95–4.91 (m, 1H, C4-H), 3.90 (d, J = 5.9 Hz, 2 H, C5-H), 2.93 (s, 3H, C6-H), 
1.59 (s, 3H, C1-H), 1.59 (s, 3H, C1-H); 13C NMR (125 MHz) ! 204.5 (C3), 151.2 
(C7), 130.9 (C9), 118.3 (C10), 114.8 (C8), 98.5 (C2), 86.3 (C4), 54.0 (C5), 39.9 



















14 15  
1.166 
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2-(4-Methylpenta-2,3-dienyloxy)biphenyl (1.166) (AJS-III-48).  Allenic 
carbonate 1.143 (25 mg, 0.16 mmol) was added to a solution of [Rh(CO)2Cl]2 (10 
mol%, 0.016, 6 mg) in THF (0.8 mL), and the solution was stirred for 5 min at 
room temperature.  In a separate flask, a solution of LiHMDS (1 M in THF, 0.32 
mL) was added via syringe to a solution of "-phenylphenol (68 mg, 0.40 mmol), 
copper(I) iodide (76 mg, 0.40 mmol), and dry THF (0.8 mL) at room temperature, 
followed by stirring for approximately 20 min and transfer via syringe to the 
solution of [Rh(CO)2Cl]2 and 1.143.  The resultant mixture was stirred at room 
temperature for 16 h, under an atmosphere of argon and then heated to 60 ˚C (oil 
bath temperature) for 1 h.  The reaction was diluted with water (2 mL) and Et2O 
(2 mL), and the layers were separated.  The aqueous phase was extracted with 
Et2O (3 x 1 mL) and the combined organic fractions were dried (MgSO4). The 
solvent was removed under reduced pressure and the crude residue was purified 
by flash chromatography, eluting with pentane/Et2O (10:1) to yield 1.166 as a 
colorless oil: 1H NMR (400 MHz) ! 7.57–7.54 (m, 2H), 7.41–7.25 (m, 5H), 7.03–
6.99 (m, 2H), 5.15–5.09 (m, 1H), 4.53 (d, J = 6.1 Hz, 2H), 1.65 (s, 3H), 1.65 (s, 
3H); 13C NMR (125 MHz) ! 202.9, 155.2, 138.7, 131.1, 130.9, 129.6, 128.3, 
127.9, 126.8, 120.9, 113.4, 97.2, 85.7, 66.8, 20.1; IR (thin film) 2980(m), 
2908(m), 1969(w), 1481(s), 1434(s), 1212(s), 1005(s), 751(s), 698(s) cm–1; 
HRMS calculated for C18H18O 241.1436, found 251.1442. 
NMR Assignments. 1H NMR (400 MHz) ! 7.57–7.54 (m, 2H, aromatic 
C-H), 7.41–7.25 (m, 5H, aromatic C-H), 7.03–6.99 (m, 2H, aromatic C-H), 5.15–
5.09 (m, 1H, C4-H), 4.53 (d, J = 6.1 Hz, 2H, C5-H), 1.65 (s, 3H, C1-H), 1.65 (s, 
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3H, C1-H); 13C NMR (125 MHz) ! 202.9 (C3), 155.2 (C6), 138.7 (C12), 131.1 
(C11), 130.9 (C8), 129.6 (C14), 128.3 (C15), 127.9 (C13), 126.8 (C10), 120.9 
(C9), 113.4 (C7), 97.2 (C2), 85.7 (C4), 66.8 (C5), 20.1 (C1); IR (thin film) 
2980(m), 2908(m), 1969(w), 1481(s), 1434(s), 1212(s), 1005(s), 751(s), 698(s) 
cm–1; HRMS cacld for C18H18O 241.1436, found 251.1442. 
4.3 ENANTIOSELECTIVE CONJUGATE ADDITION METHODOLOGY 
General Procedure for the Preparation of Heteroaryl Titanates. 
Solutions of the 2-lithiated heterocycles were prepared by deprotonation in THF 
according to known literature procedures.157 A 0.5 M solution of the lithiated 
heterocycle in THF was transferred via cannula to a 1 M solution of titanium 
tetraisopropoxide, which had been distilled immediately prior to use, in THF at –
78 ˚C.  The resultant mixture was stirred for 45 min at –78 ˚C and used 
immediately. 
General Procedure for the Preparation of 2-Heteroaryl Zinc 
Chlorides. Solutions of the 2-lithiated heterocycles were prepared in THF 
according to known literature procedures.157 A 0.5 M solution of the lithiated 
heterocycle in THF was transferred via cannula to a 1 M solution of freshly fused 
ZnCl2 in THF at 0 ˚C.  The resultant mixture was stirred for 45 min at 0 ˚C and 
used immediately. 
Determination of Enantiomeric Excess. Enantiomers were separated via 
chiral HPLC with an AD or OD-H DAICEL chiral column, using a 90:10 to 99:1 
solvent ratio of hexanes to isopropanol as the solvent system, at flow rates of 0.5–
1.0 mL/min. HPLC analysis was performed on the derivative alcohols, formed by 
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NaBH4 reduction of the conjugate addition product, for compounds 2.100, 2.118, 
2.148, and 2.138. 
General Procedure for Procedure for Deuterium Quench of 2-
Heteroaryllithium Compounds. Solutions of the 2-lithiated heterocycles were 
prepared in THF according to known literature procedures.157 The reaction 
mixture was then quenched with CD3OD at 0 ºC. The organic layer was extracted 
with Et2O, dried (MgSO4), and concentrated under reduced pressure. 
1H NMR 
analysis was performed on the crude product.  
General Procedure for Enantioselective Conjugate Addition 
Employing 2-Heteroaryl Titanates (Method A). A solution of [Rh(acac)((R)-
MeO-BIPHEP)] was generated by heating [Rh(acac)(COD)] (9.3 mg, 0.03 mmol) 
and (R)-MeO-BIPHEP (19 mg, 0.033 mmol) in THF (1 mL) for 30 min at 50 °C. 
The Michael acceptor (0.3 mmol) and ClSiMe3 (49 mg, 0.45 mmol, 58 mL) were 
added, and the solution was cooled to –78 °C, whereupon the solution of the 2-
heteroaryl titanate (0.6 mmol) was added via cannula. The resultant mixture was 
stirred at –78 ˚C for 30 min (unless otherwise indicated) and then at room 
temperature until the starting material was consumed (as indicated by TLC 
analysis).158 Aqueous 1 N HCl (1 mL) was added, and the resultant solution was 
stirred for 20 min.  The layers were separated, and the aqueous layer was 
extracted with Et2O (5 x 3 mL) or EtOAc (5 x 3 mL). The combined organic 
layers were washed with saturated aqueous NaHCO3 (1 mL). The organic layer 
was dried (MgSO4) and concentrated under reduced pressure, and the residue was 
purified by flash chromatography to yield the addition product.   
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General Procedure for Enantioselective Conjugate Addition 
Employing 2-Heteroaryl Zinc Chlorides (Method B). A solution of 
[Rh(acac)((R)-MeO-BIPHEP)] was generated by heating [Rh(acac)(COD)] (9.3 
mg, 0.03 mmol) and (R)-MeO-BIPHEP (19 mg, 0.033 mmol) in THF (1 mL) for 
30 min at 50 °C. The Michael acceptor (0.3 mmol) and ClSiMe3 (49 mg, 0.45 
mmol, 58 mL) were added, and the solution was cooled to –78 °C, whereupon the 
solution of the 2-heteroaryl zinc chloride (0.6 mmol) was added via cannula. The 
resultant mixture was then stirred at room temperature until the starting material 
was consumed (as indicated by TLC analysis).159 Aqueous 1 N HCl (1 mL) was 
added, and the resultant solution was stirred for 20 min. The layers were 
separated, and the aqueous layer was extracted with Et2O (5 x 3 mL) or EtOAc (5 
x 3 mL). The combined organic layers were washed with saturated aqueous 
NaHCO3 (1 mL). The organic layer was dried (MgSO4) and concentrated under 
reduced pressure, and the residue was purified by flash chromatography to yield 
















3-(5-Methylfuran-2-yl)cyclopentanone (2.100). Adduct 2.100 was 
prepared according to method A. The residue was purified by flash 
chromatography, eluting with pentane/Et2O (5:1) to yield 44 mg (90%) of 2.100 
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as a colorless oil; 1H NMR (600 MHz) ! 5.92 (d, J = 3.0 Hz, 1 H), 5.86 (d, J = 3.0 
Hz, 1 H), 3.47-3.42 (m, 1 H), 2.56 (dd, J = 18.4, 8.2 Hz, 1 H), 2.42-2.32 (comp, 3 
H), 2.26-2.21 (m, 1 H), 2.22 (s, 3 H), 2.12-2.06 (m, 1 H); 13C NMR (150 MHz) 
! 218.4, 154.8, 151.2, 105.9, 105.2, 43.7, 37.8, 35.5, 28.6, 13.5; IR (CDCl3) 2967, 
2921, 1744, 1612, 1570, 1405, 1218, 1150, 1022, 784 cm-1; mass spectrum (CI) 
m/z 165.0916 [C10H13O2 (M+1) requires 165.0916], 133, 165 (base), 193. 90% 
ee;    OD-H Column, Hexanes/i-PrOH 98/2, 1.0 mL/min, rt; first enantiomeric 
pair; 16.5, 16.8 (Maj);  second enantiomeric pair; 17.6, 21.2 (Maj). 
NMR Assignments: ! 5.92 (d, J = 3.0 Hz, 1 H, C3-H), 5.86 (d, J = 3.0 
Hz, 1 H, C4-H), 3.47-3.42 (m, 1 H, C6-H), 2.56 (dd, J = 18.4, 8.2 Hz, 1 H, C10-
H), 2.42-2.32 (comp, 3 H, C7-H, C8-H, & C10-H), 2.26-2.21 (m, 1 H, C8-H), 
2.22 (s, 3 H, C1-H), 2.12-2.06 (m, 1 H, C7-H); 13C NMR (150 MHz) ! 218.4 
(C9), 154.8 (C5), 151.2 (C2), 105.9 (C3), 105.2 (C4), 43.7 (C10), 37.8 (C8), 35.5 














3-(5-Methylfuran-2-yl)cyclopentanol. (AJS-III-235). (Prepared for 
determination of the enantiomeric excess of 2.100.) NaBH4 (14 mg, 0.38 mmol) 
was added in one portion to a solution of furan 2.100 (52 mg, 0.32 mmol) in 
THF/MeOH (1mL/1mL) at 0 ˚C.  The reaction was warmed to room temperature 
and stirred for an additional 1.5 h, whereupon H2O (2 mL) was added.  The 
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aqueous layer was extracted with Et2O (3 x 5 mL) and the combined organic 
layers were dried (MgSO4) and concentrated under reduced pressure. The residue 
was purified by flash chromatography, eluting with Pentane/Et2O (4:1) to yield 42 
mg (90%) of 3-(5-methylfuran-2-yl)cyclopentanol as a 3:1 cis/trans mixture as a 
colorless oil:  1H NMR (500 MHz) ! 5.89 (dd, J = 2.9, 0.4 Hz, 0.75 H), 5.85-5.83 
(m, 1.25 H), 4.47 (dddd, J = 2.5, 2.5, 5.2, 5.2 Hz, 0.25 H), 4.38 (m, 0.75 H), 3.38 
(app p, J = 8.0, 0.25 H), 3.10 (app p, J = 8.0 Hz, 0.75 H), 2.35 (ddd, J = 6.3, 8.8, 
13.7 Hz, 1 H), 2.25 (s, 3 H), 2.21-1.62 (comp, 5.25 H) ; 13C NMR (125 MHz) 
! 157.3 , 150.4, 105.7, 105.6, 104.2, 104.1, 73.6, 73.5, 41.6, 41.2, 36.8, 36.2, 35.6, 
35.1, 29.7, 29.6, 13.6; IR (CDCl3) 3346, 2958, 2922, 2873, 1616, 1569, 1438, 
1342, 1220, 1082, 1021, 1000, 944, 779 cm-1; mass spectrum (CI) m/z 167.1073 
[C10H13O2 (M+1) requires 167.1072], 149 (base), 167. 
NMR Assignments:  1H NMR (500 MHz) ! 5.89 (dd, J = 2.9, 0.4 Hz, 
0.75 H, C3-H)), 5.85-5.83 (m, 1.25 H, C4-H), 4.47 (dddd, J = 2.5, 2.5, 5.2, 5.2 
Hz, 0.25 H, C9-H), 4.38 (m, 0.75 H, C9-H), 3.38 (app p, J = 8.0, 0.25 H, C6-H), 
3.10 (app p, J = 8.0 Hz, 0.75 H, C6-H), 2.35 (ddd, J = 6.3, 8.8, 13.7 Hz, 1 H, C10-
H), 2.25 (s, 3 H, C1-H), 2.21-1.62 (comp, 5.25 H, C10-H, C8-H, C7-H, & O-H); 
13C NMR (125 MHz) ! 157.3 (C2), 150.4 (C5), 105.7 (C3), 105.6 (C3), 104.2 
(C4), 104.1 (C4), 73.6 (C9), 73.5 (C9), 41.6 (C6), 41.2 (C6), 36.8 (C10), 36.2 
















3-(Furan-2-yl)cyclopentanone (2.118). Adduct 2.118 was prepared 
according to method A. The residue was purified by flash chromatography, 
eluting with pentane/Et2O (5:1) to yield 41 mg (90%) of 2.118 as a colorless oil; 
1H NMR (600 MHz) ! 7.34 (dd, J = 1.8, 0.7 Hz, 1 H), 6.30 (dd, J = 3.2, 1.8 Hz, 1 
H), 6.06 (dt, J = 3.2, 0.7 Hz, 1 H), 3.53-3.48 (m, 1 H), 2.59 (dd, J = 18.2, 7.8 Hz, 
1 H), 2.42-2.34 (comp, 3 H), 2.30–2.23 (m, 1 H), 2.14–2.08 (m, 1 H); 13C NMR 
(150 MHz) ! 217.7, 156.6, 141.6, 110.1, 104.6, 43.5, 37.8, 35.5, 28.6; IR (CDCl3) 
2968, 2901, 1742, 1507, 1405, 1152, 1012, 736 cm-1; mass spectrum (CI) m/z 
151.0759 [C9H11O2 (M+1) requires 151.0759], 151 (base). 97% ee; OD-H 
Column, Hexanes/i-PrOH 98/2, 1.0 mL/min, rt; first enantiomeric pair; 16.8 
(Maj), 17.8; second enantiomeric pair; 20.8, 26.1 (Maj). 
NMR Assignments. 1H NMR (600 MHz) ! 7.34 (dd, J = 1.8, 0.7 Hz, 1 H, 
C1-H), 6.30 (dd, J = 3.2, 1.8 Hz, 1 H, C2-H), 6.06 (dt, J = 3.2, 0.7 Hz, 1 H, C3-
H), 3.53-3.48 (m, 1 H, C5-H), 2.59 (dd, J = 18.2, 7.8 Hz, 1 H, C8-H), 2.42-2.34 
(comp, 3 H, C8-H, C7-H, & C6-H), 2.30–2.23 (m, 1 H, C7-H), 2.14–2.08 (m, 1 
H, C6-H); 13C NMR (150 MHz) ! 217.7 (C9), 156.6 (C4), 141.6 (C1), 110.1 (C2), 





3-(Furan-2-yl)cyclopentanol (2.119). (AJS-V-160). (Prepared for 
determination of the enantiomeric excess of 2.118). To a solution of 2.118 (40 
mg, 0.26 mmol) in THF (0.75 mL) and MeOH (0.75 mL) was added NaBH4 (10 
mg, 0.26 mmol) at 0 °C.   After 30 minutes an aqueous solution of NH4Cl (2 mL) 
and CH2Cl2 (2 mL) were added. The layers were separated, and the aqueous layers 
were extracted with CH2Cl2.  The combined organic layers were dried (MgSO4) 
and concentrated under reduced pressure. The residue was purified by flash 
chromatography, eluting with pentane/EtOAc (2:1) to yield 40 mg (100%) of 
2.119 as a colorless oil:  !"#NMR (500 MHz) in CDCl3 !  5.89 (dd, J= 4.0, 0.5 
Hz, 1H), 5.83-5.85 (m, 1.6 H), 4.47 (sep, J = 3.5, 0.3 H), 4.38 (m, 1 H), 3.38 (p, 
J= 10.5 Hz, 0.3 H), 3.10 (p, J= 10.5 Hz, 1 H), 2.30-2.38 (m, 1 H), 2.25 (s, 4H),  
1.62-2.21 (comp, 8.8 H); 13C NMR (125 MHz) in CDCl3 ! 157.3, 150.4, 105.7, 
105.6, 104.2, 104.1, 73.6, 73.5, 41.6, 41.2, 36.9, 36.2, 35.6, 35.1, 29.7, 13.6; IR 
3326, 2957, 1568, 1437, 1219, 1021, 779 cm-1; mass spectrum (CI) m/z 167.107 
(C9H11SO (M+1) requires 167.107), 167 (base). 0% ee; OD-H Column, 
Hexanes/i-PrOH 98/2, 1.0 mL/min, rt; first enantiomeric pair; 16.5, 16.8 (Maj);  
second enantiomeric pair; 17.6, 21.2 (Maj). 
NMR ASSIGNMENTS: 1H NMR (500 MHz) in CDCl3 !  5.89 (dd, J= 
4.0, 0.5 Hz, 1H, C2-H or C3-H), 5.83-5.85 (m, 1.6 H, C2-H & C3-H), 4.47 (sep, J 
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= 3.5, 0.3 H, C5-H), 4.38 (m, 1 H, C5-H), 3.38 (p, J= 10.5 Hz, 0.3 H, C7-H), 3.10 
(p, J= 10.5 Hz, 1 H, C7-H), 2.30-2.38 (m, 1 H, OH), 2.25 (s, 4H, C10-H),  1.62-
2.21 (comp m, 8.8 H, C8-H & C9-H & C6-H); 13C NMR (125 MHz) in CDCl3 ! 
157.3 (C1), 150.4 (C4), 105.7 (C3), 105.6 (C3), 104.2 (C2), 104.1 (C2), 73.6 
(C7), 73.5 (C7), 41.6 (C6), 41.2 (C6), 36.9 (C5), 36.2 (C5), 35.6 (C8), 35.1 (C8), 


















3-(Benzofuran-2-yl)cyclopentanone (2.126). Adduct 2.126 was prepared 
according to method A. The residue was purified by flash chromatography, 
eluting with pentane/Et2O (2:1) to yield 58 mg (96%) of 2.126 as a pale yellow 
oil.  1H NMR (600 MHz) ! 7.50 (ddd, J = 7.6, 1.3, 0.7 Hz, 1 H), 7.42 (dd, J = 8.1, 
0.9 Hz, 1 H), 7.24 (app td, J = 7.3, 1.5 Hz, 1 H), 7.20 (app td, J = 7.3, 1.0 Hz, 1 
H), 6.45 (app t, J = 0.9 Hz, 1H), 3.67-3.61 (m, 1 H), 2.67 (dd, J = 18.2, 7.8 Hz, 1 
H), 2.52 (ddd, J = 18.2, 9.0, 1.1 Hz, 1 H), 2.49-2.43 (comp, 2 H), 2.34-2.28 (m, 1 
H), 2.26-2.19 (m, 1 H); 13C NMR (150 MHz) ! 217.2, 159.5, 154.8, 128.4, 123.8, 
122.7, 120.6, 110.9, 101.7, 43.3, 37.7, 35.8, 28.4; IR(CHCl3) 2965, 1741, 1455, 
1253, 1166, 1136, 750 cm-1; mass spectrum (CI) m/z 201.0916 (C13H13O2 (M+1) 
requires 201.0916), 201(base). >98% ee; OD-H Column, Hexanes/i-PrOH 98/2, 
1.0 mL/min, rt; 24.2 (Maj), 27.2. 
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NMR ASSIGNMENTS: 1H NMR (600 MHz) ! 7.50 (d, J = 7.6, 1 H, C7-
H)), 7.42 (d, J = 8.1, 1 H, C4-H), 7.24 (app td, J  = 8.1, 1.5 Hz, 1 H, C5-H), 7.20 
(app td, J = 7.6, 1.0 Hz, 1 H, C6-H), 6.45 (app t, J = 0.9 Hz, 1H, C2-H), 3.67-3.61 
(m, 1 H, C9-H), 2.67 (dd, J = 18.2, 7.8 Hz, 1 H, C13-H), 2.52 (ddd, J = 18.2, 9.0, 
1.1 Hz, 1 H, C13-H), 2.49-2.43 (comp, 2 H, C11-H & C10-H), 2.34-2.28 (m, 1 H, 
C11-H), 2.26-2.19 (m, 1 H, C10-H); 13C NMR (150 MHz) ! 217.2 (C12), 159.5 
(C1), 154.8 (C8), 128.4 (C3), 123.8 (C5), 122.7 (C6), 120.6 (C7), 110.9 (C4), 


















3-(Benzo[b]thiophen-2-yl)cyclopentanone (2.128). 2.128 was prepared 
according to method B. The residue was purified by flash chromatography, 
eluting with pentane/Et2O (5:1 to 1:1) to yield 49 mg (75%) of 2.128 as a brown 
solid; mp = 84.5–85.5˚C.  1H NMR (500 MHz) ! 7.78 (d, J = 7.9 Hz, 1 H), 7.69 
(d, J = 7.5 Hz, 1 H), 7.33 (app td, J = 7.5, 1.2 Hz, 1 H), 7.29 (app td, J = 7.9, 1.3 
Hz, 1 H), 7.08 (s, 1 H), 3.79-3.72 (m, 1 H), 2.77 (dd, J = 18.8, 7.5 Hz, 1 H), 2.59-
2.45 (comp, 3 H), 2.37-2.29 (m, 1 H), 2.19-2.12 (m, 1 H); 13C NMR (125 MHz) 
! 216.9, 147.9, 139.7, 138.9, 124.4, 124.0, 123.1, 122.3, 119.8, 46.2, 38.4, 38.3, 
31.6.  IR (CHCl3) 2963, 1736, 1436, 1399, 1171, 834, 771, 746, 728 cm-1; mass 
spectrum (CI) m/z 217.0686 (C13H13SO (M+1) requires 217.0687), 217 (base).  
98% ee; OD-H Column, 98/2 Hexanes/i-PrOH,1 mL/min, rt; 27.2 (maj), 29.3. 
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NMR ASSIGNMENTS: 1H NMR (500 MHz) ! 7.78 (d, J = 7.8 Hz, 1 H, 
C7-H), 7.69 (d, J = 7.5 Hz, 1 H, C4-H), 7.33 (app td, J = 7.5, 1.2 Hz, 1 H, C5-H), 
7.29 (app td, J = 7.8, 1.3 Hz, 1 H, C6-H), 7.08 (s, 1 H, C2-H), 3.77 (m, 1 H, C9-
H), 2.77 (dd, J = 18.8, 7.5 Hz, 1 H, C12-H), 2.59-2.45 (comp, 3 H, C13-H & C10-
H), 2.37-2.29 (m, 1 H, C10-H), 2.19-2.12 (m, 1 H, C12-H); 13C NMR (125 MHz) 
! 216.9 (C11), 147.9 (C8), 139.7 (C1), 138.9 (C3), 124.4 (C5), 124.0 (C6), 123.1 





















3-(1-Methyl-1H-indol-2-yl)cyclopentanone (2.130). Adduct 2.130 was 
prepared according to method A. (Note; after addition of the N-methylindol-2-yl 
titanate to the Michael acceptor (0.30 mmol), 10 mol % [Rh(acac)((R)-MeO-
BIPHEP)] and ClSiMe3 (49 mg, 0.45 mmol, 58 µL) in THF (1 mL) at –78 ˚C, the 
resultant mixture was stirred at –78 ˚C for 2 h, followed by stirring at room 
temperature until the starting material was consumed.) The residue was purified 
by flash chromatography, eluting with pentane/Et2O (2:1) to yield 30 mg (47%) of 
2.130 as a brown solid; mp = 124–125 ˚C; 1H NMR (600 MHz) ! 7.55 (app dt, J = 
7.9, 1.1 Hz, 1 H), 7.29 (dd, J = 8.2, 0.8 Hz, 1 H), 7.19 (ddd, J = 8.2, 7.0, 1.2 Hz, 1 
H), 7.09 (ddd, J = 7.9, 7.0, 1.0 Hz, 1 H), 6.29 (app t, J = 0.8 Hz, 1 H), 3.74 (s, 3 
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H), 3.65-3.59 (m, 1 H), 2.72 (dd, J = 18.4, 7.9 Hz, 1 H), 2.52-2.43 (comp, 3 H), 
2.37-2.27 (m, 1 H), 2.17-2.10 (m, 1 H); 13C NMR (150 MHz) ! 217.5, 142.2, 
137.8, 127.5, 121.4, 120.2, 119.7, 108.8, 97.7, 44.7, 37.5, 34.0, 29.8, 29.2; 
IR(CHCl3) 3050, 2960, 1740, 1467, 1400, 1313, 1232, 1169, 1153, 1133, 750 cm-
1; mass spectrum (CI) m/z 214.1228 (C14H16NO (M+1) requires 214.1232), 
214(base). 90% ee; AD Column, Hexanes/i-PrOH 95/5, 1.0 mL/min, rt; 14.4, 16.1 
(Maj). 
NMR ASSIGNMENTS: 1H NMR (600 MHz) ! 7.55 (app dt, J = 7.9, 1.2 
Hz, 1 H, C4-H), 7.29 (dd, J = 8.2, 0.8 Hz, 1 H, C7-H), 7.19 (ddd, J = 8.2, 7.0, 1.2 
Hz, 1 H, C6-H), 7.09 (ddd, J = 7.9, 7.0, 0.8 Hz, 1 H, C5-H), 6.29 (app t, J = 0.8 
Hz, 1 H, C2-H), 3.74 (s, 3 H, C14-H), 3.65-3.59 (m, 1 H, C9-H), 2.72 (dd, J = 
18.4, 7.9 Hz, 1 H, C13-H),  2.52-2.43 (comp, 3 H, C13-H & C11-H & C10-H), 
2.37-2.27 (m, 1H, C11-H), 2.17-2.10 (m, 1 H, C10-H); 13C NMR (150 MHz) ! 
217.5 (C12), 142.2 (C1), 137.8 (C8), 127.5 (C3), 121.4 (C6), 120.2 (C4), 119.7 













3-(Thiophen-2-yl)cyclopentanone (2.138). 2.138 was prepared according 
to method A. The residue was purified by flash chromatography, eluting with 
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pentane/Et2O (5:1) to yield 30 mg (60%) of 2.138 as a colorless oil. 
 1H NMR 
(600 MHz) ! 7.18 (dd, J = 5.1, 1.2 Hz, 1 H), 6.95 (dd, J = 5.1, 3.5 Hz, 1 H), 
 6.87 (app dt, J = 3.5, 1.2 Hz, 1 H), 3.71-3.65 (m, 1 H), 2.72 (dd, J = 18.1, 7.6 Hz, 
1 H), 2.54-2.43 (comp, 2 H), 2.39 (ddd, J = 18.1, 10.3, 1.4 Hz, 1 H), 2.33-2.27 
(m, 1 H), 2.09-2.02 (m, 1 H); 13C NMR (150 MHz) ! 217.4, 147.4, 126.9, 123.5, 
123.4, 46.8, 38.5, 37.6, 32.1; IR (CHCl3) 2963, 1741, 1401, 1242, 1135, 913, 743, 
699 cm-1; mass spectrum (CI) m/z 167.0533 (C9H11SO (M+1) requires 167.0531), 
167(base). 95% ee; OD-H Column, Hexanes/i-PrOH 98/2, 1.0 mL/min, rt; First 
enantiomeric pair; 29.5 (Maj), 32.1; Second enantiomeric pair; 42.9, 54.5 (Maj). 
NMR ASSIGNMENTS: 1H NMR (CDCl3, 600 MHz) ! 7.18 (dd, J = 5.1, 
1.2 Hz, 1 H, C1-H), 6.95 (dd, J = 5.1, 3.5 Hz, 1 H, C2-H),  6.87 (app dt, J = 3.5, 
1.2 Hz, 1 H, C3-H), 3.71-3.66 (m, 1 H, C5-H), 2.70 (dd, J = 18.1, 6.8 Hz, 1 H, 
C9-H), 2.53-2.51 (m, 1 H, C6-H), 2.46-2.41 (m, 1 H, C7-H), 2.39-2.27 (comp, 2 
H, C7-H & C9-H), 2.09-2.02 (m, 1 H, C6-H); 13C NMR (150 MHz) ! 217.4 (C8), 




3-(Thiophen-2-yl)cyclopentanol (AJS-V-143). (Prepared for 
determination of enantiomeric excess of 2.138). To a solution of compound 2.138 
(46 mg, 0.28 mmol) in THF (0.5 mL) and MeOH (0.5 mL) was added sodium 
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borohydride (11 mg, 0.28 mmol) at 0 °C.   After 30 minutes NH4Cl (saturated 
aqueous, 2 mL) and CH2Cl2 (2 mL) were added to the reaction mixture. The 
layers were separated and the aqueous layers were extracted with Et2O (3 x 1.5 
mL).  The combined organic layers were dried (MgSO4).# The solvent was 
removed under reduced pressure and the residue was purified via flash 
chromatography, eluting with pentane/Et2O (2:1) to furnish 47 mg (100%) of 3-
(thiophen-2-yl)cyclopentanol as a mixture of cis/trans isomers (0.4:1) and as a 
colorless oil: 1H NMR (500 MHz) in CDCl3 !  7.12 (dd, J= 4.0, 1.0 Hz, 1H), 7.11 
(dd, J= 4.0, 1.0 Hz, 0.4 H), 6.92 (dd, J= 4.0, 3.0 Hz, 1.4 H), 6.84 (dt, J = 2.5, 1.0 
Hz, 1 H), 6.81 (dt, J = 2.5, 1.0 Hz, 1 H), 4.51 (m,  0.4 H), 4.42 (m, 1 H), 3.65 (app 
p, J= 7.0 Hz, 0.4 H), 3.30 (app p, J= 7.0 Hz, 1 H), 2.56-2.51 (m, 1 H), 2.36-2.27 
(m, 0.4 H), 2.22-2.09 (comp, 1.8 H), 1.99-1.55 (comp m, 5.2 H); 13C NMR (125 
MHz) in CDCl3 ! 150.0, 126.6, 122.8, 122.7, 122.6, 73.4, 45.3, 44.9, 39.3, 38.4, 
35.7, 35.4, 33.6, 33.4; IR 3339, 2956, 1439, 1340, 1080, 823 cm-1; mass spectrum 
(CI) m/z 168.061 (C9H11SO (M+1) requires 168.061), 168 (base); 95% ee; OD-H 
Column, Hexanes/i-PrOH 98/2, 1.0 mL/min, rt; First enantiomeric pair; 29.5 
(Maj), 32.1; Second enantiomeric pair; 42.9, 54.5 (Maj). 
NMR Assignments: 1H NMR (500 MHz) in CDCl3 !  7.12 (dd, J= 4.0, 
1.0 Hz, 1H, C4-H), 7.11 (dd, J= 4.0, 1.0 Hz, 0.4 H, C4-H), 6.92 (dd, J= 4.0, 3.0 
Hz, 1.4 H, C3-H), 6.84 (dt, J = 2.5, 1.0 Hz, 1 H, C2-H), 6.81 (dt, J = 2.5, 1.0 Hz, 
1 H, C2-H), 4.51 (m,  0.4 H, C7-H), 4.42 (m, 1 H, C7-H), 3.65 (app p, J= 7.0 Hz, 
0.4 H, C5-H), 3.30 (app p, J= 7.0 Hz, 1 H, C5-H), 2.56-2.51 (m, 1 H, C6-H), 
2.36-2.27 (m, 0.4 H, C6-H), 2.22-2.09 (comp, 1.8 H, C8-H & C6-H), 1.99-1.55 
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(comp m, 5.2 H, C8-H & C9-H); 13C NMR (125 MHz) in CDCl3 ! 150.0 (C1), 
126.6 (C3), 122.8 (C2), 122.7 (C2), 122.6 (C4), 73.4 (C7), 45.3 (C6), 44.9 (C6), 














3-(1-Methyl-1H-pyrrol-2-yl)cyclopentanone (2.140). 2.140 was prepared 
according to method A. (Note; TESCl was used in place of TMSCl.) The residue 
was purified by flash chromatography, eluting with hexanes/EtOAc (4:1) to yield 
21 mg (42%, 93% ee) of 2.140 as a brown oil.  1H NMR (500 MHz) ! 6.59 (app t, 
J = 1.9 Hz, 1 H), 6.08 (dd, J = 3.4, 2.9 Hz, 1 H), 5.93 (ddd, J = 3.6, 1.7, 0.7 Hz, 1 
H), 3.61 (s, 3 H), 3.45-3.38 (m, 1 H), 2.63 (dd, J = 18.3, 7.8 Hz, 1 H), 2.48-2.36 
(comp, 2 H), 2.34-2.23 (comp, 2 H), 2.05-1.98 (m, 1 H); 13C NMR (125 MHz) ! 
218.2, 134.6, 122.2, 106.8, 104.4, 45.1, 37.9, 33.8, 33.8, 29.5. IR (CHCl3) 2963, 
1741, 1492, 1404, 1299, 1147, 1090, 713 cm-1; mass spectrum (CI) m/z 164.1075 
[C10H14NO (M+1) requires 164.1075], 164 (base). 93% ee; OD-H Column, 
Hexanes/i-PrOH 96/4, 0.5 mL/min, rt; 49.2, 50.6 (Maj). 
NMR ASSIGNMENTS: 1H NMR (CDCl3, 500 MHz) ! 6.59 (m, 1 H, C1-
H), 6.08 (dd, 3.4, 2.9 Hz, 1 H, C2-H), 5.93 (ddd, J = 3.4, 1.7, 0.7 Hz, 1 H, C3-H), 
3.61 (s, 3 H, C10-H), 3.45-3.38 (m, 1 H, C5-H), 2.63 (dd, J = 18.3, 7.8 Hz, 1 H, 
C9-H), 2.48-2.36 (comp, 2 H, C7-H & C6-H), 2.34-2.23 (comp, 2 H, C9-H & C7-
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H), 2.06-1.98 (m, 1 H, C6-H); 13C NMR (125 MHz) ! 218.2, 134.6, 122.2, 106.8, 















3-(Furan-2-yl)cyclohexanone (2.148). 2.148 was prepared according to 
method A. The residue was purified by flash chromatography, eluting with 
pentane/Et2O (5:1) to yield 30 mg (60%) of 2.148 as a colorless oil; 
1H NMR (500 
MHz) ! 7.32 (dd, J = 1.8, 0.8 Hz, 1 H), 6.29 (dd, J = 3.2, 1.8 Hz, 1 H), 6.02 (app 
dt, J = 3.2, 0.8 Hz, 1 H), 3.22–3.17 (m, 1 H), 2.68 (app ddt, J = 14.3, 4.8, 1.7 Hz, 
1 H), 2.53 (ddd, J = 14.3, 10.6, 1.3 Hz, 1 H), 2.42 (app dtdd, J = 14.5, 5.1, 1.8, 1.2 
Hz, 1 H), 2.34 (dddd, J = 14.5, 10.9, 5.8, 1.3 Hz , 1 H), 2.19–2.13 (m, 1 H). 2.06-
1.99 (m, 1 H), 1.92-1.84 (m, 1 H), 1.82-1.73 (m, 1 H);13C NMR (125 MHz) 
! 210.1 , 157.2, 141.3, 110.1, 104.5, 45.6, 41.3, 37.6, 29.9, 24.4; IR (CDCl3) 
2944, 2866, 1711, 1505, 1224, 1010, 738 cm-1; mass spectrum (CI) m/z 165.0915 
[C10H13O2 (M+1) requires 165.0916], 165 (base). 92% ee; OD-H Column, 
Hexanes/i-PrOH 98/2, 0.5 mL/min, rt; first enantiomeric pair; 30.2 (Maj), 33.1; 
second enantiomeric pair; 37.5 (Maj), 39.2. 
NMR Assignments: 1H NMR (500 MHz) ! 7.32 (dd, J = 1.8, 0.8 Hz, 1 H, 
C1-H), 6.29 (dd, J = 3.2, 1.8 Hz, 1 H, C2-H), 6.02 (dd, J = 3.2, 0.8 Hz, 1 H, C3-
H), 3.22–3.17 (m, 1 H, C5-H), 2.68 (app ddt, J = 14.3, 4.7, 1.7 Hz, 1 H, C6-H), 
2.53 (ddd, J = 14.3, 10.6, 1.3 Hz, 1 H, C6-H), 2.42 (app dt, J = 14.5, 5.1 Hz, 1 H, 
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C8-H), 2.34 (dddd, J = 14.5, 10.8, 5.9, 1.3 Hz, 1 H, C8-H), 2.19–2.13 (m, 1 H, 
C10-H). 2.02 (m, 1 H, C9-H), 1.88 (dddd, J = 13.4, 10.8, 10.8, 3.5 Hz, 1 H, C10-
H), 1.78 (ddddd, J = 13.8, 13.1, 10.8, 5.1, 3.5, 1 H, C9-H); 13C NMR (125 MHz) 
! 210.2 (C7), 157.2 (C4), 141.3 (C1), 110.1 (C2), 104.5 (C3), 45.6 (C6), 41.3 













3-(Furan-2-yl)cyclohexanol (AJS-V-168). NaBH4 (12 mg, 0.31 mmol) 
was added in one portion to a solution of furan 2.148 (51 mg, 0.31 mmol) in 
THF/MeOH (0.75mL/0.75mL) at 0 ˚C.  The reaction was warmed to room 
temperature and stirred for an additional 1.5 h, whereupon H2O (2 mL) was 
added.  The aqueous layer was extracted with Et2O (3 x 5 mL) and the combined 
organic layers were dried (MgSO4) and concentrated under reduced pressure. The 
residue was purified by flash chromatography, eluting with pentane/Et2O (2:1 to 
1:1) to yield 52 mg (100%) of 3-(furan-2-yl)cyclohexanol as a cis/trans mixture 
(8:1 ) and as a colorless oil: 1H NMR (500 MHz) for the major diastereomer ( 
7.30 (dd, J = 1.9, 0.7 Hz, 1 H), 6.28 (dd, J = 3.2, 1.9 Hz, 1 H), 5.97 (dt, J = 3.2, 
0.7 Hz, 1 H), 3.70 (dddd, J = 11.0, 11.0, 4.2, 4.2 Hz, 1 H), 2.69 (dddd, J = 12.5, 
12.5, 3.7, 3.7 Hz, 1 H), 2.32 (m, 1 H), 2.05–1.97 (comp, 2 H), 1.87 (m, 1 H), 
1.46–1.33 (comp, 3 H), 1.29–1.20 (comp, 2 H); 13C NMR (125 MHz) ! 159.4, 
140.7, 109.9, 102.9, 70.4, 40.4, 35.9, 35.4, 30.6, 23.8; IR (CH2Cl2) 3343, 2934, 
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2859, 1505, 1450, 1362, 1054, 1010, 729, 598 cm-1; mass spectrum (CI) m/z 
166.0995 [C10H14O2 (M+1) requires 166.0994], 166, 149 (base).  
NMR Assignments: 1H NMR (500 MHz) ( 7.30 (dd, J = 1.9, 0.7 Hz, 1 H, 
C1-H), 6.28 (dd, J = 3.2, 1.9 Hz, 1 H, C2-H), 5.97 (dt, J = 3.2, 0.7 Hz, 1 H, C3-
H), 3.70 (dddd, J = 11.0, 11.0, 4.2, 4.2 Hz, 1 H, C7-H), 2.69 (dddd, J = 12.5, 12.5, 
3.7, 3.7 Hz, 1 H, C5-H), 2.32 (m, 1 H, C6-H), 2.05–1.97 (comp, 2 H, C10-H & 
C8-H), 1.87 (m, 1 H, C9-H), 1.46–1.33 (comp, 3 H, OH, C10-H & C6-H), 1.29–
1.20 (comp, 2 H, C8-H & C9-H); 13C NMR (125 MHz) ! 159.4 (C4), 140.7 (C1), 
109.9 (C2), 102.9 (C3), 70.4 (C7), 40.4 (C5), 35.9 (C6), 35.4 (C8), 30.6 (C10), 














4-(Furan-2-yl)-dihydrofuran-2(3H)-one (2.149). 2.149 was prepared 
according to method A. The residue was purified by flash chromatography, 
eluting with pentane/Et2O (4:1 to 2:1) to yield 27 mg (55%) of 2.149 as a 
colorless oil. 1H NMR (600 MHz) ! 7.37 (dd, J = 1.9, 0.8 Hz, 1 H), 6.33 (dd, J = 
3.2, 1.9 Hz, 1 H), 6.17 (app dt, J = 3.2, 0.8 Hz, 1 H),  4.57 (dd, J = 9.0, 7.8 Hz, 1 
H), 4.34 (dd, J = 9.0, 7.3 Hz, 1 H), 3.85 (app pentet, J = 8.2 Hz, 1 H), 2.84 (dd, J 
= 17.5, 8.7 Hz, 1 H), 2.76 (dd, J = 17.5, 8.4 Hz, 1 H); 13C NMR (150 MHz) ! 
175.7, 152.2, 142.5, 110.4, 106.3, 71.5, 34.9, 33.4; IR (CDCl3) 3539, 3121, 2975, 
2915, 1778, 1507, 1480, 1422, 1373, 1335, 1171, 1012, 741 cm-1; mass spectrum 
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(CI) m/z 153.0555 (C8H9O3 (M+1) requires 153.0552), 153 (base). >98% ee; OD-
H Column, Hexanes/i-PrOH 98/2, 1.0 mL/min, rt; 29.3 (Maj), no other isomer 
detected.  
NMR Assignments: 1H NMR (600 MHz) ! 7.37 (dd, J = 1.9, 0.8 Hz, 1 H, 
C1-H), 6.33 (dd, J = 3.2, 1.9 Hz, 1 H, C2-H), 6.17 (app dt, J = 3.2, 0.8 Hz, 1 H, 
C3-H), 4.57 (dd, J = 9.0, 7.8 Hz, 1 H, C6-H), 4.34 (dd, J = 9.0, 7.3 Hz, 1 H, C6-
H), 3.85 (app pentet, J = 8.2 Hz, 1 H, C5-H), 2.84 (dd, J = 17.5, 8.7 Hz, 1 H, C8-
H), 2.76 (dd, J = 17.5, 8.4 Hz, 1 H, C8-H); 13C NMR (150 MHz) ! 175.7 (C7), 















4-(Furan-2-yl)tetrahydro-2H-pyran-2-one (2.150). 2.150 was prepared 
according to method A. The residue was purified by flash chromatography, 
eluting with pentane/EtOAc (2:1) to yield 21 mg (42%) of 2.150 as a colorless oil; 
1H NMR (500 MHz) ! 7.36 (dd, J = 1.7, 0.7 Hz, 1 H), 6.32 (dd, J = 3.2, 1.7 Hz, 1 
H), 6.09 (app dt, J = 3.2, 0.7 Hz, 1 H), 4.42 (ddd, J = 11.5, 5.6, 4.6 Hz, 1 H), 4.36 
(ddd, J = 11.5, 8.8, 4.1 Hz, 1 H ), 3.40–3.34 (m, 1 H), 2.93 (ddd, J = 17.6, 6.3, 1.2 
Hz, 1 H), 2.72 (dd, J = 17.6, 9.3 Hz, 1 H), 2.27–2.21 (m, 1 H), 2.08–2.01 (m, 1 
H); 13C NMR (125 MHz) ! 170.0, 155.4, 142.0, 110.2, 105.1, 67.9, 34.5, 31.0, 
27.8; IR(CHCl3) 2966, 2912, 1736, 1507, 1405, 1255, 1221, 1073, 1013, 741, 599 
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cm-1; mass spectrum (CI) m/z 167.0707 (C9H11O3 (M+1) requires 167.0708), 167 
(base). 97% ee; OD-H Column, Hexanes/i-PrOH 98/2, 1.0 mL/min, rt; 51.3, 52.7 
(Maj).  
NMR Assignments: 1H NMR (600 MHz) ! 7.36 (dd, J = 1.7, 0.7 Hz, 1 H, 
C9-H), 6.32 (dd, J = 3.2, 1.7 Hz, 1 H, C8-H), 6.09 (app td, J = 3.2, 0.7 Hz, 1 H, 
C7-H), 4.42 (ddd, J = 11.5, 5.6, 4.6 Hz, 1 H, C1-H), 4.36 (ddd, J = 11.5, 8.8, 4.1 
Hz, 1 H, C1-H), 3.40–3.34 (m, 1 H, C3-H), 2.93 (ddd, J = 17.6, 6.3, 1.2 Hz, 1 H, 
C4-H), 2.72 (dd, J = 17.6, 9.3 Hz, 1 H, C4-H), 2.27–2.21 (m, 1 H, C2-H), 2.08–
2.01 (m, 1 H, C2-H); 13C NMR (150 MHz) ! 170.0 (C5), 155.4 (C6), 142.0 (C9), 



















4-(Benzofuran-2-yl)tetrahydro-2H-pyran-2-one (2.151). Adduct 2.151 
was prepared according to method A. The residue was purified by flash 
chromatography, eluting with hexanes/EtOAc (3:1) to yield 46 mg (70%) of 2.151 
as a white solid; mp = 95–96 ˚C;  1H NMR (500 MHz) ! 7.52 (ddd, J = 7.7, 1.4, 
0.7 Hz, 1 H), 7.43 (dd, J = 8.1, 1.0 Hz, 1 H), 7.26 (app td, J = 8.1, 1.4 Hz, 1 H), 
7.22 (app td, J = 7.7, 1.0 Hz, 1 H), 6.45 (app t, J = 1.0 Hz, 1H), 4.48 (ddd, J = 
11.5, 5.7, 4.6 Hz, 1 H), 4.41 (ddd, J = 11.5, 8.8, 4.0 Hz, 1 H), 3.54–3.49 (m, 1 H), 
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3.01 (ddd, J = 17.5, 6.3, 1.2 Hz, 1 H), 2.84 (dd, J = 17.5, 9.2 Hz, 1 H), 2.36–2.31 
(m, 1 H), 2.17 (dddd, J = 13.5, 8.8, 8.8, 4.6 Hz, 1 H); 13C NMR (150 MHz) 
! 169.7, 158.2, 154.8, 128.1, 124.2, 122.9, 120.8, 111.0, 102.2, 67.9, 34.2, 31.4, 
27.6; IR(CHCl3) 2960, 2920, 1734, 1455, 1253, 1074, 753 cm-1; mass spectrum 
(CI) m/z 217.0859 (C13H13O3 (M+1) requires 217.0862), 217, 164(base), 120. 
>98% ee; OD-H Column, Hexanes/i-PrOH 2/1, 0.8 mL/min, rt; 46.2 (Maj). No 
minor isomer detected.  
NMR Assignments: 1H NMR (600 MHz) ! 7.52 (d, J = 7.7 Hz, 1 H, C9-
H), 7.43 (d, J = 7.3 Hz, 1 H, C12-H), 7.26 (app td, J = 7.3, 1.3 Hz, 1 H, C11-H), 
7.23 (app td, J = 7.7, 1.0 Hz, 1 H, C10-H), 6.45 (s, 1H, C7-H), 4.48 (ddd, J = 
11.5, 5.7, 4.6 Hz, 1 H, C1-H), 4.41 (ddd, J = 11.5, 8.8, 4.0 Hz, 1 H, C1-H), 3.54–
3.49 (m, 1 H, C3-H), 3.01 (ddd, J = 17.5, 6.2, 1.2 Hz, 1 H, C4-H), 2.84 (dd, J = 
17.5, 9.1 Hz, 1 H, C4-H), 2.36–2.31 (m, 1 H, C2-H), 2.17 (dddd, J = 13.5, 8.8, 
8.8, 4.6 Hz, 1 H, C2-H); 13C NMR (150 MHz) ! 169.7 (C5), 158.2 (C6), 154.8 
(C13), 128.1 (C8), 124.2 (C11), 122.9 (C10), 120.8 (C9), 111.0 (C12), 102.2 



















3-(Benzofuran-2-yl)cyclohexanone (2.153). 2.153 was prepared 
according to method B. The residue was purified by flash chromatography, 
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eluting with pentane/Et2O (2:1) to yield 60 mg (93%) of 2.153 as a colorless oil.  
1H NMR (500 MHz) ! 7.50 (ddd, J = 7.6, 1.4, 0.7 Hz, 1 H), 7.42 (ddd, J = 8.0, 
1.7, 1.0 Hz, 1 H), 7.24 (ddd, J = 8.0, 7.3, 1.4 Hz, 1 H), 7.19 (app td, J = 7.6, 1.3 
Hz, 1 H), 6.42 (app t, J = 1.0 Hz, 1 H), 3.37-3.31 (m, 1 H), 2.77 (app ddt, J = 
14.4, 4.8, 1.6 Hz, 1 H), 2.66 (ddd, J = 14.4, 10.4, 1.3 Hz, 1 H), 2.46 (app dt, J = 
14.6, 5.2, 1 H), 2.39 (dddd, J = 14.6, 10.6, 5.8, 1.3, 1 H), 2.28–2.23 (m, 1 H), 
2.10–1.98 (comp, 2 H), 1.87–1.79 (m, 1 H); 13C NMR (125 MHz) ! 209.8, 159.9, 
154.6, 128.4, 123.7, 122.7, 120.6, 110.9, 101.7, 45.3, 41.3, 37.9, 29.7, 24.4.  IR 
(CHCl3) 2945, 2865, 1713, 1454, 1254, 1169, 752, cm-1; mass spectrum (CI) m/z 
215.1077 (C14H15O2 (M+1) requires 215.1072), 215 (base).  90% ee; OD-H 
Column, 90/10 Hexanes/i-PrOH, 0.5 mL/min, rt; 35.2, 36.2 (Maj). 
NMR ASSIGNMENTS: 1H NMR (500 MHz) ! 7.50 (ddd, J = 7.6, 1.4, 
0.7 Hz, 1 H), 7.42 (ddd, J = 8.0, 1.7, 1.0 Hz, 1 H), 7.24 (ddd, J = 8.0, 7.3, 1.4 Hz, 
1 H), 7.19 (ddd, J = 7.6, 7.3, 1.0 Hz, 1 H), 6.42 (app t, J = 1.0 Hz, 1 H, C8-H), 
3.37–3.31 (m, 1 H, C5-H), 2.77 (app ddt, J = 14.4, 4.8, 1.6 Hz, 1 H, C6-H), 2.66 
(ddd, J = 14.4, 10.4, 1.3 1.0 Hz, 1 H, C6-H), 2.46 (app dt, J = 14.6, 5.2, 1 H, C2-
H), 2.39 (dddd, J = 10.6, 7.1, 5.8, 1.2, 1 H, C3-H), 2.28–2.23 (m, 1 H, C2-H), 
2.10–2.01 (comp, 2 H, C3-H & C4-H), 1.87–1.79 (m, 1 H, C4-H); 13C NMR (125 
MHz) ! 209.8 (C1), 159.9 (C7), 154.6 (C14), 128.4 (C9), 123.7 (C10), 122.7 
(C13), 120.6 (C12), 110.9 (C11), 101.7 (C8), 45.3 (C6), 41.3 (C2), 37.9 (C5), 





















4-(Benzofuran-2-yl)-dihydrofuran-2(3H)-one (2.154). 2.154 was 
prepared according to method B. The residue was purified by flash 
chromatography, eluting with hexanes/EtOAc (3:1) to yield 39 mg (64%) of 3.154 
as a yellow solid; mp = 80–81 ˚C; 1H NMR (600 MHz) ! 7.52 (ddd, J = 7.7, 1.3, 
0.7 Hz, 1 H), 7.44 (ddd, J = 8.3, 1.7, 0.9 Hz, 1 H), 7.28 (app td, J = 7.3, 1.3 Hz, 1 
H), 7.23 (app td, J = 7.7, 1.0 Hz, 1 H), 6.57 (app t, J = 0.9, 1 H), 4.65 (dd, J = 9.1, 
7.9 Hz, 1H), 4.47 (dd, J = 9.1, 7.2 Hz, 1H) 4.01–3.96 (m, 1 H), 2.94 (dd, J = 17.5, 
8.8 Hz, 1 H), 2.89 (dd, J = 17.5, 8.2 Hz, 1 H); 13C NMR (150 MHz) ! 175.4, 
155.0, 154.9, 127.9, 124.5, 123.1, 120.9, 111.1, 103.4, 71.1, 35.3, 33.1; 
IR(CHCl3) 2917, 1781, 1455, 1254, 1172, 1026, 753 cm-1; mass spectrum (CI) 
m/z 203.0703 (C12H11O3 (M+1) requires 203.0707), 203(base). >98% ee; OD-H 
Column, Hexanes/i-PrOH 90/10, 1.0 mL/min, rt; 36.0, 40.3 (Maj). 
1H NMR (600 MHz) ! 7.52 (ddd, J = 7.7, 1.3, 0.7 Hz, 1 H, C4-H), 7.44 
(ddd, J = 8.3, 1.7, 0.9 Hz, 1 H, C7-H), 7.28 (app td, J = 7.3, 1.3 Hz, 1 H, C6-H), 
7.23 (app td, J = 7.7, 1.0 Hz, 1 H, C5-H), 6.57 (app t, J = 0.9, 1 H, C2-H), 4.65 
(dd, J = 9.1, 7.9 Hz, 1H, C10-H), 4.47 (dd, J = 9.1, 7.2 Hz, 1H, C10-H) 4.01–3.96 
(m, 1 H, C9-H), 2.94 (dd, J = 17.5, 8.8 Hz, 1 H, C12-H), 2.89 (dd, J = 17.5, 8.2 
Hz, 1 H, C12-H); 13C NMR (150 MHz) ! 175.4 (C11), 155.0 (C1), 154.9 (C8), 
127.9 (C3), 124.5 (C5), 123.1 (C6), 120.9 (C4), 111.1 (C7), 103.4 (C2), 71.1 
(C10), 35.3 (C12), 33.1 (C9). 
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2-Methyl-3-(5-methylfuran-2-yl)cyclopentanone (3.159). (AJS-IV-112). 
Tetrabutylammonium trifluorodiphenylsilicate (151 mg in CH2Cl2, 3 mL) was 
added via cannula to a solution of Et3N (67 mg, 0.67 mmol, 92µL) and 3.161 (50 
mg, 0.19 mmol) in PhMe (3 mL) at rt.  The resultant mixture was stirred at rt for 
24 h. 1 N aqueous HCl (2 mL) was added, and the resultant mixture was stirred 
for 30 min. The layers were separated, and the aqueous layer was extracted with 
CH2Cl2 (3 x 3 mL).  The combined organic layers were dried (MgSO4) and 
concentrated under reduced pressure. The residue was purified by flash 
chromatography, eluting with pentane/Et2O (1:1) to yield 19 mg (58%) of 3.159  
as a colorless oil: 1H NMR (500 MHz) ! 5.96 (d, J = 2.9 Hz, 1 H), 5.89 (dd, J = 
2.9, 1.0 Hz, 1 H), 2.86 (td, J =  11.5, 5.9 Hz, 1 H), 2.48 (dd, J = 9.4, 18.8 Hz, 1 
H), 2.34-2.17 (comp, 7 H), 2.05-1.95 (comp, 1 H), 1.13 (d, J = 7.0 Hz, 3 H); 13C 
NMR (125 MHz) ! 219.7, 154.6, 151.3, 106.1, 105.8, 49.6, 44.1, 37.5, 26.9, 13.8, 
13.0; IR (CDCl3) 2964, 2874, 1742, 1568, 1454, 1407, 1217, 1160, 1021, 783 
cm-1; mass spectrum (CI) m/z 179.1077 [C18H20O3 (M+1) requires 179.1072], 
179 (base), 192, 207.   
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NMR Assignments: 1H NMR (500 MHz) ! 5.96 (d, J = 2.9 Hz, 1 H, C4-
H), 5.89 (dd, J = 2.9, 1.0 Hz, 1 H, C3-H), 2.86 (td, J = 11.5, 11.5, 5.9 Hz, 1 H, 
C6-H), 2.48 (dd, J = 9.4, 18.8 Hz, 1 H, C8-H), 2.34-2.17 (comp, 4 H, C7-H, C8-
H, C10-H), 2.27 (s, 3 H, C1-H) 2.05-1.95 (comp, 1 H, C7-H), 1.13 (d, J = 7.0 Hz, 
3 H, C11-H); 13C NMR (125 MHz) ! 219.7 (C9), 154.6 (C2), 151.3 (C5), 106.1 















(2-(Furan-2-yl)ethoxyl)triisopropylsilane (3.163).  (AJS-III-103). 2-
furylethanol 3.162 (500 mg, 4.5 mmol) was added to a solution of imidazole (769 
mg, 11.3 mmol, 2.5 eq) and chlorotriisopropylsilane (1.14 g, 5.9 mmol, 1.3 eq) in 
DMF (50 mL) at 0 ˚C.  The resultant mixture was stirred at 0 ˚C for 30 min.  The 
cold bath was removed, and the reaction mixture was stirred for 12 h at room 
temperature.  The reaction mixture was washed with 1 N HCl (50 mL), and the 
layers were separated.  The aqueous layer was extracted with CH2Cl2 (5 x 50 mL) 
and the combined organic layers were dried (MgSO4) and concentrated under 
reduced pressure. The residue was purified by flash chromatography, eluting with 
pentane/Et2O (4:1) to yield 904 mg (80%) of 3.163 as a colorless oil: 
1H NMR 
(500 MHz) ! 7.30 (dd, J = 1.8, 0.9 Hz, 1 H), 6.28 (dd, J = 3.1, 1.8 Hz, 1 H), 6.06 
 216 
(dd, J = 3.1, 0.9 Hz, 1 H), 3.92 (t, J = 7.0 Hz, 2 H), 2.88 (t, J = 7.0 Hz, 2 H), 1.09–
1.02 (m, 21 H); 13C NMR (125 MHz) ! 153.4, 140.9, 110.2, 106.0, 62.0, 32.1, 
17.9, 11.9. IR (CDCl3) 2942, 2866, 1463, 1109, 883, 728, 681 cm-1; mass 
spectrum (CI) m/z 269.1942 [C15H29O2Si (M+1) requires 269.1937], 225, 269 
(base), 271 (base). 
NMR Assignments. 1H NMR (500 MHz) ! 7.30 (dd, J = 1.8, 0.9 Hz, 1 H, 
C1-H), 6.28 (dd, J = 3.1, 1.8 Hz, 1 H, C2-H), 6.06 (dd, J = 3.1, 0.9 Hz, 1 H, C3-
H), 3.92 (t, J = 7.0 Hz, 2 H, C6-H), 2.88 (t, J = 7.0 Hz, 2 H, C5-H), 1.09–1.02 (m, 
21 H, C7-H & C8-H); 13C NMR (125 MHz) ! 153.4 (C4), 140.9 (C1), 110.2 (C2), 
















2-(2-(Benzyloxy)ethyl)furan (3.164). (AJS-III-100). Benzyl bromide 
(168 mg, 117 µL, 0.98) was added to a solution of sodium hydride (39 mg, 0.98 
mmol, 60% wt. in mineral oil) and 3.162 (100 mg, 0.89 mmol) in DMF (3 mL) at 
0 ˚C. The resultant mixture was warmed to room temperature over 2 h and then 
stirred for an additional 12 h at room temperature.  Saturated aqueous NH4Cl (2 
mL) was added, and the layers were separated.  The aqueous layer was extracted 
with CH2Cl2 (3 x 10 mL), and the combined organic layers were dried (MgSO4) 
and concentrated under reduced pressure. The residue was purified by flash 
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chromatography, eluting with pentane/Et2O (4:1) to yield 117 mg (65%) of 3.164 
as a colorless oil: 1H NMR (500 MHz) ! 7.35–7.26 (m, 6 H), 6.30 (dd, J = 3.1, 1.8 
Hz, 1 H), 6.07 (dd, J = 3.1, 0.8 Hz, 1 H), 4.53 (s, 2 H), 3.73 (t, J = 7.0 Hz, 2 H), 
2.95 (t, J = 7.0 Hz, 2 H); 13C NMR (125 MHz) ! 153.1, 141.1, 138.3, 128.4, 
127.6, 127.5, 110.2, 105.9, 72.9, 68.3, 28.9; IR (CDCl3) 3030, 2909, 2860, 1598, 
1506, 1454, 1363, 1178, 1103, 1007, 802, 734, 698, 600 cm-1; mass spectrum 
(CI) m/z 203.1077 [C13H15O2 (M+1) requires 203.1072], 185, 203 (base), 293. 
NMR Assignments. 1H NMR (500 MHz) ! 7.35–7.26 (m, 5 H, Ph-H & 
C1-H), 6.30 (dd, J = 3.1, 1.8 Hz, 1 H, C2-H), 6.07 (dd, J = 3.1, 0.8 Hz, 1 H, C3-
H), 4.53 (s, 2 H, C7-H), 3.73 (t, J = 7.0 Hz, 2 H, C6-H), 2.95 (t, J = 7.0 Hz, 2 H, 
C5-H); 13C NMR (125 MHz) ! 153.1 (C4), 141.1 (C1), 138.3 (C8), 128.4 (C9), 
























102).  sec-BuLi (1.4 M in cyclohexane/hexane, 70 µL, 0.10 mmol) was added to a 
solution of  3.164 (20 mg, 0.10 mmol) in THF (400 µL) at –78 ˚C.  The resultant 
solution was warmed from –78 ˚C to 0 ˚C over 2 h and then transferred via 
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cannula to a vial charged with fused ZnCl2 (20 mg, 0.15 mmol) at 0 ˚C.  The 
resultant mixture was stirred for 30 min and then added to a solution of 
cyclopentenone (6 mg, 0.075 mmol, 6 µL), 10 mol % [RhCl((S)-binap)]2 
(generated in situ from [Rh(cod)Cl]2 and (S)-BINAP), and ClSiMe3 (16 mg, 0.15 
mmol, 19 µL) in THF (400 µL).  The mixture was stirred at room temperature for 
12 h. Aqueous HCl (0.5 N, 2.0 mL) was added and the layers were separated. The 
aqueous layer was extracted with Et2O (3 x 3 mL).  The combined organic layers 
were dried (MgSO4) and concentrated under reduced pressure. The residue was 
purified by flash chromatography, eluting with pentane/Et2O (5:1) to yield 10 mg 
(42%) of 3.168 as a colorless oil: 1H NMR (500 MHz) ! 7.37-7.26 (m, 5 H), 5.97 
(d, J = 3.1 Hz, 1 H), 5.95 (dd, J = 3.1, 0.7 Hz, 1 H),  4.54 (s, 2H), 3.71 (t, J = 6.9 
Hz. 2 H), 3.48-3.41 (m, 1 H), 2.91 (t, J = 6.9 Hz, 2 H), 2.55 (dd, J = 18.6, 7.8 Hz, 
1 H), 2.41-2.31 (m, 3 H), 2.27-2.21 (m, 1 H), 2.12-2.04 (m, 1 H)  ; 13C NMR (125 
MHz) ! 217.9, 155.1, 152.1, 138.3, 128.6, 128.4, 127.6, 126.9, 106.4, 105.2, 72.9, 
68.3, 43.6, 37.7, 35.5, 28.9, 28.6; IR (CDCl3) 2943, 2866, 1745, 1463, 1107, 
1013, 882, 818, 739, 679 cm-1; mass spectrum (CI) [C18H20O3 (M+1) requires 
285], 163, 177, 207, 267 (base), 285.   
NMR Assignments: 1H NMR (500 MHz) ! 7.37-7.26 (m, 5 H, Ph-H), 
5.97 (d, J = 3.1 Hz, 1 H, C2-H)), 5.95 (dd, J = 3.1, 0.7 Hz, 1 H, C3-H)),  4.54 (s, 
2H, C7-H), 3.71 (t, J = 6.9 Hz, 2 H, C6-H), 3.48-3.41 (m, 1 H, C9-H), 2.91 (t, J = 
6.9 Hz, 2 H, C5-H), 2.55 (dd, J = 18.6, 7.8 Hz, 1 H, C10-H), 2.41-2.31 (m, 3 H, 
C10-H, C12-H, & C13-H)), 2.27-2.21 (m, 1 H, C12-H), 2.12-2.04 (m, 1 H, C13-
H)  ; 13C NMR (125 MHz) ! 217.9 (C11), 155.1 (C1), 152.1 (C4), 138.3 (C8), 
 219 
128.4 (C10), 127.6 (C9), 126.9 (C11), 106.4 (C2), 105.2 (C3), 72.9 (C7), 68.3 





















2-(2-triisopropylsiloxyethyl)-5-(3-cylopentanone)furan (3.169).  (AJS-
III-104). sec-BuLi (1.4 M in cyclohexane/hexane, 214 µL, 0.30 mmol) was added 
to a solution of 3.163 (100 mg, 0.37 mmol) in anhydrous THF (2 mL) at –78 ˚C.  
The resultant solution was slowly warmed from –78 ˚C to 0 ˚C over 2 h and then 
transferred via cannula to a vial charged with fused ZnCl2 (50 mg, 0.37 mmol) at 
0 ˚C.  The resultant mixture was stirred for 30 min, and the solution was added to 
a solution of cyclopentenone (12 mg, 0.15 mmol, 12 µL), 10 mol % [RhCl((S)-
binap)]2 (generated in situ from [Rh(cod)Cl]2 and (S)-BINAP), and ClSiMe3 (25 
mg, 0.23 mmol, 29 µL) in THF (2 mL). The mixture was stirred at room 
temperature for 14 h. Aqueous HCl (0.5 N, 2.0 mL) was added, and the layers 
were separated. The aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The 
combined organic layers were dried (MgSO4) and concentrated under reduced 
pressure. The residue was purified by flash chromatography, eluting with 
pentane/Et2O (3:1) to yield 44 mg (80%) of 3.169 as a colorless oil: 
1H NMR (500 
MHz) !  5.97 (d, J = 3.0 Hz, 1 H), 5.94 (dd, J = 3.0, 0.9 Hz, 1 H), 3.91 (t, J = 6.9 
 220 
Hz, 2 H), 3.47-3.41 (m, 1 H), 2.83 (t, J = 6.9 Hz, 2 H), 2.55 (dd, J = 18.5, 7.8 Hz, 
1 H), 2.41-2.31 (comp, 3 H), 2.27-2.22 (comp, 1 H), 2.12-2.04 (comp, 1 H), 1.10-
1.01 (comp, 21 H); 13C NMR (125 MHz) ! 218.0, 154.9, 152.5, 106.6, 105.1, 
61.9, 43.6, 37.8, 35.5, 32.1, 28.6, 17.9, 11.9; IR (CDCl3) 2943, 2866, 1745, 1463, 
1107, 1013, 882, 818, 739, 679 cm-1; mass spectrum (CI) m/z 353.2505 
[C20H37O3Si (M+1) requires 353.2512], 179, 310, 335, 353 (base), 355.   
NMR Assignments: 1H NMR (500 MHz) !  5.97 (d, J = 3.0 Hz, 1 H, C2-
H), 5.94(dd, J = 3.0, 0.9 Hz, 1 H, C3-H), 3.91 (t, J = 6.9 Hz, 2 H, C6-H), 3.47-
3.41 (m, 1 H, C9-H), 2.83 (t, J = 6.9 Hz, 2 H, C5-H), 2.55 (dd, J = 18.5, 7.8 Hz, 1 
H, C10-H), 2.41-2.31 (comp, 3 H, C10-H, C12-H, C13-H), 2.27-2.22 (comp, 1 H, 
C12-H)), 2.12-2.04 (comp, 1 H, C13-H), 1.10-1.01 (comp, 21 H, C7-H & C8-H); 
13C NMR (125 MHz) ! 218.0 (C11), 154.9 (C1), 152.5 (C4), 106.6 (C3), 105.1 
(C2), 61.9 (C6), 43.6 (C10), 37.8 (C12), 35.5 (C9), 32.1 (C5), 28.6 (C13), 17.9 
















(3.161). Furyltitanate 2.116 (0.34 M in THF/cyclohexane/hexane, 2.3 mL, 0.79 
mmol) was added to a solution of cyclopentenone (50 mg, 0.61 mmol, 51 µL), 
ClSiEt3 (138 mg, 0.92 mmol, 154 µL), and 10 mol % [RhCl((rac)-Binap)]2 
(generated in situ from [Rh(cod)Cl]2 and (rac)-BINAP) in THF (2.0 mL).  The 
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resultant mixture was stirred at room temperature for 12 h and then transferred via 
cannula to a suspension of celite (5 g) in saturated aqueous NaHCO3 (10.0 mL).  
The biphasic mixture was stirred for 1 h.  The layers were separated, and the 
aqueous layer was extracted with CH2Cl2 (3 x 3 mL).  The combined organic 
layers were dried (MgSO4), concentrated under reduced pressure, and the residue 
was purified by flash chromatography (neutral Al2O3), eluting with pentane to 
yield 162 mg (95 %) of 3.161 as a colorless oil. 1H NMR (400 MHz) ! 5.83-5.81 
(comp, 2 H), 4.70 (app dt, J = 2.0, 1.6 Hz, 1 H), 3.82 (m, 1 H), 2.45-2.20 (comp, 7 
H), 0.98 (t, J = 8.0 Hz, 9 H), 0.70 (q, J = 8.0 Hz, 6 H); 13C NMR (125 MHz) ! 
158.7, 156.9, 150.5, 105.9, 104.1, 103.6, 40.9, 33.1, 28.7, 13.8, 6.8, 5.0; IR (neat) 
2955, 2877, 1742, 1644, 1459, 1342, 1248, 1073, 1018 cm-1; mass spectrum (CI) 
m/z 279.1777 [C18H20O3 (M+1) requires 279.1780], 279 (base).   
NMR Assignments: 1H NMR (400 MHz) ! 5.83-5.81 (comp, 2 H, C3-H 
& C4-H), 4.70 (app dt,  J = 2.0, 1.6, 1 H, C7-H), 3.85-3.80 (m, 1 H, C6-H), 2.45-
2.20 (comp, 7 H, C1-H & C10-H & C9-H), 0.98 (t, J = 8.0 Hz, 9 H, C12-H), 0.70 
(q, J = 8.0 Hz, 6 H, C11-H); 13C NMR (125 MHz) ! 158.7 (C8), 156.9 (C5), 150.5 
(C2), 105.9 (C4), 104.1 (C3), 103.6 (C7), 40.9 (C6), 33.1 (C9), 28.7 (C10), 13.8 




















(AJS-IV-40).  Silyl enol ether 3.161 (20 mg, 0.07 mmol) was added to a solution 
of samarium(III) triflate (84 mg, 0.14 mmol) and formaldehyde (100 µL, 40% wt. 
in H2O) in THF (300 µL).  The resultant mixture was stirred at room temperature 
for 24 h, and CH2Cl2 (2 mL) was added. The layers were separated, and the 
aqueous layer was extracted with CH2Cl2 (3 x 3 mL).  The combined organic 
layers were washed with brine (1 x 5 mL), dried (MgSO4) and concentrated under 
reduced pressure. The residue was purified by flash chromatography, eluting with 
pentane/Et2O (1:1) to yield 6 mg (44%) of 3.181 as a colorless oil.  
1H NMR (400 
MHz) ! 5.99 (d, J = 3.2 Hz, 1 H), 5.88 (dd, J = 3.2, 0.8 Hz, 1 H), 3.96 (ddd, J =  
11.2, 7.2, 4.4 Hz, 1 H), 3.75 (dt, J = 11.2, 5.6 Hz, 1 H), 3.26 (td, J = 11.2, 6.8 Hz, 
1 H), 2.54-2.21 (comp, 8 H), 2.10-2.09 (m, 3 H); 13C NMR (125 MHz) ! 219.7, 
153.6, 151.3, 105.9, 105.9, 60.2, 55.9, 38.1, 37.8, 26.6, 13.5; IR (neat) 3456, 
2922, 2881, 1740, 1218, 1022, 785 cm-1. 
NMR Assignments: 1H NMR (400 MHz) ! 5.99 (d, J = 3.2 Hz, 1 H, C3-
H), 5.88 (dd, J = 3.2, 0.8 Hz, 1 H, C4-H), 3.96 (ddd, J =  11.2, 7.2, 4.4 Hz, 1 H, 
C11-H), 3.75 (dt, J = 11.2, 5.6 Hz, 1 H, C11-H), 3.26 (td, J = 11.6, 6.0 Hz, 1 H, 
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C6-H), 2.54-2.21 (comp, 8 H, C10-H & C9-H & C7-H & C1-H), 2.10-2.09 (m, 1 
H, OH); 13C NMR (125 MHz) ! 219.7 (C9), 153.6 (C2), 151.3 (C5), 105.9 (C3), 

















50). Methanesulfonylchloride (6.4 mg, 0.06 mmol, 5 µL) and N,N-
diisopropylethylamine (18 mg, 0.138 mmol, 24 µL) were added to a solution of 
3.184 (9 mg, 0.046 mmol) in CH2Cl2 (100 µL) at 0 ˚C. After 30 min, the ice bath 
was removed, and the reaction was stirred at rt for 24 h. Aqueous 1N HCl (0.1 
mL) was added.  The layers were separated, and the aqueous layers were 
extracted with CH2Cl2 (3 x 1 ml). The organic layers were dried (MgSO4) and 
concentrated under reduced pressure. The residue was purified by flash 
chromatography, eluting with pentane/Et2O (10:1) to yield 4 mg (50%) of 3.187 
as a colorless oil. 1H NMR (400 MHz) !  6.13 (dd, J  = 2.7, 1.0 Hz, 1 H), 5.97 (d, 
J = 3.1 Hz, 1 H), 5.89 (dd, J = 3.1, 1.0 Hz, 1 H), 5.35 (dd, J = 2.4, 1.0 Hz, 1 H), 
4.04–3.96 (m, 1 H), 2.54–2.06 (comp, 4 H), 2.26 (s, 3 H); 13H NMR (100 MHz) !  
206.0, 153.7, 151.8, 146.1, 119.5, 106.8, 106.2, 41.0, 37.3, 26.2, 14.3. 
NMR Assignments: 1H NMR (400 MHz) !  6.13 (dd, J  = 2.7, 1.0 Hz, 1 
H, C11-H), 5.97 (d, J = 3.1 Hz, 1 H, C3-H), 5.89 (dd, J = 3.1, 1.0 Hz, 1 H, C4-H), 
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5.35 (dd, J = 2.4, 1.0 Hz, 1 H, C11-H), 4.04–3.96 (m, 1 H, C6-H), 2.54–2.06 
(comp, 4 H, C8-H & C7-H), 2.26 (s, 3 H, C1-H); 13H NMR (100 MHz) !  206.0 
(C9), 153.7 (C10), 151.8 (C5), 146.1 (C2), 119.5 (C11), 106.8 (C3), 106.2 (C4), 















3-(Furan-2-yl)-2-methylcyclopentanone (3.178). n-BuLi (2.23 M in 
hexanes, 1.22 mmol, 0.54 mL) was added to a solution of furan (84 mg, 1.2 
mmol, 90 µL) in THF (2 mL) at –78 ˚C.  The resultant solution was stirred –78 ˚C 
for 20 min and 0 ˚C for 2 h, whereupon  Ti(OiPr)4 (398 mg, 1.4 mmol, 416 µL) 
was added at –78 ˚C.  The reaction mixture was stirred for 1 h and then added via 
cannula to a solution of cyclopentenone (49 mg, 0.6 mmol, 50 µL), 10 mol % 
[RhCl((S)-binap)]2 (generated in situ from [Rh(cod)Cl]2 and (S)-BINAP), and 
ClSiEt3 (98 mg, 0.9 mmol, 115 µL) in THF (2 mL).  The reaction mixture was 
stirred at room temperature for 12 h.  Saturated aqueous NaHCO3 (2.0 mL) was 
added, and the biphasic mixture was filtered through celite, eluting with Et2O.  
The layers were separated and the aqueous layer was extracted with Et2O (3 x 3 
mL).  The combined organic layers were dried (MgSO4), concentrated under 
reduced pressure, and used without further purification. Methyllithium (1.53 M in 
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Et2O, 0.60 mL, 0.92 mmol) was added to a solution of the TES enol ether 
intermediate in PhMe (5 mL) at –78 ˚C.  This solution was stirred at –78 ˚C for 20 
min, and at 0 ˚C for 30 min.  The reaction was warmed to 0 ˚C and stirred for 30 
min.  HMPA (515 mg, 0.5 mL, 2.9 mmol) was added to the solution and stirring 
was continued for 15 min.  ClTi(OiPr)3 (81 mg, 0.31 mmol, 74 µL) was then 
added and the resultant solution was stirred for 30 min.  The mixture was cooled 
to –78 ˚C, MeI (264 mg, 1.86 mmol, 116 µL) was added, and the resultant 
mixture was stirred for 16 h at –78 ˚C.  Saturated aqueous NH4Cl (3 mL) and Et2O 
(5 mL) were added and the layers were separated.   The aqueous layer was 
extracted with Et2O (3 x 3 mL) and the combined organic layers were dried 
(MgSO4) and concentrated under reduced pressure.  The residue was purified by 
flash chromatography, eluting with pentane/Et2O (4:1) to yield 70 mg (70%) of 
3.178 as a colorless oil. 1H NMR (400 MHz) ! 7.35 (dd, J = 1.8, 0.8 Hz, 1 H), 
6.32 (dd, J = 3.1, 1.8 Hz, 1 H), 6.10 (app dt, J = 3.1, 0.8 Hz, 1 H), 2.93 (app td, J 
= 11.4, 6.1 Hz, 1 H), 2.49 (dd, J = 18.6, 8.1 Hz 1 H), 2.36-2.19 (comp, 3 H), 2.07-
1.96 (m, 1 H), 1.13 (d, J = 7.0 Hz); 13C NMR (125 MHz) ! 219.1, 156.2, 141.5, 
110.1, 104.9, 49.4, 43.8, 37.2, 26.6, 12.8; IR (neat) 2968, 2877, 1800, 1740, 1456, 
1164, 1150, 1011, 739 cm-1; mass spectrum (CI) m/z 165.0918 (C10H13O2 (M+1) 
requires 165.0916), 111 (base).   
NMR Assignments: 1H NMR (400 MHz) ! 7.35 (dd, J = 1.8, 0.8 Hz, 1 H, 
C1-H), 6.32 (dd, J = 3.1, 1.8 Hz, 1 H, C2-H), 6.10 (app dt, J = 3.1, 0.8 Hz, 1 H, 
C3-H), 2.93 (app td, J = 11.4, 6.1 Hz, 1 H, C5-H), 2.49 (dd, J = 18.6, 8.1 Hz 1 H, 
C7-H), 2.36-2.19 (comp, 3 H, C9-H & C6-H & C7-H), 2.07-1.96 (m, 1 H, C6-H), 
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1.13 (d, J = 7.0 Hz, 3 H, C10-H); 13C NMR (125 MHz) ! 219.1 (C8), 156.2 (C4), 
















Racemic 3-(Furan-2-yl)-2-methylcyclopentanone (3.178) (AJS-V-197). 
This procedure was used for the preparation of racemic 3.178 on large scale. 
Furan-2-yl zinc chloride 2.102 was prepared according to the general procedure 
(vide supra). The solution of 2.102 (0.5 M in THF, 200 mL) was transferred via 
cannula to a solution of 2-methylcyclopent-2-enone (7.70 g, 80.0 mmol, 7.9 mL) 
and TMSCl (13.1 g, 120 mmol, 15.3 mL) in THF (100 mL) and stirred at room 
temperature for 12 h. Aqueous 1N HCl (80 mL) was added to the reaction and the 
resultant mixture was stirred at room temperature for 30 min. The layers were 
separated and the aqueous layer was extracted with Et2O (5 x 50 mL). The organic 
layers were combined and washed with NaHCO3 (80 mL). The organic layers 
were dried (MgSO4) and concentrated under reduced pressure. The residue was 
purified by flash chromatography, eluting with pentane/Et2O (4:1) to yield 13.14 g 
(100%) of 3.178 as a colorless oil and as a mixture of cis/trans isomers (0.6:1.0): 
1H NMR (600 MHz) ! 7.35 (dd, J = 1.8, 0.8 Hz, 1 H, trans-isomer), 7.30 (dd, J = 
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1.8, 0.8 Hz, 0.6 H, cis-isomer), 6.32 (dd, J = 3.1, 1.8 Hz, 1 H, trans-isomer), 6.28 
(dd, J = 3.2, 1.8 Hz, 0.6 H, cis-isomer), 6.10 (app dt, J = 3.1, 0.8 Hz, 1 H, trans-
isomer), 6.04 (app dt, J = 3.2, 0.8 Hz, 0.6 H, cis-isomer), 3.61–3.59 (m, 0.6 H, 
cis-isomer), 2.93 (app td, J = 11.4, 6.1 Hz, 1 H, trans-isomer), 2.49 (comp, 2.2 
H), 2.36-2.19 (comp, 4.8 H), 2.07-1.96 (m, 1 H), 1.13 (d, J = 7.0 Hz, 3 H, trans-
isomer), 0.84 (d, J = 7.3 Hz, 1.8 H, cis-isomer); 13C NMR (125 MHz) ! 219.9 
(cis-isomer), 219.0 (trans-isomer), 156.2 (trans-isomer), 155.7 (cis-isomer), 141.6 
(cis-isomer), 141.5 (trans-isomer), 110.1 (trans-isomer), 109.9 (cis-isomer), 106.2 
(cis-isomer), 104.9 (trans-isomer), 49.4 (trans-isomer), 47.8 (cis-isomer), 43.8 
(trans-isomer), 39.9 (cis-isomer), 37.2 (trans-isomer), 36.1 (cis-isomer), 26.6 
(trans-isomer), 25.5 (cis-isomer), 12.8 (trans-isomer), 10.6 (cis-isomer); IR (neat) 
2970, 1740, 1275, 1261, 1150, 1010, 750 cm-1; mass spectrum (CI) m/z 165.0917 
(C10H13O2 (M+1) requires 165.0916), 165 (base).   
NMR Assignments: 1H NMR (600 MHz) ! 7.35 (dd, J = 1.8, 0.8 Hz, 1 H, 
trans-isomer, C1-H), 7.30 (dd, J = 1.8, 0.8 Hz, 0.6 H, cis-isomer, C1-H), 6.32 (dd, 
J = 3.1, 1.8 Hz, 1 H, trans-isomer, C2-H), 6.28 (dd, J = 3.2, 1.8 Hz, 0.6 H, cis-
isomer, C2-H), 6.10 (app dt, J = 3.1, 0.8 Hz, 1 H, trans-isomer, C3-H), 6.04 (app 
dt, J = 3.2, 0.8 Hz, 0.6 H, cis-isomer, C3-H), 3.61–3.59 (m, 0.6 H, cis-isomer, C5-
H), 2.93 (app td, J = 11.4, 6.1 Hz, 1 H, trans-isomer, C5-H), 2.49 (comp, 2.2 H, 
C9-0.6H, C7-0.6H, C7-H), 2.36-2.19 (comp, 4.8 H, C7-H, C7-0.6H, C9-H, C6-H, 
C6-1.2H), 2.07-1.96 (m, 1 H, C6-H), 1.13 (d, J = 7.0 Hz, 3 H, trans-isomer, C10-
H), 0.84 (d, J = 7.3 Hz, 1.8 H, cis-isomer, C10-1.8 H); 13C NMR (125 MHz) ! 
219.9 (cis-isomer, C8), 219.0 (trans-isomer, C8), 156.2 (trans-isomer, C4), 155.7 
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(cis-isomer, C4), 141.6 (cis-isomer, C1), 141.5 (trans-isomer, C1), 110.1 (trans-
isomer, C2), 109.9 (cis-isomer, C2), 106.2 (cis-isomer, C3), 104.9 (trans-isomer, 
C3), 49.4 (trans-isomer, C9), 47.8 (cis-isomer, C9), 43.8 (trans-isomer, C5), 39.9 
(cis-isomer, C5), 37.2 (trans-isomer, C7), 36.1 (cis-isomer, C7), 26.6 (trans-




















ynyl)cyclopentanone (3.188) (AJS-V-266).  NaHMDS (1.9 M in THF, 3.15 
mmol, 57 µL) was added to a solution of 3.178 (575 mg, 3.5 mmol) in THF (30 
mL) at –78 ˚C.  After stirring for 20 min, the cold bath was removed, and stirring 
was continued at room temperature for 1.5 h.  3-(Iodoprop-1-ynyl)trimethylsilane 
(86 mg, 0.36 mmol, prepared immediately prior to usei) was added at 0 ºC and the 
resultant solution was stirred for 2 h. Saturated aqueous NH4Cl (1.0 mL) and Et2O 
(15 mL) were added and the layers were separated. The aqueous layer was 
extracted with Et2O (3 x 15 mL). The combined organic layers were dried 
(MgSO4) and concentrated under reduced pressure. The residue was purified by 
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flash chromatography, eluting with pentane/Et2O (4:1) to yield  778 mg (81%) of 
3.188 as a colorless oil.  1H NMR (400 MHz) ! 7.36 (dd, J = 1.9, 0.9 Hz, 1 H), 
6.33 (ddd, J = 3.2, 1.9, 0.3 Hz, 1 H), 6.14 (dt, J = 3.2, 0.8 Hz, 1 H), 3.78 (dd, J = 
11.4, 6.3, 1 H), 2.58 (d, J = 16.8 Hz, 1 H), 2.40 (d, J = 16.8 Hz, 1 H), 2.57-2.52 
(m, 1 H),  2.32-2.10 (comp, 3 H), 0.70 (s, 3 H), 0.13 (s, 9 H); 13C NMR (125 
MHz) ! 219.4, 154.8, 141.7, 109.9, 106.5, 103.4, 87.4, 52.4, 42.3, 37.6, 27.5, 
22.8, 18.3, 0.1; IR (CH2Cl2) 2963, 2899, 2175, 1745, 1250, 844, 760 cm-1; mass 
spectrum (CI) m/z 275.1472 [C16H23O2Si (M+1) requires 275.1467], 275 (base), 
259.  
NMR Assignments: 1H NMR (400 MHz) ! 7.36 (dd, J = 1.9, 0.9 Hz, 1 H, 
C1-H), 6.33 (ddd, J = 3.2, 1.9, 0.3 Hz, 1 H, C2-H), 6.14 (dt, J = 3.2, 0.8 Hz, 1 H, 
C3-H), 3.78 (dd, J = 11.4, 6.3, 1 H, C5-H), 2.58 (d, J = 16.8 Hz, 1 H), 2.40 (d, J = 
16.8 Hz, 1 H), 2.57-2.52 (m, 1 H, C7-H),  2.32-2.10 (comp, 3 H, C7-H & C6-H), 
0.70 (s, 3 H, C10-H), 0.13 (s, 9 H, C14-H);13C NMR (125 MHz) ! 219.4 (C8), 
154.8 (C4), 141.7 (C1), 109.9 (C2), 106.5 (C3), 103.4 (C13), 87.4 (C12), 52.4 




























ynyl)cyclopentanone (3.193) (AJS-V-230). NaHMDS (1.91 M in THF, 9.0 
mmol, 4.7 mL) was added to a solution of 3.198 (2.04 g, 10 mmol) in THF (100 
mL) at –78 ˚C.  After stirring for 10 min at –78 ˚C, the cold bath was removed, 
and stirring was continued for 1 h.  (3-iodoprop-1-ynyl)trimethylsilane (3.57 g, 
15.0 mmol, prepared immediately prior to use according to literature 
procedures)160, 161 was added at 0 ˚C and the resultant solution was stirred for 2 h. 
Saturated aqueous NH4Cl (5.0 mL) and Et2O (50 mL) were added and the layers 
were separated. The aqueous layer was extracted with Et2O (3 x 25 mL). The 
combined organic layers were dried (MgSO4) and concentrated under reduced 
pressure. The residue was purified by flash chromatography, eluting with 
pentane/Et2O (4:1) to yield 2.61 g (83%) of 3.193 as a single diastereomer and as 
a colorless oil. 1H NMR (600 MHz) !  6.03 (d, J = 3.1 Hz, 1H), 5.95 (d, J = 3.1 
Hz, 1H), 5.80 (ddt, J = 16.6, 10.1, 6.5 Hz, 1 H), 5.12 (dq, J = 16.6, 1.6 Hz, 1 H), 
5.10 (dq, J = 10.1, 1.4 Hz, 1 H), 3.72 (dd, J = 11.4, 6.1 Hz, 1 H), 3.36 (dd, J = 6.5, 
1.1 Hz, 2 H), 2.57 (d, J = 16.9 Hz, 1 H), 2.53 (m, 1 H), 2.36 (d, J = 16.9 Hz, 1 H), 
2.29–2.25 (m, 1 H), 2.25–2.19 (m, 1 H), 2.14–2.07 (m, 1 H), 0.71 (s, 3 H), 0.13 
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(s, 9 H); 13C NMR (150 MHz) ! 219.7, 153.4, 153.0, 133.9, 116.7, 107.2, 105.9, 
103.6, 87.3, 52.3, 42.4, 37.6, 32.6, 27.5, 22.8, 18.4, 0.12; IR (CH2Cl2) 2963, 
2899, 2175, 1745, 1249, 843, 786, 759 cm-1; mass spectrum (CI) m/z 315.1776 
[C19H27O2Si (M+1) requires 315.1780], 315 (base), 299. 
NMR Assignments: 1H NMR (600 MHz) !  6.03 (d, J = 3.1 Hz, 1H, C5-
H), 5.95 (d, J = 3.1 Hz, 1H, C6-H), 5.80 (ddt, J = 16.6, 10.1, 6.5 Hz, 1 H, C2-H), 
5.12 (dq, J = 16.6, 1.6 Hz, 1 H, C1-H), 5.10 (dq, J = 10.1, 1.4 Hz, 1 H, C1-H), 
3.72 (dd, J = 11.4, 6.1 Hz, 1 H, C8-H), 3.36 (dd, J = 6.5, 1.1 Hz, 2 H, C3-H), 2.57 
(d, J = 16.9 Hz, 1 H, C14-H), 2.53 (m, 1 H, C11-H), 2.36 (d, J = 16.9 Hz, 1 H, 
C14-H), 2.29–2.25 (m, 1 H, C12-H), 2.25–2.19 (m, 1 H, C11-H), 2.14–2.07 (m, 1 
H, C12-H), 0.71 (s, 3 H, C13-Me), 0.13 (s, 9 H, TMS); 13C NMR (150 MHz) ! 
219.7 (C10), 153.4 (C4), 153.0 (C7), 133.9 (C2), 116.7(C1), 107.2 (C5), 105.9 
(C6), 103.6 (C16), 87.3 (C15), 52.3 (C9), 42.4 (C8), 37.6 (C11), 32.6 (C3), 27.5 





































ynyl)cyclopentylidene)-2-(4-nitrophenyl)hydrazine (3.199) (AJS-V-225). Para-
nitrophenylhydrazine (9.2 mg, 0.06 mmol) was added to a solution of 3.193 (19 
mg, 0.06 mmol) in acetic acid (0.6 mL) and stirred at rt for 20 min and then at 80 
˚C for 2 h. The reaction mixture was poured onto wet ice; extracted with EtOAc 
(3 x 3 ml); washed with saturated aqueous NaHCO3; dried (MgSO4); and 
concentrated. 17.5 mg (65%) of 3.199 was isolated. 1H NMR (600 MHz) !   8.15 
(d, J = 9.3 Hz, 2H), 7.29 (s, 1 H), 7.07 (d, J = 9.3 Hz, 2H), 6.02 (d, J = 3.1 Hz, 1 
H), 5.95 (d, J = 3.1 Hz, 1 H), 5.92 (ddt, J = 16.7, 10.1, 6.5 Hz, 1 H), 5.13 (dq, J = 
16.7, 1.6 Hz, 1 H), 5.10 (dq, J = 10.1, 1.6 Hz, 1 H), 3.50 (dd, J = 11.2, 6.5 Hz, 1 
H), 3.36 (dd, J = 6.5, 1.1 Hz, 2 H), 2.73 (d, J = 16.7 Hz, 1 H), 2.66–2.61 (m, 1 H), 
2.52 (d, J = 16.7 Hz, 1 H), 2.33–2.13 (comp, 3 H), 0.89 (s, 3 H), 0.09 (s, 9 H); 13C 
NMR (150 MHz) ! 161.3, 153.1, 152.9, 150.4, 140.0, 134.0, 126.1, 116.7, 111.8, 
107.4, 105.9, 105.0, 88.7, 49.5, 44.5, 32.6, 29.8, 25.8, 25.1, 21.6, 0.2. 
NMR Assignments: 1H NMR (600 MHz) !   8.15 (d, J = 9.3 Hz, 2H, 
C20-H), 7.29 (s, 1 H, N-H), 7.07 (d, J = 9.3 Hz, 2H, C19-H), 6.02 (d, J = 3.1 Hz, 
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1 H, C5-H), 5.95 (d, J = 3.1 Hz, 1 H, C6-H), 5.92 (ddt, J = 16.7, 10.1, 6.5 Hz, 1 
H, C2-H), 5.13 (dq, J = 16.7, 1.6 Hz, 1 H, C1-H), 5.10 (dq, J = 10.1, 1.6 Hz, 1 H, 
C1-H), 3.50 (dd, J = 11.2, 6.5 Hz, 1 H, C8-H), 3.36 (dd, J = 6.5, 1.1 Hz, 2H, C3-
H), 2.73 (d, J = 16.7 Hz, 1 H, C14-H), 2.66–2.61 (m, 1 H, C11-H), 2.52 (d, J = 
16.7 Hz, 1 H, C14-H), 2.33–2.13 (comp, 3 H, C11-H & C12-H), 0.89 (s, 3 H, 
C13-Me), 0.09 (s, 9 H, C17-H); 13C NMR (150 MHz) ! 161.3 (C10), 153.1 (C18), 
152.9 (C4), 150.4 (C7), 140.0 (C21), 134.0 (C2), 126.1 (C20), 116.7 (C1), 111.8 
(C19), 107.4 (C5), 105.9 (C6), 105.0 (C15), 88.7 (C16), 49.5 (C9), 44.5 (C8), 



























(trimethylsilyl)prop-2-ynyl)cyclopentanone (3.200) (AJS-V-248). Furan 3.193 
(587 mg, 1.83 mmol) was added to a solution of ADMix-# (2.6 g) and 
methanesulfonamide (348 mg, 3.66 mmol) in tBuOH/H2O (9 mL:9 mL) at room 
temperature. The resultant mixture was stirred at room temperature for 4 d. 
Saturated aqueous sodium metabisulfite (10.0 mL) and EtOAc (10.0 mL) were 
added, and the layers were separated. The aqueous layer was extracted with 
EtOAc (2 x 50 mL), and the combined organic layers were dried (MgSO4) and 
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concentrated under reduced pressure. The excess methanesulfonamide was 
removed via precipitation with CH2Cl2. The residue was purified by flash 
chromatography, eluting with pentane/EtOAc (4:1%1:1) to yield 319 mg (50%) 
of 3.200 as a colorless oil:  1H NMR (500 MHz) !  6.08–6.06 (comp, 2 H), 4.00–
3.98 (m, 1 H), 3.75–3.69 (comp, 2 H), 3.53 (ddd, J = 11.2, 6.3, 1.5 Hz, 1 H), 2.82 
(d, J = 6.6 Hz, 2 H), 2.62 (d, J = 16.8 Hz, 0.5 H), 2.60 (d, J = 16.8 Hz, 0.5 H), 
2.56–2.52 (comp, 2 H), 2.37 (d, J = 16.8 Hz, 0.5 H), 2.36 (d, J = 16.8 Hz, 0.5 H), 
2.29–2.08 (comp, 4 H), 1.95–1.90 (br s, 1 H), 0.71 (s, 3 H), 0.13 (s, 9 H); 13C 
NMR (125 MHz) ! 219.3, 153.84, 153.82, 150.9, 150.8, 107.7, 107.6, 107.3, 
107.2, 103.2, 87.4, 70.6, 70.5, 65.9, 52.2, 43.4, 42.2, 42.1, 37.4, 32.3, 27.3, 22.6, 
22.5, 18.3, 0.1; IR (CH2Cl2) 3399, 2961, 2898, 1742, 1329, 1249, 1074, 1032, 
844, 760 cm-1; mass spectrum (CI) m/z 349.1837 [C19H29O4Si (M+1) requires 
349.1835], 377, 349 (base), 333. 
NMR Assignments: 1H NMR (500 MHz) !  6.08–6.06 (comp, 2 H, C5-H 
& C6-H), 4.00–3.98 (m, 1 H, C2-H), 3.75–3.69 (comp, 2 H, C1-H & C8-H), 3.53 
(ddd, J = 11.2, 6.3, 1.5 Hz, 1 H, C1-H), 2.82 (d, J = 6.6 Hz, 2 H, C3-H), 2.62 (d, J 
= 16.8 Hz, 0.5 H, C14-H), 2.60 (d, J = 16.8 Hz, 0.5 H, C14-H), 2.56–2.52 (m, 1 
H, C10-H), 2.37 (d, J = 16.8 Hz, 0.5 H, C14-H), 2.36 (d, J = 16.8 Hz, 0.5 H, C14-
H), 2.29–2.08 (comp, 4 H, C10-H, C9-H, & OH), 1.95–1.90 (br s, 1 H, OH), 0.71 
(s, 3 H, C13-H), 0.13 (s, 9 H, C17-H); 13C NMR (125 MHz) ! 219.3 (C11), 
153.84 (C4), 153.82 (C4), 150.9 (C7), 150.8 (C7), 107.7 (C5), 107.6 (C5), 107.3 
(C6), 107.2 (C6), 103.2 (C16), 87.4 (C15), 70.6 (C2), 70.5 (C2), 65.9 (C1), 52.2 
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(C12), 42.2 (C8), 42.1 (C8), 37.4 (C10), 32.3 (C3), 27.3 (C14), 22.6 (C9), 22.5 



















7-(furan-2-yl)-6-methyl-1,4-dioxaspiro[4.4]nonane (3.196) (AJS-V-24). 
Pyridinium para-toluenesulfonate (56 mg, 0.24 mmol) and ethylene glycol (379 
mg, 341 µL) were added to a solution of 3.178 (200 mg, 1.22 mmol) in benzene 
(12.0 mL). The solution was heated under reflux with a Dean-Stark apparatus for 
4 h. Saturated aqueous NaHCO3 (2.0 mL) was added, followed by CH2Cl2 (5.0 
mL).  The layers were separated and the aqueous layer was extracted with CH2Cl2 
(5 x 10 mL). The combined organic layers were dried (MgSO4), concentrated 
under reduced pressure, and the residue was purified by flash chromatography, 
eluting with pentane/Et2O (10:1) to yield 254 mg (100%) of 3.196 as a colorless 
oil: 1H NMR (500 MHz) !  7.32 (dd, J = 1.8, 0.7 Hz, 0.2 H), 7.31 (dd, J = 1.8, 0.9 
Hz, 0.8 H), 6.29 (ddd, J = 3.2, 1.9, 0.4 Hz, 0.2 H), 6.28 (ddd, J = 3.2, 1.9, 0.4 Hz, 
0.8 H), 6.04 (dt, J = 3.2, 0.9 Hz, 0.2 H), 6.02 (dt, J = 3.2, 0.8 Hz, 0.8 H), 3.98–
3.86 (comp, 4 H), 3.47 (dd, J = 17.6, 7.7 Hz, 0.2 H), 2.81 (dt, J = 11.2, 8.9 Hz, 0.8 
H), 2.29–2.24 (m, 0.2 H), 2.19–2.15 (m, 0.8 H), 2.10–1.94 (comp, 2 H), 1.93–
1.79 (comp, 2 H), 0.96 (d, J = 6.8 Hz, 2.4 H), 0.68 (d, J = 7.3 Hz, 0.6 H); 13C 
NMR (125 MHz) !  157.9, 157.0, 141.1, 141.0, 118.7, 117.4, 109.9, 109.8, 105.7, 
104.3, 64.9, 64.88, 64.82, 64.0, 46.7, 43.8, 43.7, 40.0, 35.4, 33.2, 27.5, 24.3, 11.6, 
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10.4; IR (CH2Cl2) 2969, 2878, 1507, 1149, 1110, 1034, 948, 912, 731 cm-1; 
mass spectrum (CI) m/z 209.1176 [C12H17O3 (M+1) requires 209.1178], 209, 197 
(base). 
NMR Assignments: 1H NMR (500 MHz) !  7.32 (dd, J = 1.8, 0.7 Hz, 0.2 
H, C1-H), 7.31 (dd, J = 1.8, 0.9 Hz, 0.8 H, C1-H), 6.29 (ddd, J = 3.2, 1.9, 0.4 Hz, 
0.2 H, C2-H), 6.28 (ddd, J = 3.2, 1.9, 0.4 Hz, 0.8 H, C2-H), 6.04 (dt, J = 3.2, 0.9 
Hz, 0.2 H, C3-H), 6.02 (dt, J = 3.2, 0.8 Hz, 0.8 H, C3-H), 3.98–3.86 (comp, 4 H, 
C11-H & C12-H), 3.47 (dd, J = 17.6, 7.7 Hz, 0.2 H, C5-H), 2.81 (dt, J = 11.2, 8.9 
Hz, 0.8 H, C5-H), 2.29–2.24 (m, 0.2 H, C9-H), 2.19–2.15 (m, 0.8 H, C9-H), 2.10–
1.94 (comp, 2 H, C7-H), 1.93–1.79 (comp, 2 H, C6-H), 0.96 (d, J = 6.8 Hz, 2.4 H, 
C10-Me), 0.68 (d, J = 7.3 Hz, 0.6 H, C10-Me); 13C NMR (125 MHz) !  157.9 
(C4-major), 157.0 (C4-minor), 141.1 (C1-major), 141.0 (C1-minor), 118.7 (C8-
minor), 117.4 (C8-major), 109.9 (C2-major), 109.8 (C2-minor), 105.7 (C3-
minor), 104.3 (C3-major), 64.9 (C11-minor), 64.88 (C11-major), 64.82 (C12-
major), 64.0 (C12-minor), 46.7 (C9-major), 43.8 (C9-minor), 43.7 (C5-major), 
40.0 (C5-minor), 35.4 (C7-major), 33.2 (C7-minor), 27.5 (C6-major), 24.3 (C6-























3-(5-allylfuran-2-yl)-2-methylcyclopentanone (3.198). (AJS-V-228). 
Pyridinium p-toluenesulfonate (3.58g, 15.6 mmol) was added to a solution of 
3.197 (6.46g, 26 mmol) in 260 mL of acetone:H2O (14:1). The resultant solution 
was heated under reflux for 4 h. Saturated aqueous NaHCO3 (20.0 mL) and Et2O 
(25.0 mL) were added. The layers were separated and the aqueous layer was 
extracted with Et2O (5 x 50 mL). The combined organic layers were dried 
(MgSO4) and concentrated under reduced pressure. The residue was purified by 
flash chromatography, eluting with pentane/Et2O (10:1) to yield 5.31 g (100%) of 
3.198 as a colorless oil:  1H NMR (500 MHz) !  6.00 (d, J = 3.1 Hz, 1 H), 5.98–
5.89 (comp, 2 H), 5.16–5.09 (comp, 2 H), 3.37 (dd, J = 6.5, 1.2 Hz, 2 H), 2.88 (td, 
J = 11.4, 6.0 Hz, 1 H), 2.47 (dd, J = 18.1, 8.7 Hz, 1 H), 2.34–2.19 (comp, 3 H), 
2.04–1.95 (m, 1 H), 1.13 (d, J = 7.0, 3 H); 13C NMR (125 MHz) ! 219.3, 154.9, 
152.9, 133.9, 116.8, 105.9, 105.5, 49.4, 43.9, 37.2, 32.6, 26.7, 12.8; IR (CHCl2) 
2967, 2932, 2878, 1742, 1564, 1456, 1161, 1015, 919, 786 cm-1; mass spectrum 
(CI) m/z 205.1223 [C13H17O2 (M+1) requires 205.1229], 205 (base). 
NMR ASSIGNMENTS: 1H NMR (500 MHz) !  6.00 (d, J = 3.1 Hz, 1 H, 
C6-H), 5.98–5.89 (comp, 2 H, C5-H & C2-H), 5.16–5.09 (comp, 2 H, C1-H), 3.37 
(dd, J = 6.5, 1.2 Hz, 2 H, C3-H), 2.88 (td, J = 11.4, 6.0 Hz, 1 H, C8-H), 2.47 (dd, 
J = 18.1, 8.7 Hz, 1 H, C11-H), 2.34–2.19 (comp, 3 H, C11-H, C12-H, & C9-H), 
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2.04–1.95 (m, 1 H, C12-H), 1.13 (d, J = 7.0, 3 H, C13-Me); 13C NMR (125 MHz) 
! 219.3 (C10), 154.9 (C4), 152.9 (C7), 133.9 (C2), 116.8 (C1), 105.9 (C5), 105.5 
























diol (3.204). Furan 3.203 (250 mg, 1.01 mmol) was added to a solution of 
ADMix-$ and methanesulfonamide (192 mg, 2.02 mmol) in tBuOH-H2O (5 mL:5 
mL) at rt. The resultant mixture was stirred for 2.5 d. Two major diastereomers 
were isolated. Saturated aqueous sodium metabisulfite (5 mL) was added, 
followed by EtOAc (5.0 mL).  The layers were separated and the aqueous layer 
was extracted with EtOAc (3 x 10 mL). The combined organic layers were dried 
(MgSO4) and concentrated under reduced pressure. The excess 
methanesulfonamide was removed via precipitation with CH2Cl2. The residue was 
purified by flash chromatography, eluting with pentane/EtOAc (4:1%1:1) to yield 
141 mg (50%) of 3.204 as a colorless oil. 1H NMR (500 MHz) !  6.02 (d, J = 2.9 
Hz, 1 H), 5.94 (d, J = 3.2 Hz, 1 H), 4.07–3.87 (comp, 5 H), 3.72–3.68 (m, 1 H), 
3.55–3.51 (m, 1 H), 2.80 (d, J = 4.1 Hz, 2 H), 2.78–2.74 (m, 1 H), 2.21 (d, J = 4.1 
Hz, 1 H), 2.13 (ddd, J = 13.4, 11.2, 6.6 Hz, 1 H), 2.05–1.9 (comp, 3 H), 1.87–1.77 
(comp, 2 H), 0.95 (d, J = 6.8 Hz, 2.6 H, methyl), 0.67 (dd, J = 7.1, 3.2 Hz, 0.4 H, 
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methyl); 13C NMR (125 MHz) !  157.3, 150.1, 117.4, 107.72, 107.70, 105.1, 70.8, 
70.7, 66.0, 64.9, 64.8, 46.7, 46.6, 43.7, 43.5, 35.4, 32.4, 27.5, 27.4, 11.7; IR 
(CH2Cl2) 3368, 2964, 2879, 1457, 1328, 1155, 1107, 1032, 913, 787 cm-1; mass 
spectrum (CI) m/z 283.1544 [C15H23O5 (M+1) requires 283.1545], 283, 265 
(base). 
NMR Assignments: 1H NMR (500 MHz) !  6.02 (d, J = 2.9 Hz, 1 H, C5-
H), 5.94 (d, J = 3.2 Hz, 1 H, C6-H), 4.07–3.87 (comp, 5 H, C15-H, C14-H, & C2-
H), 3.72–3.68 (m, 1 H, C1-H), 3.55–3.51 (m, 1 H, C1-H), 2.80 (d, J = 4.1 Hz, 2 
H, C3-H), 2.78–2.74 (m, 1 H, C8-H), 2.21 (d, J = 4.1 Hz, 1 H, C12-H), 2.13 (ddd, 
J = 13.4, 11.2, 6.6 Hz, 1 H, C9-H), 2.05–1.9 (comp, 3 H, C11-H & OH), 1.87–
1.77 (comp, 2 H, C12-H & OH), 0.95 (d, J = 6.8 Hz, 3 H, methyl); 13C NMR (125 
MHz) !  157.3 (C4), 150.1 (C7), 117.4 (C10), 107.72 (C5), 107.70 (C5), 105.1 
(C6), 70.8 (C2), 70.7 (C2), 66.0 (C1), 64.9 (C14), 64.8 (C15), 46.7 (C9), 46.6 






















Sodium periodate (188 mg, 0.88 mmol) was added to a solution of diol 3.204 (125 
mg, 0.44 mmol) in THF/H2O (2.2mL:2.2mL) at 0 ºC. The reaction was complete 
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within 45 min at 0 ºC. The THF/H2O layers were extracted with Et2O (3 x 5 mL), 
washed with brine and dried (MgSO4). The solvent was removed under reduced 
pressure to yield 110 mg (100%) of 3.205 as a colorless oil, which was carried on 
without further purification. A 0.45:0.55 mixture of cis/trans isomers was isolated. 
1H NMR (600 MHz, CH2Cl2) ! 9.69 (t, J = 2.1 Hz, 0.45 H), 9.68 (t, J = 2.2 Hz, 
0.55 H), 6.19 (dt, J = 3.2, 0.8 )z, 0.45 H), 6.14 (dt, J = 3.2, 0.8 Hz, 0.55 H), 6.10 
(dd, J = 3.2, 0.4 Hz, 0.45 H), 6.01 (dd, J = 3.1, 0.3 Hz, 0.55 H), 3.95–3.84 (comp, 
4 H), 3.68 (d, J = 1.9, 0.9 Hz, 0.9 H), 3.66 (d, J = 2.2 Hz, 1.1 H), 2.91 (td, J = 
11.4, 5.9 Hz, 0.55 H), 2.78–2.73 (m, 0.45 H), 2.44 (ddt, J = 18.2, 8.1, 1.5 Hz, 0.55 
H), 2.33–2.18 (comp, 2 H), 2.09 (dq, J = 11.5, 7.1 Hz, 0.55 H), 2.02–1.74 (comp, 
1.9 H), 1.10 (d, J = 6.9 Hz, 1.35 H), 0.91 (d, J = 6.8 Hz, 1.65 H);  13C NMR (125 
MHz) ! 218.8, 197.5, 197.3, 158.8, 157.1, 145.9, 145.3, 117.6, 109.6, 109.4, 
106.3, 105.8, 65.3, 65.2, 64.1, 49.7, 47.1, 44.2, 44.1, 43.7, 43.4, 43.3, 37.5, 35.7, 
27.8, 26.9, 12.9, 11.8; IR (CH2Cl2) 2963, 2928, 1731, 1328, 1157, 1110, 1029, 
789 cm-1; mass spectrum (CI) m/z 251.1282 [C14H19O4 (M+1) requires 
251.1283], 253 (base), 251. 
NMR ASSIGNMENTS: 1H NMR (600 MHz, CH2Cl2) ! 9.69 (t, J = 2.1 
Hz, 0.45 H, C1-H), 9.68 (t, J = 2.2 Hz, 0.55 H, C1-H), 6.19 (dt, J = 3.2, 0.8 )z, 
0.45 H, C4-H), 6.14 (dt, J = 3.2, 0.8 Hz, 0.55 H, C4-H), 6.10 (dd, J = 3.2, 0.4 Hz, 
0.45 H, C5-H), 6.01 (dd, J = 3.1, 0.3 Hz, 0.55 H, C5-H), 3.95–3.84 (comp, 4 H, 
C13-H & C14-H), 3.68 (d, J = 1.9, 0.9 Hz, 0.9 H, C2-H), 3.66 (d, J = 2.2 Hz, 1.1 
H, C2-H), 2.91 (td, J = 11.4, 5.9 Hz, 0.55 H, C7-H), 2.78–2.73 (m, 0.45 H, C7-H), 
2.44 (ddt, J = 18.2, 8.1, 1.5 Hz, 0.55 H, C11-H), 2.33–2.18 (comp, 2 H, C10-H), 
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2.09 (dq, J = 11.5, 7.1 Hz, 0.55 H, C8-H), 2.02–1.74 (comp, 1.9 H, C8-H & C11-
H), 1.10 (d, J = 6.9 Hz, 1.35 H, C12), 0.91 (d, J = 6.8 Hz, 1.65 H);  13C NMR (125 
MHz) ! 218.8 (C1), 158.8 (C9-major), 157.1 (C9-minor), 145.9 (C6-major), 
145.3 (C6-minor), 117.6 (C3), 109.6 (C4-major), 109.4 (C4-minor), 106.3 (C5-
major), 105.8 (C5-minor), 65.3 (C13), 65.2 (C14), 49.7 (C8-major), 47.1 (C8-
minor), 44.2 (C7-major), 44.1 (C7-minor), 43.4 (C2-major), 43.3 (C2-minor), 
37.5 (C10-major) , 35.7 (C10-minor), 27.8 (C11-major), 26.9 (C11-minor), 12.9 






p-Tolylvinyl sulfoxide (3.212). (AJS-III-195). Vinyl Grignard (0.7 M in 
THF, 5.1 mmol, 7.3 mL, prepared fresh from vinyl bromide and magnesium 
turnings) was added dropwise over 20 min to a solution of (–)-menthyl-p-
tolylsulfinate (1.16 g, 3.9 mmol) in benzene (20 mL) at room temperature.  The 
reaction was stirred at room temperature for 30 min. Saturated aqueous NH4Cl (10 
mL) was added and the layers were separated. The aqueous layer was extracted 
with CH2Cl2 (3 x 20 mL).  The combined organic layers were dried (MgSO4) and 
concentrated under reduced pressure. The reside was purified by flash 
chromatography, eluting with Et2O/EtOAc (4:1) to yield 414 mg  (64%) of 3.212.  



















































exo-3.214). (AJS-III-203). 2,5-Dimethylfuran (53 mg, 0.55 mmol, 59µL) was 
added to a solution of 3.212 (30 mg, 0.11 mmol) in CH2Cl2 (100 µL) at –20 ˚C.  
The reaction mixture was stirred at –20 ˚C for 36 h.  Aqueous NaOH (0.2 M, 0.5 
mL) was then added, and the cold bath was removed.  The reaction mixture was 
stirred at room temperature for 30 min.  The aqueous layer was extracted with 
CH2Cl2 (3 x 3 mL), and the combined organic layers were washed with brine, 
dried (MgSO4), and concentrated under reduced pressure to yield 29 mg (73%) of 
an endo/exo mixture of 3.214 (endo/exo = 2:1, endo d.e. = 77%, exo d.e. = 82%, 
established by 1H NMR):  1H NMR for 3.214-endo (400 MHz) ! 7.62 (d, J = 8.2 
Hz, 1 H), 7.55 (d, J = 8.2 Hz, 1 H), 7.29 (d, J = 8.2 Hz, 2 H), 6.53 (d, J = 5.5 Hz, 
1 H), 6.36 (d, J = 5.5 Hz, 1 H), 3.20 (dd, J = 8.9, 3.8 Hz, 0.9 H), 3.05 (d, J = 8.6, 
4.1 Hz, 0.1 H), 2.40 (s, 3 H), 1.96 (s, 3 H), 1.84 (s, 3 H), 1.64 (dd, J = 12.3, 8.9 







(M+1) requires 263.1106], 263 (base), 267. 
1H NMR for 3.214-exo (500 MHz, CDCl3) " 7.65 – 7.54 (m, 2H), 7.27 (d, 
J = 7.8 Hz, 2H), 6.19 (d, J = 5.5 Hz, 1H), 6.13 (d, J = 5.5 Hz, 1H), 2.88 (dd, J = 
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8.0, 4.6  Hz, 1H), 2.38 (s, 3H), 1.93 (s, 3H), 1.52 (s, 3H), 1.27 (dd, J = 12.5, 8.0 
Hz, 1H), 1.07 (dd, J = 12.5, 4.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) " 142.40, 
140.83, 140.48, 139.25, 130.09, 126.14, 87.92, 85.46, 70.91, 37.76, 21.68, 18.65, 






S (M+1) requires 263.1106], 263 
(base). 
NMR Assignments FOR 3.214-endo: 1H NMR (500 MHz, CDCl3) " 
7.61 – 7.47 (m, 2H, C10-H), 7.26 (dd, J = 8.5, 0.6 Hz, 2H, C11-H), 6.50 (d, J = 
5.6 Hz, 1H, C2-H), 6.33 (d, J = 5.6 Hz, 1H, C1-H), 3.19 (dd, J = 8.8, 3.9  Hz, 1H, 
C4-H), 2.38 (s, 3H, C13-H), 1.81 (s, 3H, C7-H), 1.61 (dd, J = 12.2 9.0 Hz, 1H, 
C5-H), 1.51 (s, 3H, C8-H), 1.15 (dd, J = 12.3, 3.9 Hz, 1H, C5-H); 13C NMR (125 
MHz, CDCl3) " 142.25 (C9), 140.88(C12), 140.74(C1), 136.82(C2), 130.2(C11), 
125.3(C10), 88.6(C3), 85.6(C6), 71.3(C4), 36.2(C5), 21.6(C13), 19.9(C7), 
18.8(C8). 
NMR ASSIGNMENTS FOR 3.214-exo: 1H NMR (500 MHz, CDCl3) " 
7.65 – 7.54 (m, 2H, C10-H), 7.27 (d, J = 7.8 Hz, 2H, C11-H), 6.19 (d, J = 5.5 Hz, 
1H, C1-H), 6.13 (d, J = 5.5 Hz, 1H, C2-H), 2.88 (dd, J = 8.0, 4.6 Hz, 1H, C4-H), 
2.38 (s, 3H, C13-H), 1.93 (s, 3H, C8-H), 1.52 (s, 3H, C7-H), 1.27 (dd, J = 12.5, 
8.0 Hz, 1H, C5-H), 1.07 (dd, J = 12.5, 4.6 Hz, 1H, C5-H); 13C NMR (125 MHz, 
CDCl3) " 142.4 (C9), 140.8 (C12), 140.5 (C2), 139.3 (C1), 130.1 (C11), 126.1 





























yl)cyclopentanone (3.xx) (AJS-III-219). Furan 2.100 (40 mg, 0.24 mmol) was 
added to a solution of 3.212 (17 mg, 0.6 mmol) in CH2Cl2 (200 µL) at –20 ˚C.  
The reaction mixture was stirred at –20 ˚C for 36 h.  Aqueous NaOH (0.2 M, 0.5 
mL) was added, and the reaction mixture was warmed to room temperature and 
stirred for an additional 30 min.  The aqueous layer was extracted with CH2Cl2 (3 
x 3 mL), and the combined organic layers were washed with brine, dried (MgSO4) 
and concentrated under reduced pressure. The residue was purified by flash 
chromatography, eluting with Et2O/EtOAc (4:1) to yield 10 mg (50%) of 3.215 as 
a colorless oil:  1H NMR for 3.215 (400 MHz) ! 7.61 (d, J = 7.9 Hz, 2 H), 7.35 (d, 
J = 7.9 Hz, 2 H), 6.63 (dd, J = 5.5, 2.4 Hz, 1 H), 6.50 (d, J = 5.6 Hz, 1 H), 6.49 (d, 
J = 5.6 Hz, 1 H), 3.30 (s, 3 H), 3.15 (dd, J = 8.8, 3.9 Hz, 1 H), 2.65-2.59 (m, 1 H), 
2.36 (s, 3 H), 2.68-1.93 (comp, 6 H), 1.81-1.61 (comp, 2 H), 1.66 (s, 3 H), 1.13 
(ddd, J = 16.3, 12.3, 3.9 Hz, 1 H); 13 C NMR (125MHz)  !  217.6, 217.5, 141.5, 
140.7, 138.5, 138.4, 136.4, 136.1, 129.9, 125.1, 90.4, 90.2, 87.5, 87.4, 69.7, 69.6, 























ynyl)cyclopentyl)furan-2-yl)acetaldehyde (3.20) (AJS-V-232). Sodium 
periodate (1.01 g, 4.7 mmol) was added to a solution of diol 3.200 (818 mg, 2.35 
mmol) in THF/H2O (12mL:12mL) at 0 ºC. The reaction was complete within 45 
min at 0 ºC. The THF/H2O layers were extracted with EtOAc (3 x 15 mL), 
washed with brine and dried (MgSO4).  The solvent was removed under reduced 
pressure to yield 744 mg (100%) of 3.20 as a colorless oil, which was used 
without further purification. 1H NMR (500 MHz) !  9.71 (t, J = 2.0 Hz, 1 H), 6.19 
(d, J = 3.2 Hz, 1 H), 6.13 (dd, J = 3.2, 0.7 Hz, 1 H), 3.76–3.73 (m, 1 H), 3.70 (d, J 
= 2.0 Hz, 2 H), 2.58 (d, J = 16.8 Hz, 1 H), 2.56–2.51 (m, 1 H), 2.35 (d, J = 16.8 
Hz, 1 H), 2.31–2.09 (comp, 4 H), 0.72 (s, 3 H), 0.13 (s, 9 H); 13C NMR (125 
MHz) !  219.2, 196.6, 155.1, 145.4, 109.3, 107.8, 103.4, 87.5, 52.4, 42.9, 42.3, 
37.6, 27.5, 22.7, 18.4, 0.1; IR (CH2Cl2) 2962, 2175, 1741, 1249, 1028, 843, 760 
cm-1; mass spectrum (CI) m/z 317.1571 [C18H25O3Si (M+1) requires 317.1573], 
317 (base), 301.  
NMR Assignments: 1H NMR (500 MHz) !  9.71 (t, J = 2.0 Hz, 1 H, C1-
H), 6.19 (d, J = 3.2 Hz, 1 H, C4-H), 6.13 (dd, J = 3.2, 0.7 Hz, 1 H, C5-H), 3.76–
3.73 (m, 1 H, C7-H), 3.70 (d, J = 2.0 Hz, 2 H, C2-H), 2.58 (d, J = 16.8 Hz, 1 H, 
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C13-H), 2.56–2.51 (m, 1 H, C9-H), 2.35 (d, J = 16.8 Hz, 1 H, C13-H), 2.31–2.09 
(comp, 3 H, C9-H & C8-H), 0.72 (s, 3 H, C12-H), 0.13 (s, 9 H, C16-H); 13C NMR 
(125 MHz) !  219.2 (C10), 196.6 (C1), 155.1 (C3), 145.4 (C6), 109.3 (C4), 107.8 
(C5), 103.4 (C15), 87.5 (C14), 52.4 (C11), 42.9 (C7), 42.3 (C2), 37.6 (C9), 27.5 



























(trimethylsilyl)prop-2-ynyl)cyclopentanone (3.228) (AJS-V-249). 
Chlorotriethylsilane (57 mg, 0.38 mmol, 64 µL) was added dropwise to a solution 
of 3.200 (120 mg, 0.34 mmol) and triethylamine (41 mg, 0.40 mmol, 56 µL) in 
CH2Cl2 (3 mL) at –15 ˚C. The reaction mixture was stirred at –15 ˚C for 1 h. 
Saturated aqueous NaHCO3 (1.0 mL); the layers were separated; and the aqueous 
layer was extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were 
dried (MgSO4) and concentrated under reduced pressure. The residue was purified 
by flash chromatography, eluting with pentane/Et2O (4:1) to yield 134 mg (85%) 
of 3.228 as a colorless oil and as a 1:1 mixture of diastereomers: 1H NMR (600 
MHz) !  6.04 (s, 2 H), 3.93 (m, 1 H), 3.73 (dd, J = 11.5, 6.2 Hz, 1 H), 3.64 (dd, J 
= 9.9, 3.8 Hz, 1 H), 3.48 (dd, J = 9.9, 6.7 Hz, 0.5 H), 3.49 (dd, J = 10.1, 6.9 Hz, 
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0.5 H), 2.82–2.75 (m, 2 H), 2.59 (d, J = 16.8 Hz, 0.5 H), 2.58 (d, J = 16.8 Hz, 0.5 
H), 2.49 (d, J = 4.1 Hz, 0.5 H), 2.48 (d, J = 4.1 Hz, 0.5 H), 2.37 (d, J = 16.8, 1 H), 
2.29–2.19 (comp, 2 H), 2.14–2.07 (m, 1 H), 0.96 (t, J = 8.1 Hz, 9 H), 0.71 (s, 3 
H), 0.61 (q, J = 7.2 Hz, 6H), 0.13 (s, 9 H); 13C NMR (150 MHz) ! 219.5, 153.5, 
151.6, 107.4, 107.3, 107.2, 103.5, 103.4, 87.4, 87.3, 70.6, 70.5, 66.04, 66.03, 
52.34, 52.33, 42.30, 42.29, 37.7, 32.1, 27.5, 22.7, 22.3, 18.4, 6.7, 4.4, 0.1;  IR 
(CH2Cl2) 3480, 2956, 2913, 2876, 2175, 1744, 1249, 1112, 843 cm-1; mass 
spectrum (CI) m/z 463.2704 [C25H43O4Si2 (M+1) requires 463.2700], 464, 463 
(base), 445, 433. 
NMR ASSIGNMENTS: 1H NMR (600 MHz) !  6.04 (s, 2 H, C5-H & 
C6-H), 3.93 (m, 1 H, C2-H), 3.73 (dd, J = 11.5, 6.2 Hz, 1 H, C8-H), 3.64 (dd, J = 
9.9, 3.8 Hz, 1 H, C1-H), 3.48 (dd, J = 9.9, 6.7 Hz, 0.5 H, C1-H), 3.49 (dd, J = 
10.1, 6.9 Hz, 0.5 H, C1-H), 2.82–2.75 (m, 2 H, C3-H), 2.59 (d, J = 16.8 Hz, 0.5 
H, C14-H), 2.58 (d, J = 16.8 Hz, 0.5 H, C14-H), 2.55–2.51 (m, 1H, C12-H), 2.49 
(d, J = 4.1 Hz, 0.5 H, OH), 2.48 (d, J = 4.1 Hz, 0.5 H, OH), 2.37 (d, J = 16.8, 1 H, 
C14-H), 2.29–2.19 (comp, 2 H, C11-H & C12-H), 2.14–2.07 (m, 1 H, C12-H), 
0.96 (t, J = 8.1 Hz, 9 H), 0.71 (s, 3 H), 0.61 (q, J = 7.2 Hz, 6H), 0.13 (s, 9 H); 13C 
NMR (150 MHz) ! 219.5 (C10), 153.5 (C4), 151.6 (C7), 107.4 (C6), 107.3 (C5), 
107.2 (C5), 103.5 (C16), 103.4 (C16), 87.4 (C16), 87.3 (C16), 70.6 (C2), 70.5 
(C2), 66.04 (C1), 66.03 (C1), 52.34 (C9), 52.33 (C9), 42.30 (C8), 42.29 (C8), 
37.7 (C11), 32.1 (C3), 27.5 (C14), 22.7 (C11), 22.3 (C11), 18.4 (C13), 6.7 (C19), 





























(trimethylsilyl)prop-2-ynyl)cyclopentanone (AJS-V-251). Further structural 
confirmation of 3.228 was made via derivatization to Keto-3.228.  A solution of 
3.228 (24 mg, 0.05 mmol) in CH2Cl2 (0.4 mL) was added to a solution of pyridine 
(49 mg, 51 µL) and chromium trioxide (31 mg, 0.31 mmol) in CH2Cl2 (1 mL) at 
rt.  The reaction mixture was stirred at rt for 1 h. The organic layers were washed 
with saturated aqueous CuSO4, dried (MgSO4), and concentrated under reduced 
pressure. The residue was filtered through a short plug of neutrala alumin to yield 
keto-3.228 as a colorless oil:  1H NMR (500 MHz) ! 6.14 (d, J = 3.1 Hz, 1 H), 
6.09 (dd, J = 3.1, 0.6 Hz, 1 H), 4.25 (s, 2 H), 3.83 (d, 2 H), 3.73 (dd, J = 11.3, 6.2 
Hz, 1 H), 2.59 (d, J = 16.8 Hz, 1 H),  2.55–2.50 (m, 1 H), 2.38 (d, J = 16.8 Hz, 1 
H), 2.31–2.06 (comp, 3 H), 0.97 (t, J = 7.9 Hz, 9 H), 0.72 (s, 3 H), 0.65 (q, J = 7.9 
Hz, 6 H), 0.13 (s, 9 H); 13C NMR (125 MHz) ! 219.4, 205.5, 154.3, 146.9, 108.8, 
107.6, 103.5, 87.3, 68.6, 52.3, 42.2, 38.2, 37.7, 27.5, 22.7, 18.4, 6.7, 4.3, 0.1;  IR 
(CH2Cl2) 2957, 2877, 2359, 2340, 2174, 1743, 1248, 1098, 1016, 843, 786, 744, 
668 cm-1; mass spectrum (CI) m/z 461.2536 [C25H41O4Si2 (M+1) requires 
461.2543], 461 (base), 431. 
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NMR ASSIGNMENTS: 1H NMR (500 MHz) ! 6.14 (d, J = 3.1 Hz, 1 H, 
C5-H), 6.09 (dd, J = 3.1, 0.6 Hz, 1 H, C6-H), 4.25 (s, 2 H, C1-H), 3.83 (d, 2 H, 
C3-H), 3.73 (dd, J = 11.3, 6.2 Hz, 1 H, C8-H), 2.59 (d, J = 16.8 Hz, 1 H, C14-
H),  2.55–2.50 (m, 1 H, C10-H), 2.38 (d, J = 16.8 Hz, 1 H, C14-H), 2.31–2.06 
(comp, 3 H, C10-H & C9-H), 0.97 (t, J = 7.9 Hz, 9 H, C9-H), 0.72 (s, 3 H, C13-
H), 0.65 (q, J = 7.9 Hz, 6 H, C18-H), 0.13 (s, 9 H, C17-H); 13C NMR (125 MHz) 
! 219.4, 205.5, 154.3, 146.9, 108.8, 107.6, 103.5, 87.3, 68.6, 52.3, 42.2, 38.2, 


































(3.224) (AJS-V-250). Vinylsulfonylchloride (20 mg, 0.16 mmol) was added to a 
solution of 3.228 (75 mg, 0.16 mmol) and triethylamine (33 mg, 0.32 mmol, 45 
µL) in THF (0.7 mL) at 0 ˚C. The reaction mixture was stirred at 0 ˚C for 2 h and 
then at room temperature for 12 h. The reaction was poured onto ice and the 
mixture was extracted with Et2O (3 x 3 mL). The combined organic layers were 
washed with brine (5 mL), aqueous 1 N HCl (1 mL), and saturated aqueous 
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NaHCO3 (2 mL).  The layers were dried (MgSO4) and the solvent was removed 
under reduce pressure. The residue was purified by flash chromatography, eluting 
with pentane/Et2O (4:1) to yield 88 mg (100%) of 3.224 as a colorless oil: 
1H 
NMR (500 MHz) ! 6.42 (dd, J = 16.7, 9.8 Hz, 0.5 H), 6.35 (dd, J = 16.6, 9.2 Hz), 
6.30 (d, J = 16.7 Hz, 0.5 H), 6.28 (d, J = 16.6 Hz, 0.5 H), 6.07 (m, 1 H), 6.04 (m, 
1 H), 5.96 (d, J = 9.8 Hz, 0.5 H), 5.93 (d, J = 9.2 Hz, 0.5 H), 4.69–4.62 (m, 1 H), 
3.74–3.67 (comp, 3 H), 3.06 (dd, J = 15.4, 5.7 Hz, 1 H), 2.99 (dd, J = 15.4, 6.8 
Hz, 0.5 H), 2.98 (dd, J = 15.4, 6.7 Hz, 0.5 H), 2.58 (d, J = 16.9 Hz, 0.5 H), 2.57 
(d, J = 16.8 Hz, 0.5 H), 2.36 (d, J = 16.9 Hz, 0.5 H), 2.35 (d, J = 16.8 Hz, 0.5 H), 
2.55–2.41 (m, 1 H), 2.32–2.03 (comp, 3 H), 0.94 (t, J = 7.9 Hz, 9 H), 0.69 (s, 3 
H), 0.60 (q, J = 7.9 Hz, 6 H), 0.11 (s, 9 H); 13C NMR (125 MHz) !  219.3, 219.2, 
154.0, 153.9, 149.1, 149.1, 133.5, 133.3, 128.6, 128.5, 108.7, 107.6, 107.5, 103.4, 
103.1,  88.1, 88.0, 87.4, 87.3, 81.7, 63.7, 63.6, 52.3, 42.3, 42.2, 37.6, 30.4, 30.3, 
27.5, 27.4, 22.7, 18.4, 18.3, 6.4, 4.3, 4.2, 0.08, 0.06; IR (CH2Cl2) 2958, 2877, 
2175, 1744, 1641, 1367, 1249, 1173, 921, 845, 747 cm-1; mass spectrum (CI) m/z 
553.2465 [C27H45O6Si2S (M+1) requires 553.2475], 553 (base), 554. 
NMR Assignments: 1H NMR (500 MHz) ! 6.42 (dd, J = 16.7, 9.8 Hz, 0.5 
H, C20-H), 6.35 (dd, J = 16.6, 9.2 Hz, C20-H), 6.30 (d, J = 16.7 Hz, 0.5 H, C21-
H), 6.28 (d, J = 16.6 Hz, 0.5 H, C21-H), 6.07 (m, 1 H, C5-H), 6.04 (m, 1 H, C6-
H), 5.96 (d, J = 9.8 Hz, 0.5 H, C21-H), 5.93 (d, J = 9.2 Hz, 0.5 H, C21-H), 4.69–
4.62 (m, 1 H, C2-H), 3.74–3.67 (comp, 3 H, C1-H & C8-H), 3.06 (dd, J = 15.4, 
5.7 Hz, 1 H, C3-H), 2.99 (dd, J = 15.4, 6.8 Hz, 0.5 H, C3-H), 2.98 (dd, J = 15.4, 
6.7 Hz, 0.5 H, C3-H), 2.58 (d, J = 16.9 Hz, 0.5 H, C14-H), 2.57 (d, J = 16.8 Hz, 
 251 
0.5 H, C14-H), 2.36 (d, J = 16.9 Hz, 0.5 H, C14-H), 2.35 (d, J = 16.8 Hz, 0.5 H, 
C14-H), 2.55–2.41 (m, 1 H, C10-H), 2.32–2.03 (comp, 3 H, C10-H & C9-H), 
0.94 (t, J = 7.9 Hz, 9 H, C19-H), 0.69 (s, 3 H, C13-H), 0.60 (q, J = 7.9 Hz, 6 H, 
C18-H), 0.11 (s, 9 H, C17-H); 13C NMR (125 MHz) !  219.3 (C11), 219.2 (C11), 
154.0 (C4), 153.9 (C4), 149.1 (C7), 149.0 (C7), 133.5 (C20), 133.3 (C20), 128.6 
(C21), 128.5 (C21), 108.7 (C5), 107.6 (C6), 107.5 (C6), 103.4 (C16), 103.1 
(C16),  88.1 (C15), 88.0 (C15), 81.7 (C2), 63.7 (C1), 63.6 (C1), 52.3 (C12), 42.3 
(C8), 42.2 (C8), 37.6 (C14), 30.4 (C3), 30.3 (C3), 27.5 (C10), 27.4 (C10), 22.7 





































Diels-Alder Cycloaddition to Furnish Cycloadduct 3.223. A solution of 
3.224 (15 mg, 0.03 mmol) in benzene (0.3 mL) was heated at 75 ˚C for 12 h. The 
solution was cooled to room temperature and concentrated under reduced 
pressure. The residue was purified via flash chromatography, eluting with 
pentane/Et2O (3:1) to give two diastereomers (1:1 ratio). 3.223 (first 
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diastereomer): 1H NMR (500 MHz) ! 6.85 (d, J = 5.6 Hz, 1 H), 6.09 (d, J = 5.6 
Hz, 1 H), 4.87 (dtd, 12.3, 4.1, 2.1 Hz, 1 H), 3.92 (dd, J = 11.6, 4.1 Hz, 1 H), 3.85 
(dd, J = 11.6, 4.1 Hz, 1 H), 3.18–3.12 (comp, 2 H), 2.75 (d, J = 17.2 Hz, 1 H), 
2.60 (dd, J = 12.3, 3.2 Hz, 1 H), 2.54–2.47 (comp, 2 H), 2.28 (d, J = 17.2 Hz, 1 
H), 2.27–2.02 (comp, 4 H), 1.82 (dd, J = 12.1, 7.9 Hz, 1 H), 0.98 (t, J = 7.8 Hz, 9 
H), 0.96 (s, 3 H),0.65 (q, J = 7.8 Hz, 6 H), 0.13 (s, 9 H); 13C NMR (125 MHz) 
!  219.6, 141.3, 135.8, 103.1, 90.6, 88.8, 87.8, 80.5, 63.9, 58.6, 51.8, 43.4, 36.6, 
32.8, 29.3, 28.3, 20.4, 19.7, 6.7, 4.3, 0.1; IR (CH2Cl2) 2957, 2876, 2174, 1742, 
1366, 1249, 1173, 1140, 912, 845, 746 cm-1; mass spectrum (CI) m/z 553.2484 
[C27H45O6Si2S (M+1) requires 553.2475], 553 (base), 554, 523. 
NMR Assignments FOR 3.223 (first diastereomer): 1H NMR (500 
MHz) ! 6.85 (d, J = 5.6 Hz, 1 H, C5-H), 6.09 (d, J = 5.6 Hz, 1 H, C6-H), 4.87 
(dtd, 12.3, 4.1, 2.1 Hz, 1 H, C2-H), 3.92 (dd, J = 11.6, 4.1 Hz, 1 H, C1-H), 3.85 
(dd, J = 11.6, 4.1 Hz, 1 H, C1-H), 3.18–3.12 (comp, 2 H, C9-H & C10-H), 2.75 
(d, J = 17.2 Hz, 1 H, C16-H), 2.60 (dd, J = 12.3, 3.2 Hz, 1 H, C8-H), 2.54–2.47 
(comp, 2 H, C3-H & C12-H), 2.28 (d, J = 17.2 Hz, 1 H, C16-H), 2.27–2.02 
(comp, 4 H, C11-H & C3-H), 1.82 (dd, J = 12.3, 7.9 Hz, 1 H, C8-H), 0.98 (t, J = 
7.8 Hz, 9 H, C21-H), 0.96 (s, 3 H, C15-H), 0.65 (q, J = 7.8 Hz, 6 H, C20-H), 0.13 
(s, 9 H, C19-H); 13C NMR (125 MHz) !  219.6 (C13), 141.3 (C5), 135.8 (C6), 
103.1 (C18), 90.6 (C17), 88.8 (C4), 87.8 (C7), 80.5 (C2), 63.9 (C1), 58.6 (C9), 
51.8 (C14), 43.4 (C10), 36.6 (C12), 32.8 (C8), 29.3 (C3), 28.3 (C16), 20.4 (C11), 
19.7 (C15), 6.7 (C21), 4.3 (C20), 0.1 (C19). 
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3.223 (second diastereomer): 1H NMR (500 MHz) ! 6.54 (d, J = 5.6 Hz, 
1 H), 6.06 (d, J = 5.6 Hz, 1 H), 4.86 (dtd, J = 12.1, 4.0, 2.0 Hz), 3.90 (dd, J = 
11.6, 4.0 Hz, 1 H), 3.85 (dd, J = 11.6, 4.0 Hz, 1 H), 3.19 (dd, J = 7.9, 3.3 Hz, 1 
H), 3.14 (dd, J = 12.6, 6.0 Hz, 1 H), 2.68 (d, J = 17.0 Hz, 1 H), 2.54–2.43 (comp, 
3 H), 2.50 (d, J = 17.0 Hz, 1 H), 2.31 (dd, J = 15.3, 2.0 Hz, 1 H), 2.24–2.14 
(comp, 2 H), 1.97 (dd, J = 12.1, 7.9 Hz, 1 H), 1.94–1.89 (m, 1 H), 1.02 (s, 3 H), 
0.98 (t, J = 8.0 Hz, 9 H), 0.65 (q, J = 8.0 Hz, 6 H), 0.13 (s, 9H); 13C NMR (125 
MHz) !  219.6, 141.9, 134.7, 103.5, 91.2, 88.1, 88.0, 80.4, 63.9, 58.9, 51.8, 44.4, 
37.2, 33.7, 29.3, 28.6, 21.9, 18.8, 6.7, 4.3, 0.09; IR (CH2Cl2) 2957, 2876, 1742, 
1365, 1249, 1172, 1138, 1039, 898, 845, 746 cm-1; mass spectrum (CI) m/z 
553.2469 [C27H45O6Si2S (M+1) requires 553.2475], 553 (base), 554, 523. 
NMR Assignments: 3.223 (second diastereomer): 1H NMR (500 MHz) 
! 6.54 (d, J = 5.6 Hz, 1 H, C5-H), 6.06 (d, J = 5.6 Hz, 1 H, C6-H), 4.86 (dtd, J = 
12.1, 4.0, 2.0 Hz, C2-H), 3.90 (dd, J = 11.6, 4.0 Hz, 1 H, C1-H), 3.85 (dd, J = 
11.6, 4.0 Hz, 1 H, C1-H), 3.19 (dd, J = 7.9, 3.3 Hz, 1 H, C9-H), 3.14 (dd, J = 
12.6, 6.0 Hz, 1 H, C10-H), 2.68 (d, J = 17.0 Hz, 1 H, C16-H), 2.54–2.43 (comp, 3 
H, C8-H, C3-H, & C12-H), 2.50 (d, J = 17.0 Hz, 1 H, C16-H), 2.31 (dd, J = 15.3, 
2.0 Hz, 1 H, C3-H), 2.24–2.14 (comp, 2 H, C12-H & C11-H), 1.97 (dd, J = 12.1, 
7.9 Hz, 1 H, C8-H), 1.94–1.89 (m, 1 H, C11-H), 1.02 (s, 3 H, C14-H), 0.98 (t, J = 
8.0 Hz, 9 H, C21-H), 0.65 (q, J = 8.0 Hz, 6 H, C20-H), 0.13 (s, 9H, C19-H); 13C 
NMR (125 MHz) !  219.6 (C13), 141.9 (C5), 134.7 (C6), 103.5 (C18), 91.2 
(C17), 88.1 (C4), 88.0 (C7), 80.4 (C2), 63.9 (C1), 58.9 (C9), 51.8 (C14), 44.4 
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(C10), 37.2 (12), 33.7 (C8), 29.3 (C3), 28.6 (C16), 21.9 (C11), 18.8 (C15), 6.7 























CRYSTAL STRUCTURE DATA 
Crystal Data for 2.126: 
 
Table 1.  Crystallographic Data for 2.126. 
Table 2. Fractional coordinates and equivalent isotropic thermal parameters (Å2) 
for the non-hydrogen atoms of 2.126. 
Table 3.  Bond Lengths (Å) and Angles (o) for the non-hydrogen atoms of 2.126. 
Table  4.   Anisotropic thermal parameters for the non-hydrogen atoms of 2.126. 
Table 5. Fractional coordinates and isotropic thermal parameters (Å2) for the 
hydrogen atoms of  2.126. 
Table 6.  Torsion Angles (o) for the non-hydrogen atoms of 2.126. 
 
Table 1.  Crystal data and structure refinement for 1. 
Empirical formula  C13 H12 O2 
Formula weight  200.23 
Temperature  100(2) K 
Wavelength  1.54180 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 6.5551(5) Å $= 90°. 
 b = 7.0695(8) Å #= 
99.376(4)°. 
 c = 11.0981(10) Å & = 90°. 
Volume 507.43(8) Å3 
Z 2 
Density (calculated) 1.310 Mg/m3 
Absorption coefficient 0.703 mm-1 
F(000) 212 
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Crystal size 0.28 x 0.22 x 0.03 mm 
Theta range for data collection 6.85 to 69.83°. 
Index ranges -7<=h<=7, -6<=k<=8, -13<=l<=13 
Reflections collected 6565 
Independent reflections 1662 [R(int) = 0.0726] 
Completeness to theta = 69.83° 94.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.98 and 0.70 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1662 / 1 / 137 
Goodness-of-fit on F2 1.108 
Final R indices [I>2sigma(I)] R1 = 0.0591, wR2 = 0.1209 
R indices (all data) R1 = 0.0735, wR2 = 0.1425 
Absolute structure parameter 0.1(5) 
Largest diff. peak and hole 0.216 and -0.218 e.Å-3 
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) 
for 1.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
_______________________________________________________________________________
_  
 x y z U(eq) 
_______________________________________________________________________________
_   
O1 3045(3) 7853(4) 1814(2) 41(1) 
O2 10972(4) 9707(5) 5098(2) 52(1) 
C1 5040(5) 8574(6) 1940(3) 37(1) 
C2 5512(5) 9174(6) 874(3) 39(1) 
C3 3729(5) 8832(6) -33(3) 35(1) 
C4 3212(6) 9099(6) -1301(3) 42(1) 
C5 1275(6) 8571(7) -1870(3) 47(1) 
C6 -173(6) 7766(7) -1215(3) 45(1) 
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C7 310(6) 7508(7) 29(4) 41(1) 
C8 2250(5) 8032(6) 579(3) 37(1) 
C9 6202(5) 8515(7) 3214(3) 39(1) 
C10 8516(5) 8833(7) 3310(3) 40(1) 
C11 9202(6) 9541(7) 4599(3) 45(1) 
C12 7307(5) 10015(8) 5152(3) 44(1) 
C13 5545(5) 10045(8) 4055(3) 50(1) 
Table 3.   Bond lengths [Å] and angles [°] for  1. 
O1-C1  1.389(4) 
O1-C8  1.391(4) 
O2-C11  1.208(4) 
C1-C2  1.340(5) 
C1-C9  1.493(4) 
C2-C3  1.433(4) 
C2-H2  0.9500 
C3-C8  1.391(5) 
C3-C4  1.405(5) 
C4-C5  1.375(5) 
C4-H4  0.9500 
C5-C6  1.407(6) 
C5-H5  0.9500 
C6-C7  1.378(5) 
C6-H6  0.9500 
C7-C8  1.369(5) 
C7-H7  0.9500 
C9-C10  1.520(4) 
C9-C13  1.536(6) 
C9-H9  1.0000 
C10-C11  1.513(5) 
C10-H10A  0.9900 
C10-H10B  0.9900 
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C11-C12  1.510(5) 
C12-C13  1.536(5) 
C12-H12A  0.9900 
C12-H12B  0.9900 
C13-H13A  0.9900 






















































Table 4.   Anisotropic displacement parameters  (Å2x 103) for 1.  The anisotropic 
displacement factor exponent takes the form:  -2"2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
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______________________________________________________________________________  
O1 33(1)  48(2) 44(1)  2(1) 10(1)  0(1) 
O2 39(2)  64(3) 53(2)  -6(2) 11(1)  -5(2) 
C1 34(2)  24(3) 53(2)  -5(2) 12(2)  -3(2) 
C2 34(2)  32(3) 52(2)  0(2) 13(2)  2(2) 
C3 40(2)  23(3) 44(2)  1(2) 11(1)  5(2) 
C4 50(2)  29(3) 48(2)  3(2) 14(2)  1(2) 
C5 53(2)  43(3) 44(2)  -1(2) 6(2)  5(2) 
C6 44(2)  33(3) 56(2)  -4(2) 2(2)  9(2) 
C7 37(2)  35(3) 52(2)  -1(2) 12(2)  1(2) 
C8 39(2)  29(3) 43(2)  -3(2) 9(2)  5(2) 
C9 37(2)  37(3) 43(2)  3(2) 11(1)  -3(2) 
C10 41(2)  37(3) 45(2)  1(2) 15(2)  2(2) 
C11 38(2)  50(3) 48(2)  -1(2) 10(2)  -1(2) 
C12 37(2)  52(4) 47(2)  -8(2) 15(2)  -1(2) 
C13 39(2)  63(4) 50(2)  -9(2) 19(2)  -2(2) 








H2 6783 9719 744 47 
H4 4180 9633 -1754 50 
H5 906 8755 -2726 57 
H6 -1494 7397 -1634 54 
H7 -661 6988 486 49 
H9 5977 7248 3571 46 
H10A 9231 7639 3169 48 
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H10B 8810 9784 2706 48 
H12A 7457 11263 5561 53 
H12B 7056 9042 5753 53 
H13A 5434 11297 3651 59 
H13B 4204 9727 4306 59 





































Crystal Data for Exo Diels-Alder Adduct (3.214): 
 
Table 1.  Crystal data and structure refinement for 1. 
Empirical formula  C15 H18.50 O2.25 S 
Formula weight  266.86 
Temperature  153(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 5.6100(4) Å $= 90°. 
 b = 9.1107(6) Å #= 90°. 
 c = 27.1378(14) Å & = 90°. 
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Volume 1387.04(15) Å3 
Z 4 
Density (calculated) 1.278 Mg/m3 
Absorption coefficient 0.228 mm-1 
F(000) 570 
Crystal size 0.30 x 0.07 x 0.04 mm 
Theta range for data collection 2.69 to 30.00°. 
Index ranges -7<=h<=6, -12<=k<=12, -25<=l<=38 
Reflections collected 9792 
Independent reflections 3672 [R(int) = 0.0532] 
Completeness to theta = 30.00° 98.4 %  
Absorption correction Analytical 
Max. and min. transmission 0.992 and 0.933 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3672 / 108 / 171 
Goodness-of-fit on F2 1.049 
Final R indices [I>2sigma(I)] R1 = 0.0684, wR2 = 0.1315 
R indices (all data) R1 = 0.1107, wR2 = 0.1522 
Absolute structure parameter 0.11(13) 
Largest diff. peak and hole 0.496 and -0.336 e.Å-3 
 
 
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) 
for 1.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
_______________________________________________________________________________
_  
 x y z U(eq) 
_______________________________________________________________________________
_   
S1 6994(2) 2944(1) 1271(1) 28(1) 
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O1 7235(5) 6012(3) 649(1) 41(1) 
O2 7477(5) 1517(3) 1017(1) 40(1) 
C1 5029(6) 3959(3) 856(1) 22(1) 
C2 6486(6) 4672(4) 417(1) 28(1) 
C3 4573(6) 5209(4) 67(1) 27(1) 
C4 3594(7) 6370(4) 273(1) 38(1) 
C5 4877(9) 6562(4) 761(1) 44(1) 
C6 3932(8) 5318(4) 1105(1) 35(1) 
C7 8524(6) 3826(5) 201(1) 39(1) 
C8 4989(13) 8091(4) 977(2) 78(2) 
C9 4839(6) 2577(3) 1749(1) 28(1) 
C10 3042(7) 1569(4) 1673(1) 37(1) 
C11 1458(7) 1273(5) 2053(2) 45(1) 
C12 1644(7) 1962(5) 2501(1) 45(1) 
C13 3439(8) 2980(5) 2568(1) 49(1) 
C14 5064(7) 3291(4) 2193(1) 40(1) 
C15 -82(9) 1615(6) 2908(2) 64(1) 
O1W 9620(30) 8636(17) 1175(5) 76(4) 
Table 3.   Bond lengths [Å] and angles [°] for  1. 
S1-O2  1.497(2) 
S1-C9  1.804(3) 
S1-C1  1.826(3) 
O1-C2  1.435(4) 
O1-C5  1.447(6) 
C1-C6  1.538(4) 
C1-C2  1.584(4) 
C1-H1  1.00 
C2-C7  1.498(5) 
C2-C3  1.515(5) 
C3-C4  1.316(5) 
C3-H3  0.95 
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C4-C5  1.517(5) 
C4-H4  0.95 
C5-C8  1.514(5) 
C5-C6  1.561(5) 
C6-H6A  0.99 
C6-H6B  0.99 
C7-H7A  0.98 
C7-H7B  0.98 
C7-H7C  0.98 
C8-H8A  0.98 
C8-H8B  0.98 
C8-H8C  0.98 
C9-C14  1.375(5) 
C9-C10  1.379(5) 
C10-C11  1.387(5) 
C10-H10  0.95 
C11-C12  1.372(6) 
C11-H11  0.95 
C12-C13  1.382(6) 
C12-C15  1.504(5) 
C13-C14  1.396(5) 
C13-H13  0.95 
C14-H14  0.95 
C15-H15A  0.98 
C15-H15B  0.98 










































































Table 4.   Anisotropic displacement parameters  (Å2x 103) for 1.  The anisotropic 
displacement factor exponent takes the form:  -2"2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S1 28(1)  30(1) 24(1)  4(1) -2(1)  2(1) 
O1 58(2)  36(1) 28(1)  1(1) -6(1)  -20(1) 
O2 46(2)  34(1) 40(1)  2(1) 4(1)  16(1) 
C1 23(2)  22(2) 20(1)  3(1) -1(1)  1(1) 
C2 33(2)  28(2) 22(2)  1(1) -3(1)  -9(2) 
C3 32(2)  30(2) 17(2)  3(1) -1(1)  -3(2) 
C4 57(3)  30(2) 28(2)  12(2) 4(2)  8(2) 
C5 88(3)  22(2) 23(2)  1(1) 2(2)  -1(2) 
C6 56(2)  26(2) 23(2)  3(1) 7(2)  9(2) 
C7 26(2)  54(2) 38(2)  11(2) 5(2)  3(2) 
C8 166(5)  25(2) 41(2)  -5(2) 0(3)  0(3) 
C9 29(2)  29(2) 24(2)  9(1) -1(1)  3(1) 
C10 44(2)  32(2) 35(2)  3(2) 1(2)  0(2) 
C11 38(2)  44(2) 51(2)  17(2) 0(2)  -4(2) 
C12 44(2)  56(2) 35(2)  21(2) 2(2)  11(2) 
C13 55(3)  71(3) 21(2)  2(2) -1(2)  5(3) 
C14 41(2)  52(2) 26(2)  3(2) -4(2)  -5(2) 
C15 53(3)  90(4) 48(2)  33(2) 16(2)  19(3) 









H1 3748 3302 726 26 
H3 4160 4789 -242 32 
H4 2348 6961 144 46 
H6A 4513 5438 1447 42 
H6B 2169 5275 1105 42 
H7A 9244 4395 -67 59 
H7B 7940 2888 72 59 
H7C 9721 3643 457 59 
H8A 5982 8080 1275 116 
H8B 3377 8418 1063 116 
H8C 5681 8766 735 116 
H10 2891 1083 1365 44 
H11 220 578 2002 54 
H13 3570 3477 2875 59 
H14 6305 3984 2243 48 
H15A 689 970 3150 95 
H15B -1484 1121 2771 95 
H15C -575 2527 3070 95 
 













































Crystal Data for Endo Diels-Alder Adduct: 
 
Table 1.  Crystal data and structure refinement for 1. 
Empirical formula  C15 H18 O2 S 
Formula weight  262.35 
Temperature  153(2) K 
Wavelength  0.71073 Å 
Crystal system  Orhtorhombic 
Space group  P212121 
Unit cell dimensions a = 7.04400(1) Å $= 90°. 
 b = 12.5470(2) Å #= 90°. 
 c = 15.3720(2) Å & = 90°. 
Volume 1358.59(3) Å3 
Z 4 
Density (calculated) 1.283 Mg/m3 
Absorption coefficient 0.230 mm-1 
F(000) 560 
Crystal size 0.25 x 0.20 x 0.15 mm 
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Theta range for data collection 2.10 to 32.50°. 
Index ranges -10<=h<=10, -18<=k<=18, -23<=l<=23 
Reflections collected 4901 
Independent reflections 4901 
Completeness to theta = 32.50° 99.8 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4901 / 108 / 237 
Goodness-of-fit on F2 1.022 
Final R indices [I>2sigma(I)] R1 = 0.0300, wR2 = 0.0721 
R indices (all data) R1 = 0.0356, wR2 = 0.0752 
Absolute structure parameter 0.00(4) 
Extinction coefficient 1.1(2)x10-5 
Largest diff. peak and hole 0.253 and -0.231 e.Å-3 
Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) 
for 1.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
_______________________________________________________________________________
_  
 x y z U(eq) 
_______________________________________________________________________________
_   
S1 5952(1) 3300(1) 3335(1) 21(1) 
O1 3728(1) 2636(1) 1055(1) 25(1) 
C1 5390(1) 2589(1) 2339(1) 20(1) 
O2 7634(1) 3998(1) 3139(1) 30(1) 
C2 3583(2) 1904(1) 2433(1) 22(1) 
C3 2300(1) 2385(1) 1705(1) 23(1) 
C4 1735(2) 3494(1) 2016(1) 26(1) 
C5 3279(2) 4095(1) 1934(1) 26(1) 
C6 4822(1) 3367(1) 1577(1) 23(1) 
C7 797(2) 1656(1) 1344(1) 31(1) 
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C8 6445(2) 3849(1) 1074(1) 32(1) 
C9 6809(2) 2177(1) 3938(1) 20(1) 
C10 5691(2) 1756(1) 4595(1) 24(1) 
C11 6387(2) 914(1) 5095(1) 28(1) 
C12 8176(2) 485(1) 4935(1) 28(1) 
C13 9285(2) 933(1) 4276(1) 27(1) 
C14 8625(2) 1783(1) 3781(1) 24(1) 
C15 8890(3) -457(1) 5447(1) 40(1) 
Table 3.   Bond lengths [Å] and angles [°] for  1. 
S1-O2  1.5034(9) 
S1-C9  1.7914(10) 
S1-C1  1.8157(10) 
O1-C6  1.4411(13) 
O1-C3  1.4523(13) 
C1-C2  1.5430(14) 
C1-C6  1.5763(14) 
C1-H1  0.967(13) 
C2-C3  1.5599(15) 
C2-H2A  0.991(14) 
C2-H2B  0.963(15) 
C3-C7  1.5047(15) 
C3-C4  1.5251(15) 
C4-C5  1.3295(16) 
C4-H4  0.949(15) 
C5-C6  1.5221(15) 
C5-H5  0.934(15) 
C6-C8  1.5061(15) 
C7-H7B  0.949(19) 
C7-H7A  0.991(17) 
C7-H7C  0.950(19) 
C8-H8C  0.963(16) 
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C8-H8B  1.017(17) 
C8-H8A  1.024(18) 
C9-C10  1.3859(14) 
C9-C14  1.3927(14) 
C10-C11  1.3957(16) 
C10-H10  0.982(16) 
C11-C12  1.3918(18) 
C11-H11  0.972(17) 
C12-C13  1.3974(18) 
C12-C15  1.5064(16) 
C13-C14  1.3899(15) 
C13-H13  0.970(19) 
C14-H14  0.910(16) 
C15-H15A  0.94(2) 
C15-H15B  1.00(3) 









































































Table 4.   Anisotropic displacement parameters  (Å2x 103) for 1.  The anisotropic 
displacement factor exponent takes the form:  -2"2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S1 22(1)  19(1) 21(1)  -1(1) -1(1)  3(1) 
O1 24(1)  30(1) 20(1)  -2(1) -2(1)  4(1) 
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C1 20(1)  20(1) 19(1)  0(1) -1(1)  3(1) 
O2 30(1)  25(1) 36(1)  3(1) -4(1)  -5(1) 
C2 21(1)  22(1) 24(1)  1(1) -1(1)  1(1) 
C3 20(1)  26(1) 23(1)  -2(1) -1(1)  2(1) 
C4 22(1)  29(1) 26(1)  -1(1) -3(1)  9(1) 
C5 28(1)  22(1) 27(1)  2(1) -3(1)  7(1) 
C6 22(1)  24(1) 22(1)  3(1) -1(1)  2(1) 
C7 24(1)  37(1) 32(1)  -7(1) -5(1)  -2(1) 
C8 29(1)  37(1) 29(1)  11(1) 3(1)  0(1) 
C9 23(1)  20(1) 18(1)  -1(1) -3(1)  2(1) 
C10 25(1)  27(1) 21(1)  -2(1) 1(1)  -1(1) 
C11 36(1)  26(1) 23(1)  2(1) -2(1)  -6(1) 
C12 37(1)  20(1) 25(1)  -1(1) -11(1)  -1(1) 
C13 27(1)  25(1) 30(1)  -4(1) -6(1)  5(1) 
C14 23(1)  26(1) 22(1)  -1(1) -1(1)  2(1) 















H1 6508(19) 2183(10) 2186(8) 17(3) 
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H2A 3840(20) 1141(11) 2313(9) 25(3) 
H2B 3040(20) 1936(12) 3008(10) 32(4) 
H4 540(20) 3669(11) 2261(9) 26(4) 
H5 3430(20) 4800(12) 2114(10) 27(4) 
H7B -120(30) 1489(15) 1777(12) 50(5) 
H7A 1360(20) 964(13) 1169(10) 35(4) 
H7C 160(30) 1974(15) 865(12) 49(5) 
H8C 5960(20) 4291(13) 612(10) 35(4) 
H8B 7280(20) 4277(14) 1487(11) 43(5) 
H8A 7310(30) 3264(15) 829(11) 44(5) 
H10 4430(20) 2075(13) 4694(10) 33(4) 
H11 5620(30) 672(14) 5581(11) 39(4) 
H13 10570(30) 696(14) 4165(11) 44(5) 
H14 9330(20) 2079(13) 3348(11) 36(4) 
H15A 8370(30) -470(16) 6012(14) 56(6) 
H15B 10310(40) -440(20) 5449(17) 90(8) 
H15C 8460(30) -1103(17) 5186(13) 58(6) 
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